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Abstract 
This work is focused on structural studies of the innate immune protein α2-macroglobulin from 
the horseshoe crab, Limulus Polyphemus, using crystallography and structure prediction software 
to reveal clues about the structure and function of this key immune mediator. 
The α2-macroglobulin superfamily of proteins, characterised by the presence of an internal thiol-
ester bond, is seen in humans as α2-macroglobulin, pregnancy zone protein (PZP), and 
Complement components C3, C4 and C5. α2-Macroglobulin (α2m) is a multifunctional serum 
protein, whose primary function is serving as a protease inhibitor. Rather than a traditional active-
site inhibition, α2m immobilises target proteases via proteolytic cleavage of its bait region 
resulting in structural reorganisation of α2m and molecular entrapment of the protease. The 
nature of the bait region sequence allows for cleavage by a wide number of proteases which thus 
become entrapped. Small amines such as methylamine can also induce α2m activation resulting in 
the same structural reorganisation seen in proteolytic activation. 
The crystal structure of Limulus α2m was not determined during this study, however this work 
represents the first reports of protein crystals of Limulus α2m activated with methylamine. 
Crystals were tested at the Diamond Light Source and diffraction was detected to 6Å with a 
predicted orthorhombic space group of P222 and unit cell dimensions of a = 115Å, b = 141Å, and c 
= 338Å. 
In addition to crystallographic analysis the Limulus Polyphemus α2m sequence was submitted to 
the I-TASSER server for structure prediction. I-TASSER predicted general structural homology with 
the human analogue although differences arise from the human model representing the activated 
form and I-TASSER building a native , non-activated structure for the Limulus homologue. The 
bioinfomatic analysis and structure prediction presented here provides convincing structural 
  
 
models coupled with novel insights into the activation mechanism of Limulus α2m and how this 
might relate to its functions downstream. 
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Chapter 1 – Introduction to α2-Macroglobulin: Novel Protease Inhibitor 
1 Introduction to α2-Macroglobulin: Novel Protease Inhibitor 
1.1 Introduction to Immunity 
1.1.1 The Immune System 
The immune systems of vertebrates and other highly evolved species are branched into two 
distinct yet interactive systems: the innate immune system, and the adaptive immune system. 
The antibody mediated immune system is absent in invertebrates as it evolved early on in the 
evolution of the vertebrate line.  The adaptive immune response depends upon the recognition 
and assimilation of antigens which are then processed and presented to the lymphocytes. This 
then leads to either cell mediated clearance of the pathogen or antibody mediated clearance.  
The downside to this system is that upon primary presentation of an antigen the system is slow to 
respond with an effective response (Meyers, 1991). This is likely the reason that high order 
organisms have retained their innate immune system.  Whereas the adaptive immune system 
targets specific epitopes, the innate immune system instead is non-specific relying on the 
recognition of non-self, non-specific motifs on the surface of pathogens as well as recognising 
motifs associated with damaged self-cells. This broad non-specificity allows it to be effective in 
the binding, recognition and clearance of a broad range of pathogens.  
1.1.2 Innate Immune Mechanisms 
The innate immune system itself can be divided into three branches: barrier mechanisms, cellular, 
and humoral. These three branches all play a part in the innate immune systems primary weapon 
against pathogenic invasion – the inflammatory response. Barrier mechanisms include mucus 
layers, cilia and skin. They act to prevent invasion by foreign pathogens by presenting a physical 
barrier against invasion. For example, in the lungs the cilia lining the epithelia of the bronchioles 
work in conjunction with a mucus layer, to trap pathogens and move pathogens out of the 
 2 
 
airways. Whilst not fully effective (influenza has evolved to evade this host defence mechanism); 
the importance of this mechanism can be seen in smokers, for whom the mucus layer and cilia are 
damaged.  As a result they suffer from respiratory infections and irritation far more than a non-
smoker with a healthy airway. Other barriers include physiological barriers such as temperature 
and pH, which provide hostile conditions for pathogens to proliferate.  The prime example of this 
is seen in the stomachs of new-born babies. New-borns are born with far less acidic stomach 
contents than adults, and as a result are far more prone to certain stomach infections that an 
adult would never acquire (Wood, 2006). 
The cellular component of the innate immune system is made up of phagocytes and natural killer 
(NK) cells. Phagocytic cells include neutrophils, eosinophils, monocytes and macrophages. The 
process of phagocytosis involved the ingestion and breakdown of antigens. The antigens are 
endocytosed following adhesion to the cells surface via receptors. Large protrusions called 
pseudopodia extends around the attached antigen before encapsulating and internalising the 
agent in the phagosome. The phagosome then fuses with a lysosome to form a phagolysosome, 
the formation of the phagolysosome results in the combining of the hydrolytic lysosome 
components with the entrapped antigen. This results in the breakdown of the antigen ready for 
further processing. The degraded material is then either released from the cell via exocytosis or 
some epitopes/motifs are then further processed to be later presented on class II MHC for T 
helper cell recognition (Wood, 2006). 
The humoral arm of the innate immune system contains molecular instigators of the immune 
response. Humoral components are diverse and are an ancient component of our immune 
systems; this can be best shown by the presence of the pentraxins in the phylogenetically ancient 
horseshoe crab Limulus polyphemus. Their importance in the immune system is clear although 
their full roles and mechanisms are still poorly understood (Wood, 2006). 
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The pentraxins as mentioned above are a highly evolutionarily conserved family of multimeric 
proteins (Mantovani, et al., 2008), characterised by the presence of the 200 amino acid long 
pentraxin domain in their carboxy terminal. The pentraxins can be further categorised into two 
groups: long pentraxins such as PTX3, and short pentraxins such as C-reactive protein (CRP) and 
serum amyloid P component (SAP). Pentraxins and their homologues have been found in every 
species in which they have been sought indicating that the pentraxins are more than just an 
evolutionary artefact. In humans they are typically arranged into pentameric rings; however 
different conformations are seen in different species, such as the SAP-like pentraxin found in L. 
polyphemus is found in both stacked heptameric and octomeric forms (Shrive, et al., 2009). Whilst 
CRP and SAP share sequence homology of 51% (Gewurz, et al., 1995), as well as a pentameric ring 
formation where pentraxin helices lie on one face and the other face contains the calcium binding 
sites, they do differ in binding capabilities. Whilst CRP can bind to phosphocholine and 
phosphoethanolamine in a calcium dependant manner, SAP is only capable of binding 
phosphoethanolamine in this manner. These epitopes are found on a wide range of ligands such 
as the surface of damaged host cells and bacterial surface antigens; such as the C-polysaccharide 
from Streptococcus pneumoniae, and the lipopolysaccharide of Haemophilus influenzae. SAP is 
also implicated in the binding of some carbohydrates acting as a lectin, and is also involved in 
amyloid plaque stabilisation in Alzheimer’s disease (Gewurz, et al., 1995; Mold, et al., 2012).  CRP 
also has the ability to bind and activate C1q of the complement cascade as well as playing a role in 
the clearance of nuclear debris and binding to Fcγ receptors on immune cells. 
The complement system was originally named due to its complimentary activity alongside the 
adaptive immune system, since then it has become established as a key feature of the immune 
response. The complement system is made up of three pathways: classical, lectin and alternative, 
all  of which converge on C3, the most abundant of the complement molecules, and can 
resultantly lead to the formation of the membrane attack complex (MAC) and ultimately cell 
death (Sarma, & Ward, 2011). The alternative pathway which is constitutively active is triggered 
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by non-self-epitopes in the form of lipids, proteins or carbohydrates (Qu, et al., 2009). The 
classical pathway can be activated by C1qs interactions with antigen bound IgG and IgM or by 
antigen bound CRP, before C1r and C1s are activated leading the cleavage of C4, 2 and 3 (Sarma, 
& Ward, 2011). The lectin pathway is activated by carbohydrate epitopes on pathogens being 
recognised by Mannose Binding Lectin (MBL) – a member of the collectins. Homologous to C1q – 
both sharing the bouquet of tulips conformation – MBL then activates the MASPs (MBL- 
Associated Serine Proteases) which are equivalent to the C1r and C1s (Wallis, 2007). Figure 1.1 
shows the climax of the complement cascade is the formation of the MAC, made up of C5b678 
and multiple C9 molecules forming a pore that destabilises the osmotic pressure of the target cell, 
resulting in lysis (Sarma, & Ward, 2011).  
 
Figure 1.1. The Complement system. The classical, lectin and alternative pathways all have different origins and are 
all activated differently, however they all converge at C5 convertase (C4b2a3b/C3bBb3b) before following the 
pathway to termination at the membrane attack complex (MAC) (Wood, 2006). 
Complement offers more than just cell lysis, during the cascade the various complement 
components are cleaved by others and some of the fragments act as major anaphylatoxins – C3a 
and C5a (Sarma, & Ward, 2011). These two complement components put forth a number of 
effects on the inflammatory response. They are capable of: acting as powerful chemoattractants 
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for phagocytic cells to the site of infection/injury, vasodilators inducing the contraction of smooth 
muscle, and inducing histamine release from mast cells (Markiewski, et al., 2006; Sarma, & Ward, 
2011). Deficiencies in complement proteins have been associated with several pathologies 
including: systemic lupus erythematosus, atypical haemolytic syndrome and susceptibility to 
certain infections (Sarma, & Ward, 2011). 
The collectins are a component of the C-type lectin superfamily containing a collagen-like domain 
and as with all C-type lectins a carbohydrate recognition domain (CRD). They can be distinguished 
into two subgroups dependent upon the number of Gly-X-Y repeats in their collagen-like domain. 
Those with less form bouquet like structures such as lung surfactant protein A (SP-A) and 
mannose-binding lectin (MBL) and those with more adopt a cruciform conformation (Weiser, et 
al., 1997). Both SP-A and SP-D exhibit specific interactions with a variety of different 
microorganisms and white blood cells in vitro. They consist of several units of heterotrimeric 
subunits which will normally form one of the so called stalks. 
SP-D is a usually a dodecameric structure, although isolates have shown that it may form, 
monomers, dimers, trimers and even high-order multimers (Hartshorn, et al., 1996). SP-D in its 
dodecameric form, arranges itself in a cruciform structure with each branch of the cruciform 
being made up of a trimeric subunit. The individual chains are each made up 4 discrete regions; a 
cysteine rich N-terminus, a triple-helical collagen-like region similar to that describe in C1q, a neck 
region comprising of an -helical coiled coil, and finally the C-terminus globular head region – 
carbohydrate recognition domain (CRD). 
The primary structure of Surfactant protein-A (SPA) is similar to that of SP-D with a long cysteine 
containing N-terminus, a CLR, a neck region arranged again in an α-helical coiled coil and a CRD 
domain of 123 amino acids. SP-A shares morphology with both mannose-binding lectin (MBL) and 
C1q, as it has a hexameric structure. The SP-A molecule even shares the characteristic kink in the 
collagen-like region due to an interruption of the triplet Gly-X-Y, with SP-D and MBL. Each SP-A 
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subunit is made up of one SP-A1 chain and two SP-A2 chains which are closely related yet distinct 
(Kishore, et al., 2006). The few differences between SP-A1 and SP-A2 give rise to the various 
characteristics of the SP-A hexamer. Importantly the CRD of SP-A2 is capable of binding a broader 
range of carbohydrates than its compatriot SP-A1 (Oberley, & Snyder, 2003). Both surfactant 
proteins are key components of the host defence in the lung, capable of binding to alveolar 
macrophages with high affinity and promoting chemotaxis and phagocytosis of microbes (Sano, et 
al., 1999). SP-A was shown to bind to the LPS of bacteria via its lipid A region in the presence of 
Ca2+ and Na+ (Van Iwaarden, et al., 1994), whereas SP-D binds to the lipopolysaccharides of 
bacteria by the heptoses of the LPS core (Wang, et al., 2008).  
1.1.3 Proteases and Their Inhibitors 
 
Proteases are enzymes who accomplish their functions by cleaving proteins. Proteases have a 
range of cellular and physiological functions. Their roles include, signal transduction, defence 
against foreign pathogens and injury, development and proliferation, and programmed cell death.  
Proteases cleave proteins via a hydrolysis reaction, where a water molecule is added to a peptide 
bond. Peptide bonds are highly kinetically stable, taking with a half-life of 10-1000 years at neutral 
pH. The resonance structure of a peptide bond bestows it with a partial double bond character as 
demonstrated below in Figure 1.2. 
 
Figure 1.2. The partial double bond characteristic of peptide bonds where electrons are transferred between the 
nitrogen atom of the amine group and the carbon atom of the carbonyl group, leaving a negatively charged carbonyl 
double bonded to a positively charged amine group (Berg, et al.  2006) 
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As a direct result, the carbonyl atom is less electrophilic thus protecting it from nucleophillic 
attack. This in turn means that in order to cleave the peptide bond, proteases must facilitate the 
nucleophillic attack of a normally unreactive carbonyl group.  
Proteases can be classified in two ways: by site of action (exopeptidases and endopeptidases) or 
the preferred method, by reaction mechanisms. Classification by reaction mechanism reveals four 
classes of protease: 
 Serine proteases 
 Cysteine proteases 
 Aspartyl proteases 
 Metallo-proteases 
Simply put, serine and cysteine proteases act directly as nucleophiles to attack the substrate 
whereas, aspartyl and metallo-proteases activate water molecules as the direct substrate 
attacking species. 
Chymotrypsin is often used as the model serine protease (Berg, et al. 2006). It plays a key role in 
the digestive system of mammals and other organisms, and is part of a large family of proteases 
within the serine protease classification. Chymotrypsin cleaves peptide bonds selectively on the 
carboxyl-terminal side of the large hydrophobic amino acids such as tryptophan, tyrosine, 
phenylalanine and methionine. It does this utilising the catalytic triad, a mechanism seen in all 
serine proteases. By employing serine-195 as a powerful nucleophile, thus playing a central role in 
the catalytic mechanism of chymotrypsin and forming part of the catalytic triad. The side chain of 
serine 195 is hydrogen bonded to the imidazole ring of histidine 57, which in turn is hydrogen 
bonded to the carboxyl group of aspartate 102. These three residues make up the catalytic triad. 
This arrangement leads to the positioning and polarisation of Ser-195 and its hydroxyl group. In 
the presence of substrate this hydroxyl group is deprotonated with the histidine accepting the 
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proton, this generates an alkoxide ion, on the serine, which is a far superior nucleophile compared 
to an alcohol. The histidine is enhanced as a proton acceptor due to its orientation which is 
mediated by the aspartate residue. This catalytic triad arrangement is characteristic of the serine 
protease family. Once the substrate protein is bound, the oxygen atom of the serine side chain 
instigates a nucleophillic attack on the target peptide bond. This carbonyl carbon now has four 
atoms bound to it in a tetrahedral arrangement. This tetrahedral intermediate is unstable and as a 
result passes a negative charge onto the oxygen atom of the carbonyl. The charge is stabilised by 
interactions via the NH group of the protein in a site termed the oxyanion hole. This tetrahedral 
intermediate collapses to form the acyl-enzyme in a step enabled by proton transfer from the 
histidine to the amino group that was formed by the cleavage of the peptide bond. This releases 
the amine group of the cleaved protein, which is now free from the enzyme. A water molecule 
now takes the place of the now absent amine group and trigger the deacylation of the acyl-
enzyme intermediate, back to the tetrahedral intermediate formed earlier in the process.  This is 
mediated by the histidine acting as a proton sink and drawing a proton away from the water 
molecule leaving the resultant OH- to attack the carbonyl carbon of the acyl-enzyme, thus 
restoring the tetrahedral intermediate. The tetrahedral intermediate then breaks down to form 
the carboxylic acid product which is then released from the enzyme. This model of catalysis by 
chymotrypsin also applies for trypsin and elastase, homologues with 40% sequence homology. 
This method of catalysis has been proven using site-directed mutagenesis, to highlight the key 
residues, by substituting them for other residues resulting in a massive reduction in catalytic 
activity (Berg, et al. 2006).  
Cysteine proteases, proteolytic enzyme with a cysteine residue as their main catalytic agent, are 
found in the body in the form of caspases and cathespins, as well as papain, from the papaya. 
Cysteine proteases share a similar mechanism to those of the chymotrypsin family. However, due 
to the sulphur of the cysteine residue being a much better nucleophile than the oxygen of the 
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serine, the aspartate residue of the catalytic triad is not required and cysteine proteases have 
evolved without them. 
Aspartyl proteases utilise a pair of aspartic acid residues that work together, to facilitate the 
attack of a peptide bond by a water molecule. The water is activated and poised for 
deprotonation by one of the aspartic acids (in deprotonated form), whilst the other aspartic acid 
(in protonated form) polarises the carbonyl group of the peptide leaving it more susceptible to 
attack. Aspartyl proteases in the body include the blood pressure regulatory enzyme renin and 
the digestive enzyme pepsin. A more famous member of the aspartyl protease family is HIV-1 
protease. HIV-1 protease cleaves proteins at the appropriate places to help form the infectious 
HIV virion thus playing a key role in the HIV life cycle. 
The final class of protease inhibitor is the metalloproteinases. The active site of these proteases 
contains a metal ion predominantly zinc, that much like in the aspartyl proteases, activates a 
water to act as nucleophile molecule to attack the carbonyl group of the peptide bond. Examples 
of metalloproteinases are digestive enzyme carboxypeptidase A and the bacterial thermolysin.  
Native proteases play key roles in the inflammatory process; be it internally in granules of 
phagocytic cells or externally once the granules have been exocytosed.  Neutrophils alone contain 
at least six different serine proteases in their granules.  Capable of a wide variety of functions such 
as, the formation of neutrophil extracellular traps (NETs) which are capable of binding Gram-
positive and Gram-negative bacteria, they are key to the functional effectiveness of the 
neutrophilic response (Pham, 2006). The secretion of serine proteases by the neutrophils upon 
activation also leads to their regulation of the cytokine and chemokine responses. Given that 
dysregulation of the cytokine system can lead to a cytokine storm the system regulating them also 
requires built in control mechanisms. Matrix Metalloproteinases (MMPs) are a family of proteases 
that require a zinc ion present in their active site for catalysis to occur. The family consist of over 
25 members that range in size from 28kDa to 92kDa and they have been shown to play a key role 
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in a number of both disease and healthy states such as; wound healing, angiogenesis, cancer, 
arthritis and atherosclerosis (Lindsey, 2004). Due to the range of roles the MMPs have they bind 
act upon a broad spectrum of ligands, the extracellular matrix (ECM) linked ligands such as: 
collagen, elastin, and fibronectin; as well as non-ECM ligands such as interleukins, α2m and 
Angiotensin I (Lindsey, 2004). MMP function is determined by the localisation of its target ligand 
and so the same MMP can promote or inhibit different processes dependent upon ligand 
availability and location. MMPs have been shown to be down regulated by transforming growth 
factor – β (TGF-β), a known chaperone target for α2m, in addition to the fact that α2m is known 
to bind some MMPs suggesting α2m has a role in regulating them (Overall, & Lopez-Otin, 2002). 
Pathogens also employee a host of proteases in the functional processes. Some use pathogens as 
key virulence factors aimed at disrupting the immune response, disrupting the blood clotting 
system to avoid immobilisation, increasing inflammation and tissue damage to aid their 
proliferation (Armstong, 2006). Others such as the aspartyl protease HIV-1 protease play key roles 
in the life cycle of the pathogens. Proteases are key molecules in both the host and pathogens, in 
that they can be used to regulate vital systems, as well as being a means of attack. 
Protease inhibitors occur in two classes: active-site protease inhibitors and the α2-macroglobulin 
family of protease inhibitors. Active site inhibitors as their name would suggest, prevent 
proteolysis by binding to the active site of the protease and thus blocking its proteolytic activity. 
Protein protease inhibitors that inhibit the active site can be further categorised based on the 
class of protease they inhibit: a convention that does not apply to members of the α2-
macroglobulin family as they inhibit proteases from all the major classes of protease. Serine 
protease inhibitors, inhibit proteases such as chymotrypsin, elastin and trypsin, serine proteases. 
Cysteine protease inhibitors are capable of inhibiting enzymes such as the caspases and papain. 
Protease inhibitors are important for the regulation of healthy processes going on within the 
body. C1Inh is a serine protease inhibitor deactivates C1 of the complement cascade by 
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dissociating C1r2s2 to dissociate from the C1 molecule. α1-proteinase inhibitor (α1-PI) is the major 
serine proteinase inhibitor found in circulation, a member of the serpin  family of proteinase 
inhibitors, is part of the acute phase response and  inhibits neutrophil elastase reducing the tissue 
damaged caused during neutrophilic degranulation (Hiemstra, 2002). Secretory leucocyte 
protease inhibitor (SLPI) is a broadly specific serine protease inhibitor capable of inhibiting 
enzymes such as: neutrophil elastase, cathespin G, trypsin, chymotrypsin, chymase and tryptase. 
Its homologue Eladin inhibits neutrophil elastase and proteinase 3. There is one family of protease 
inhibitors that do not discriminate against the protease mechanism of action – the α2-
macroglobulin family. 
 
1.2 The α2-Macroglobulin/ Thiol Ester Domain Superfamily 
The protease inhibitor family I39, is often referred to as the α2-macroglobulin family. This family 
of protease inhibitors in humans includes: α2-macroglobulin, pregnancy-zone protein (PZP), C3, 
C4a, C4b and C5 of the complement system, CD109 and CPAMD8 (Li, et al., 2004).  Other higher 
organisms, and invertebrates share homologues with α2m as well as α1I3 of rats and 
ovomacroglobulin of avian and reptile eggs (Armstrong, 2010). Family members share a distinct 
structural homology with regards to their domain organisation, demonstrated in Figure 1.3. 
Members of the α2m family have been shown to bind and render proteases from each major class 
inactive. They also differ in their mechanism. Rather than target the active site as is the case for 
all other protease inhibitors, the α2m family entrap their target protease inside a molecular cage 
in a manner homologous to a Venus fly trap.  
Pregnancy Zone Protein (PZP) is a member of the α2m superfamily that currently is shrouded in 
mystery. It’s found in the same gene cluster as the other members of the α2m family members on 
chromosome 12p12-13. Unlike α2m it is arranged as a homodimer of 360 kDa (Sand, et al., 1985) 
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despite that it shares 71% sequence homology with α2m (Devriendt, et al., 1991). PZP is typically 
found at trace levels in the plasma (<0.01mg/ml), during childhood levels between genders vary 
little however due to the variation in female hormone levels in adulthood, with further gains seen 
during pregnancy as early as week 5 of gestation and peaking at term with an increase of 100-200 
fold above preconception levels (Tayade, et al., 2005). PZP levels have also been shown to be 
elevated in men infected with HIV-1 (Sarcione & Biddle, 2001).The exact nature of its function like 
much of the innate immune system is still not fully clear but it is believed be a key mediator of 
foetal protection as they synergistically inhibit T cell proliferation and IL-2 production by the 
mother (Skornika, et al., 2004). 
Complement components C3, C4a, C4b and C5, are α2m family members and innate immune 
system members, that are well characterised and play key roles in the mediation of the immune 
response. C3 is considered the key complement protein as it is the convergence point for all three 
systems within complement, classical, lectin and alternative. It is capable of interacting with a 
number of other complement proteins such as receptors, regulators and proteases as well as 
none-complement proteins such as viral and bacterial proteins (Janssen, et al. 2005). When the 
mature C3 molecule, 1641 amino acids long and 187kDa, is cleaved it results in two fragments C3a 
which is 9kDa in size and has anaphylatoxic effects and C3b the major fragment (177kDa), which 
leads to the exposure of the thiol ester domain (TED) which acts as a key binding site for the 
interactions of C3b. C3 is made up of a β and an α chain of 991 and 645 residues respectively that 
form 13 domains; 8 of which are the characteristic macroglobulin domains (MG1-8), a linker 
domain (LNK), an anaphylatoxin domain (ANA) a CUB domain with an inserted TED and a C345 
domain, which exhibits a netrin-like fold. The MG domains are arranged in a manner similar to 
α2m in that they form a one and a half turn super-helical structure. When the C3 molecule is 
processed into C3c major domain rearrangements take place showing a molecular rearrangement 
and flexibility seen in α2m (Janssen, et al. 2005). 
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C4 is another key component of the innate immune system, is a 203kDa complement protein 
which takes part in both the lectin and classical pathways. C4 exists as two isoforms C4A and C4B, 
not to be confused with C4 fragments C4a and C4b, they are isoforms of the intact parent C4 
molecule with over 99% sequence identity but the C4B isoform has been shown to have 
significantly higher cytolytic effects (Dodds, & Law, 1998). C4 is cleaved by both MASP-2 protease 
and C1s of the lectin and classical pathways respectively. This forms C4a which is an anaphylatoxin 
and C4b the major fragment which goes on to form C3-convertase (C4b2a) by binding to the C2a 
fragment, or is capable of acting as an opsonin for phagocytic clearance via the complement 
receptor 1 (CR1) expressed on their cellular surface (Van den Elsen, et al. 2002). The C4 molecule 
is made up of three chains β, α, and γ with molecular weights of ~ 75kDa, 93kDa and 38kDa 
respectively (Gigli, et al. 1977). C4 in terms of domain organisation is very similar to the C3 
molecule with 8 MG domains, a LNK and ANA domain inserted into MG6, and the CUB domain 
with the TED inserted into it sitting between MG7 and MG8, a tetra arginine (RRRR) processing 
site that is in an insert of 46 amino acids of the loop between βA and βB of MG8, before the C 
terminus is finished off with the C345C domain (Janssen, et al. 2005). Again C4 shows a great deal 
of reorganisation, a family trait upon activation due to the inherent flexibility in its design 
(Kidmose, et al. 2012). 
C5 of the complement system is a 196kDa protein, made up of a β and an α chain read from N to 
C terminus as seen in C3 and C4 with the addition of the γ chain in C4, is key to the complement 
cascade as it’s cleavage leads to the formation of the membrane attack complex (MAC), the 
cytolytic component of the complement system. It is cleaved by C5 convertase of the classical and 
lectin pathways C4b2a3b or the C5 convertase of the alternative pathway C3b2Bb, specifically 
between Arg751 and Leu752 leading to the formation of C5a the anaphylatoxic fragment, which 
binds to the G-protein coupled receptor C5aR triggering an intracellular signalling cascade that 
leads to chemotaxis and the release of proinflammatory mediators from granulocytes,  and the 
major fragment and MAC constituent C5b, which binds to C6 and then C7 to initiate MAC 
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formation (Fredslund, et al. 2008). C5 like its fellow complement-component α2m super family 
members contains 8 MG domains, of which MG1-6 are arranged in the characteristic right-handed 
super-helix. The LNK domain and the ANA/C5a domain are inserted into MG6, and the LNK 
domain is packed between MG1-2 and MG4-6. MG7 then connects the MG1-6 super-helix to the 
CUB domain which features the inserted TED-homologue C5d, which lacks the presence of the 
thiol ester bond making C5 the only member of the α2m superfamily to not contain the thiol 
ester. Following CUB and the inserted C5d, is the MG8 domain which packs tightly with the 
previous two mentioned domains to form a super domain before feeding into the complement 
component characteristic domain of α2m family members, C345C (Fredslund, et al. 2008). The 
above mentioned CUB, C5d/TED, MG8 packed super domain is a conserved characteristic of the 
superfamily and serves to protect the thiol ester ,which in C5d is not present. 
CD109, a member of the α2m superfamily that maintains the characteristic domain organisation 
and large molecular weight (170kDa) is a, glycosylphosphatidylinositol (GPI)-linked glycoprotein 
found on the surface of activated platelets, T-cells and a subset of haematopoietic stem cells (Lin, 
et al. 2002). Its mechanisms and structure are still poorly understood but it has been shown to be 
a co-receptor form transforming growth factor-β (TGF-β) and acts as an inhibitor for TGF-β 
mediated signalling pathways. TGF-β is also a binding target for the chaperone activity of α2m; 
one could propose that α2m potentially delivers bound TGF-β to its family member CD109 in an 
immunoregulatory manner (Man, et al. 2012). Although no crystal structure data exists it is 
believed to exhibit similar domain organisation as seen with the other family members, including 
the highly conserved thiol ester domain (Solomon, et al. 2004). 
CPAMD8 – complement 3 and pregnancy zone protein-like, α2-macroglobulin domain-containing 
8 – is a recently discovered member of the α2m family that is found in a number of species, such 
as pigs, cows, and Fugu sharing sequence identity of 65-85%. Its exact function is unknown but it 
is known to be highly expressed in the brain and highly responsive to stimulation by IL-1β and IL-6, 
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indicating involvement in the immune response. It is like CD109 membrane bound and like other 
members of the α2m family CPAMD8 has domains that may express proteinase activity. Its C-
terminal domain contains a Karzal motif which is often found in serine protease inhibitors (Li, et 
al., 2004). 
 
Figure 1.3. Domain schematic representations of member of the α2m superfamily. A) The domain 
organisation of C3 and C5 of the complement system with the labelled MG domains following through to 
part B), C), and D) as well as the blue CUB domain and the Pink TED/C5d, the green LNK and the red ANA 
domains as well as the yellow C345C domain, which are characteristic of the complement components of 
the α2m family, carried through to part B). B) The C4 domain organisation similar to C3 and C5 but with a 
tetra Arg insert in MG8. C) The domain organisation of α2m with the bait region domain (BRD) inserted 
into MG6 in place of the LNK and ANA domains seen in the complement proteins due to their differing 
functions. D) The poorly understood CD109 is believed to exhibit similar characteristics of domain 
organisation to its fellow family members and is known to hold a thiol ester bond in its sequence. 
Adapted from (Janssen, et al. 2005). 
The structural evidence to hand has led to the development of a hypothesis that, there existed an 
ancestral molecule existed comprised of eight MG domains thought to have arisen from gene 
duplication events. This is thought to be the origin of the family due to the low levels of sequence 
identity between homologues in these domains thus indicating that these areas of sequence are 
those that have diverged furthest. The other domains are believed to have arisen from gene 
insertion events, which are characterised by domains existing within the loop regions of other 
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domains. The α2m family proteins have two such sites: MG6 and the loop region between MG7 
and 8. The emergence of this as the α2m family is believed to be marked by the insertion of the 
CUB domain with the TED inserted within it between MG7 and MG8. The occurrence of the TED 
α6-α6 fold in enzymes potentially indicates that the TED fold existed separately before being 
incorporated into the structure. Finally to further delineate the line, the insertion of genes for the 
BRD in α2m, and the LNK, ANA and C345C domains of the complement proteins, marks the 
emergence of α2m and the complement system in the innate immune system more than 700 
million years ago (Janssen, et al. 2005; Sahu, & Lambris, 2001).  
1.2.1 Human α2-Macroglobulin 
Human α2m is a key protease inhibitor that can be thought of more as a protease binding 
molecule due the fact that proteases remain active once bound. It is capable of binding a broad 
range of proteases due to its bait region containing many cleavage sites for proteases of all 
classes. Implicated in a number of disease pathologies, α2m is a key protein in the human innate 
immune system. 
1.2.1.1 Synthesis and Gene Organisation 
The human α2m gene is approximately 46kb long and spans 36 exons which range in size from 21 
to 229 bp with introns ranging from 145 to 7.5kb. A single copy gene in the human genome it is 
located on chromosome 12p12-13, as part of a gene cluster containing α2m, an α2m pseudogene, 
and PZP (Matthijs, et al. 1992; Borth, 1992). The α2m gene has been shown to contain mutations 
in the bait region as well as the thiol ester domain (TED); however despite this no functional 
changes were present (Poller, et al. 1992). α2m is synthesised in a number of cells, hepatocytes, 
astrocytes, monocytes, macrophages and lung fibroblasts all included, this broad range of cell 
types suggests that α2m gene expression is under the control of cell-type specific regulatory 
elements; with the 5’ flanking region of exon 1 of the gene containing regulatory sequences 
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homologous to the IL-6 response element as well as to the HP-1 element which is metal 
responsive, potentially important given the role of Zn2+ in the role of some cytokine binding 
(Borth, 1992). Il-6 has been shown to induce α2m synthesis in human neuronal cells, which 
matches with the IL-6 response region homology mentioned in exon 1. It is clear from a number 
of studies investigating α2m and its homologues from other species that it’s synthesis in several 
‘normal’ tissues is under humoral control (Shi, et al. 1990; Gaddy-Kurten, & Richards, 1991; 
Ramadori, et al. 1991). The synthesis and expression on cellular surfaces of the α2m receptor LRP-
1 is also under humoral control and has been shown to be regulated by insulin in adipocytes. 
1.2.1.2 Structure of Human α2-Macroglobulin 
Due to the unique mechanism of α2m, its structure has been a research interest for a number of 
years. Initial work utilising circular dichroism and gel electrophoresis (Frenoy, et al., 1977; Barrett, 
et al., 1979)  gave rise to it being known that α2m is a ~725kDa, tetramer, where the smallest 
covalent unit is the dimer molecule, and each subunit being made up predominantly of β-sheets 
with a very low number of α-helices. Gel Electrophoresis work (Figure1.4) was also the first to 
demonstrate the two forms of α2m, fast form – reacted with a protease or a small amine, and the 
slower native form (Barrett, et al., 1979). 
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Figure 1.4. Gradient polyacrylamide gel of various α2m morphologies (Barrett, et al. 1979). Band A – 
Native/’Slow’ form α2m. Bands B&C – Reacted/’Fast’ form α2m, reacted with trypsin and methylamine 
respectively. Despite the increase in molecular weight the complex is smaller than the native form and 
thus can travel further through the gel, and that the overall size is the same irrespective of protease or 
methylamine reaction, suggesting similar mechanisms following reaction. Band D – Dimeric unit of α2m, 
split from tetrameric form my exposure to pH 2.0. Band E – The monomer subunit of α2m, following 
exposure to dithiothreitol. Band F – Reacted/’Fast’ form α2m-trypsin, reduced with dithiothreitol. 
Initial studies to the crystal structure of α2m yielded little success with a maximum resolution of 
9Å being achieved (Andersen, et al., 1991; Andersen, et al. 1994), however this resolution was not 
sufficient to yield any structural data. In 2012, the crystal structure of human α2m reacted with 
methylamine was solved to 4.3Å (Marrero, et al., 2012). 
 
As previously stated human α2m is a ~720kDa homotetramer arranged into two non-covalently 
linked dimers. Each of these dimers can be thought of as an active unit and thus human α2m has 
two active units as opposed to the one of Limulus α2m. Each individual subunit is ~180kDa in size 
and is 1451 amino acids long. It has been shown that each subunit of α2m has 8 glycosylation 
sites via the N4 of the following residues: Asn32, 47, 224, 373, 387, 846, 968, 1401 (Sottrup-Jensen, et al., 
1984). The bound oligosaccharides are largely heterogeneous in size, solvent exposed, and are 
predominantly N linked acetylglucosamine (N-GlcNAc), but also containing galactose, mannose, N 
– acetylneuraminic acid, and fucose. The molecule shares a great deal of homology with the 
A               B           C          D            E             F       
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complement proteins C3, 4 &5. The α2m subunit contains  seven fibronectin type 3 folded 
macroglobulin domains (MG), an α-helix based thiol ester containing domain (TED), the 
physiologically significant bait region domain (BRD), a complement protein subcomponents 
C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1 (CUB) domain, and a 
receptor binding domain (RBD) (Marrero, et al., 2012; Wyatt, et al., 2012). The first seven 
domains of the human α2m monomer are of the MG class mentioned previously, and are referred 
to in the literature and from this point on in this work as MG1-7. The domains are approximately 
110 amino acids in length, comprising seven β-strands arranged in anti-parallel β-sandwiches of 3 
and 4 strand sheets. The CUB domain is comprised entirely of β-sheets and is made up of 116 
amino acids arranged as two four-stranded antiparallel β-sheets. The TED domain is a 315aa 
helical based domain with an α-α-toroid topology, arranged of six concentric α-hairpins organised 
as a six fold α propeller around a central axis giving rise to a thick disc with two parallel flat sides, 
and features a β-hairpin between α9 and α10. The RBD also sometimes known as MG8 is a 129 
amino acid C-terminal domain which is a variant of the typical Mg domain architecture with a β-α-
β fold inserted, resulting in a four stranded and a five stranded twisted sheet. The BRD is a 126 
amino acid long flexible domain which is roughly 85Å in length. And is more compact in structure 
at Gln579 – Thr705, and includes a long loop region Cys619 – Asp665 which protrudes from the 
monomer and is the tethering loop of the BRD (Marrero, et al. 2012).  
 
The first six MG domains are arranged as a compact ellipsoidal one and a half turn right-handed, 
super-helix as highlighted by Figure 1.5 taken from the supplementary materials to (Marrero, et 
al., 2012).  
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Figure 1.5. A) Internal view of the right-handed one and a half turn ellipsoidal super-helix arrangement of 
MG1-6 including the BRD in blue showing entrance one. B) External view of entrance one from outside of 
the tetramer only showing MG3-6 inclusive of the BRD. From the supplementary materials to (Marrero, 
et al. 2012). 
The result is such that MG3-6 enclose a central ellipsoidal opening known as entrance 1 (Marrero, 
et al. 2012). Access to this entrance is mediated by the glycan chain that is bound to Asn224 of 
MG3, one of the encircling MG domains. MG7 closes the super-helix and forms the upper limit of 
the molecule. Following on from MG7 is the CUB domain which is inserted adjacent to MG2, with 
the TED domain inserted between β3 and β4, which sits just below the CUB domain, and 
consequently lies lateral to MG1 and MG2, keeping the overall structure compact. After the 
sequence re-joins and completes the CUB domain, the sequence then enters the RBD, which sits 
behind the BUB domain, tight next to MG3 and contacts TED and CUB domains (Marrero, et al. 
2012). This overall structure leads to a convex front face and a concave back face, which leads to 
the formation of a large cavity at the rear of the monomer that harbours the BRD. 
1 
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Figure 1.6. A) A schematic representation of the domain organisation/tertiary structure of a subunit of 
human α2m; with the bait region represented as a dashed line and the star demonstrating a potential 
protease cleavage site. B) Ribbon and space fill representations of the tertiary structure of an α2m 
subunit (convex face) with the green arrow indicating the location of the bait region. C) The back/ 
concave face of the α2m subunit from humans demonstrating the bait region to the rear of the molecule. 
Diagrams edited from (Marrero, et al. 2012). 
The BRD interacts with MG1-3 as well as MG-5 the proximities of which can be seen in Figure 
1.6A. The bait region itself, Pro667 - Thr705 sits in the lumen of the cavity formed by the other ten 
domains making it highly accessible to potentially proteolytic targets, and its high flexibility 
allowing it to twist and fit almost any active-site pocket. Native α2m in human circulation is a 
tetramer and key to its tertiary and quaternary structure are the disulphide bonds present. Each 
subunit of α2m contains 13 disulphide bonds. 
 
Figure 1.7. Domain schematic of human α2m depicting the residues for each domain as well as locations of N-linked 
glycosylation sites (shown with a black diamond), and disulphide linkage sites (Marrero, et al. 2012) 
 Eleven of which are intra-subunit between residues; Cys25 - Cys63, Cys228 - Cys276, Cys246 - Cys264, 
Cys447 - Cys540, Cys572 - Cys748, Cys619 - Cys666, Cys798 - Cys826, Cys824 - Cys860, Cys898 - Cys1298, Cys1056 - 
Cys1104, Cys1329 - Cys1444, as depicted in Fig. 1.7. There are two inter-subunit disulphide bonds 
which provide covalent linkage between subunits via residues: 255A-408B, and 408A-255A, where 
A and B represent different subunits (Marrero, et al., 2012).  The interaction surface between two 
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monomers of a dimeric unit is symmetrically shaped by domains MG3 and MG4, which meet at 
the top centre of the complex, and both subunits are linked by their back/concave faces. Similarly 
symmetrical contacts are made at the MG4 and TED interfaces between subunits. The 
dimerisation of subunits leads to the formation of entrance 2. Entrance 2 is encompassed by 
MG2, MG3, MG7, CUB and TED of one monomer with the disulphide linked subunit contributing 
MG4 to the overall structure of entrance 2. 
 
Figure 1.8. Entrance 2 between a subunit of human α2m and its disulphide linked dimeric partner 
including the MG3 of the disulphide linked subunit for completeness. One subunit providing MG2, MG3, 
MG7, CUB and TED towards the entrance (solid colours), and the disulphide linked subunit providing MG4 
to the entrance super structure (semi-transparent colours). From the supplementary materials to 
(Marrero, et al. 2012). 
The tetramer is a result of non-covalent interactions between the two function unit dimers, with 
the bottom dimer referred to as the ‘vicinal’ dimer, and the subunits arranged in a manner that 
the subunits can thought of relative to a single subunit as, disulphide linked, vicinal and opposite. 
As illustrated in Figure 1.8 (Marrero, et al. 2012). 
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Figure 1.9. H- orientation, ribbon diagram of the human α2m tetramer, with trapped proteases 
demonstrated in Connelly surface in light blue and pink, as well as the RBD of the green subunit 
highlighted in yellow. Relative to the green subunit, the pink is the disulphide linked and completes the 
functional dimer. The blue subunit is vicinal to the green and the orange is opposite to the green. The 
green and pink dimer is vicinal to the blue and orange dimer. Diagram edited from (Marrero, et al. 2012) 
The TED from each subunit interacts with the TED from its vicinal subunit, therefore in Figure 1.9. 
the TED domains from the blue and green subunits are interacting with one another as are the 
TED domains form the pink and orange subunits. Further quaternary interactions occur between 
the BRDs of opposite subunits via the BRD tethering loop. 
As discussed entrance one in present in each subunit of α2m and two of entrance 2 per dimer, 
thus providing eight entrances to the molecule, there are though other entrances to the central 
‘prey chamber’. Entrance 3 is formed upon tetramerisation of α2m, this entrance is framed by the 
TED of one monomer, the tethering loop of the BRD of its vicinal subunit, and the MG4 and BRD 
of its disulphide linked subunit, illustrated in Figure 1.10. And in total there are four of these 
entrances bringing the total number of entrances to the prey chamber to twelve (Marrero, et al. 
2012). 
 24 
 
 
Figure 1.10. Entrance 3 of which in the whole tetrameric α2m there are four. The TED of one subunit is 
flanked by the MG4 and the BRD of its disulphide linked partner, and the tethered loop of the BRD from 
its vicinal subunit. From the supplementary materials to (Marrero, et al. 2012). 
Access to entrance 3 much like entrance one is mediated by the glycan chains bound to the 
molecule at Asn373 and Asn387. The central prey chamber is roughly 60Å in diameter which is 
sealed at the upper and lower limits by the MG3 and MG4 that are disulphide linked and thus 
mediate dimerisation. The prey chamber however isn’t simply a large cavity. It is restricted at its 
centre by loops provided by the TEDs resulting in two halves of the prey chamber; these loops are 
known collectively as the cavity-narrowing belt. As a result the prey chamber has room to 
accommodate two 20-30kDa proteases, one for each functional dimeric unit. In addition to the 
prey chamber the molecular arrangement results in the addition of elongated volumes housed by 
each concave face of the four subunits known as ‘substrate ante-chambers’. These substrate ante-
chambers house small substrates (6-9kDa), small enough to pass through any of the twelve 
entrances described in activated α2M; subsequently providing access to the proteases and their 
active sites, which is evident in experimental data (Marrero, et al. 2012; Barrett, et al. 1979).  
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Table 1.1. Structural feature of human α2m as found in the crystal structure (Marrero, et al. 2012; 
Rehman et al. 2013). 
Structural features  of human α2m  
Quaternary Structure Homotetramer 
Molecular Weight 720kDa 
Dimensions 140 x 140 x 210Å 
Chain Length (per subunit) 1451 
a – Alpha Helices 17 
b – Beta Strands 67 
Disulphide bonds 13 
Prey Chamber Dimensions 60Å diameter 
Prey Chamber Entrances 12 
 
In short the human α2m tetramer is a highly ordered complex which utilised its quaternary 
structure to act as a molecular venus-fly trap for protease molecules of 20-30 kDa, the flexibility in 
its structure leading to the molecular mechanism for which it is known is vital to its function. 
1.2.1.3 The α2-Macroglobulin  Receptor 
The α2-macroglobulin receptor/Low Density Lipoprotein Receptor (LRP-1/CD91) is a 600kDa cell 
surface glycoprotein (Kristensen, et al., 1990).  LRP-1 is a noncovalently linked heterodimer of 
515kDa and 85kDa subunits, following proteolysis is the trans-Golgi (Borth, et al. 1994). Its action 
is regulated by a 39kDa receptor associated protein (RAP), which contains a heparin binding 
domain (Borth, 1992; Herz, et al.1991). LRP-1 has been found on macrophages, monocytes, 
astrocytes, fibroblasts, hepatocytes, adipocytes and syncytiotrophoblasts, and it’s presence on 
the surface of early differentiated monocytes can be seen as a marker in chronic myelomonocytic 
leukemias (Moestrup, et al. 1990; Moestrup, & Hokland, 1992).  
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As a member of the LDL-receptor gene family, it shares the five common structural units that 
make up the members of this protein family. The cysteine rich ligand binding/complement 
repeats (CR) that occur in clusters of 2-11 individual repeats, the primary binding site for ligands 
of LRP-1 that have had their binding sites mapped (Herz, & Strickland, 2001;Neels, et al. 1999). 
The epidermal growth factor (EGF) precursor homology domains, these are made up of the two 
EGF receptor-like repeats and six YWTD domains in a propeller arrangement with another EGF 
following the propeller (Springer, 1998). These two motifs are repeated giving rise to 4 clusters 
within the receptor structure. Each cluster contains a varying amount of complement repeats, 
with the four clusters containing 2, 8, 10, and 11 repeats respectively (Dolmer, & Gettins, 2006). 
At the interface between the ligand binding clusters mentioned above and the membrane 
spanning region are six EGF repeats. The cytosolic side of the transmembrane region is a tail 
region containing two NPxY motifs that act as a molecular dock for the endocytic and cell 
signalling proteins (Trommsdorff, et al. 1998) 
α2M binds to its receptor via its receptor binding domain (RBD) in a reaction that is pH 
dependant, where a pH exceeding an acidity of 6.8, results in no further interactions between 
protein and receptor (Yamashiro, et al. 1989). The conformational change triggered by reaction 
with a protease or a small amine, results in the exposure of the RBD and thus allowing the binding 
of α2m by the receptor and thus the clearance of the bound proteases (Enghild, et al., 1989; 
Holtet, et al. 1994). α2M has been shown to bind to CR3,4, & 5 of cluster II of LRP-1 (Dolmer, & 
Gettins, 2006) although it has also been mapped to the CRs of cluster IV as well (Neels, et al. 
1999). The interaction between CR 3, 4 & 5 has been mapped to two lysine residues within the 
RBD, Lys1370 and Lys1374 (Dolmer, & Gettins, 2006). Lys1374 is conserved between species whereas 
Lys1370 is replaced with a glutamic acid residue in the α2M homologue from Limulus polyphemus, 
and this change may responsible for fast-form Limulus α2m reacting with LRP-1 but with a lower 
affinity than its human counterpart (Armstrong, & Quigley, 1999). Fast-form α2m is the activated 
form of the molecule referred to as such due to its ability to permeate through gels and 
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membranes faster than the native form of the molecule and thus behaving like a molecule of 
smaller molecular weight.  
 
LRP-1 has been shown to recognise no fewer than 30 distinct ligands, from several families of 
proteins serving a broad range of functions, making CD91 a broad spectrum yet highly specific 
receptor protein capable of mediating several immune functions (Herz, & Strickland, 2001). LRP-1 
has been shown to bind with α2M, ApoE, MMPs 9 and 13, hsp-96 but perhaps one of its most 
interesting interactions is that with calreticulin. It has been shown that calreticulin binds to LRP-1 
on the surface of cells (Basu, et al., 2001). Calreticulin has also been shown to bind to the collagen 
region of collectins, even when surface bound via LRP-1 (Eggleton, et al., 1994; Vandivier, et al., 
2002). This then allows SP-A, SP-D, MBL and potentially C1q, although this is currently disputed 
(Duus, et al., 2010), once ligand bound and in an aggregate state to present their collagen tails 
and producing a proinflammatory response, via upregualtion of P38 and NFκB (Gardai, et al. 
2003). 
 
1.2.1.4 Functional Mechanisms and Targets 
A lot like the protease binding capabilities of α2m, its functions too are broad, further adding to 
the speculation that α2m is a key mediator of the immune response. Along with its ability to bind 
and trap proteins its glycosylation allows it to be bound by lectins of the host system and thus 
offer a protective role. It has also been shown to act as a molecular chaperone for various 
cytokines. 
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1.2.1.4.1 Protease Clearance 
The importance of protease inhibitors cannot be stressed enough. Both parasites and bacteria 
have been shown to secrete and express proteases on their cellular surfaces. These proteases 
contribute greatly to their virulence. Across the plethora of invasive bacteria and parasites, every 
major class of protease is seen to act as a virulence factor, showing the breadth of their 
importance in pathogenicity (Armstrong, 2006). Invasive proteases seek to disrupt the natural 
defences against their invasion; such as the blood clotting system which plays an integral role in 
the immobilisation of the invasive agents. Proteases that attack this system seek to liberate the 
entrapped agents thus allowing their systemic dispersal. Some bacteria such as Yersinia pestis, the 
pathogen responsible for the black plague, go about this in an indirect manner; by releasing 
proteases targeted at plasminogen resulting in the activation of plasmin, they can thus trigger 
host fibrinolytic pathways to achieve their goals (Sodeinde, et al., 1992). 
Table 1.2. Examples of Virulence Factors from a variety of pathogens, and their roles in pathogenesis. 
Table adapted from (Armstrong, 2006) 
Pathogen Protease Role in pathogenesis References 
S. stercoralis, S. manson Ss40 Epidermal Invasion (Brindley, et 
al. 1995; 
Cohen et al., 
1991) 
Seratia, Pseudomonas Serratia 56K, Pseudomonas 
alkaline protease 
Cytolysis (Internal 
attack) 
(Maeda,  et al. 
1987; Molla, 
et al. 1987) 
E. histolytica Cysteine proteases Cytolysis (External 
attack) 
(Reed, et al., 
1993; Reed, et 
al., 1989a) 
P. chaubaudi  P68 Intracellular invasion (Breton, et al. 
1992) 
S. pyogenes, Y. Pestis,  
B. burgdoferi 
Pla, OspA Fibrinolysis (Fuchs, et al., 
1994; Poon-
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King, et al., 
1993, 
Sodeinde, et 
al. 1992) 
Pseudomonas, Serratia, 
Candida, C. salmositica 
Elastase, Serratia 56KDa 
Protease 
Depletion of 
protease inhibitors 
(Khan,  et al. 
1994; 
Rasmussen,  et 
al., 1999; Zuo, 
& Woo, 1997) 
Streptococcus, Serratia, 
Candia, C. salmositica 
Streptococcal C5a 
Protease, Candida acid 
Protease, Entamoeba 
Cysteine protease 
Deactivation of 
complement 
(Cutler, et al., 
1993; Reed, et 
al., 1989b, 
Schenkein, et 
al., 1995) 
Streptococci, Serratia, 
Candida, P. gingivalis 
IgA1 protease, Serratia 56 
K, Candida protease  
Cleavage of 
immunoglobulins 
(Kilian, & 
Reinholdt, 
1986; Plaut, 
1983) 
E.coli, Y. pestis Microbial plasminogen 
activators 
Plasmin generation 
via plasminogen 
cleavage. 
(Leytus, et al., 
1981; 
Sodeinde, et 
al., 1992) 
 
Table 1.2, highlights the key roles of proteases and thus the need to neutralise them. As 
previously mentioned there are a host of protease inhibitors at the immune systems disposal, the 
majority of which have extremely high specificity consequently the presence of a pan-proteinase 
inhibitor such as α2m and its family members is a key weapon in the arsenal of the immune 
system. 
The protease binding activity of α2m has often been described as promiscuous due to its ability to 
bind a broad range of proteases, from each major category of protease. This broad specificity is 
due to the bait region, a 39 amino acid long loop region within the BRD (Sottrup-Jensen, et al., 
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1989). Within this loop region are motifs of amino acids that are cleavage sites for a broad range 
of proteases shown below in Figure 1.11. 
 
Figure 1.11. The Bait Region of the human α2m molecule. A 39 amino acid long free loop region 
accessible by proteases for cleavage thus activating α2m and causing the cleavage of the thiol-ester 
domain and ultimately the entrapment of the protease following the molecular reorganisation of α2m 
(Sottrup-Jensen, et al., 1989). 
 
To highlight the extent at which this sequence of amino acids is capable of binding a broad range 
of protease inhibitors, I submitted the sequence of the bait region to the Expasy program 
PeptideCutter, which highlights the various cleavage sites for a range of proteases, typically used 
for proteomics and users of mass spectrometry but will serve the purpose of highlighting the 
broad nature of the bait region well in Figure 1.12. 
 
Figure 1.12. The PeptideCutter analysis of the bait region of human α2m Figure 1.10 with accompanying 
table explaining the data (Table 1.3). All but five residues provide cleavage sites for the proteases 
selected, thus highlighting just how effective the bait region is at providing cleavage sites for proteases.  
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Table 1.3. Protease cleavage site data from PeptideCutter analysis of the bait region of α2m. 
Protease 
code 
Protease No. of 
cleavages 
Position of Cleavage Sites Class of 
Protease 
ArgC Arg-C Proteinase 3 15, 26, 30 Serine 
AspN Asp-N endopeptidase 1 21 Metallo 
CNBr CNBr 2 8, 24 - 
Ch_hi Chymotrypsin – high specificity 3 6, 18, 19 Serine 
Ch_lo Chymotrypsin – low specificity 12 3, 6, 8, 9, 14, 18, 19, 24 
28, 31, 33, 38, 
Serine 
Clost Clostipain 3 15, 26, 30 Cysteine 
HCOOH Formic acid 1 22 - 
Glu Glutamyl endopeptidase 5 7, 12, 20, 35, 36 Serine 
Elast Neutrophil elastase 5 16, 23, 29, 32, 34 Serine 
Pn1.3 Pepsin (pH1.3) 5 3, 13, 14, 18, 31 Aspartyl 
Pn2 Pepsin (pH >2) 9 3, 5, 6, 13, 14, 18, 18, 19, 
31 
Aspartyl 
Prot K Proteinase K 17 3, 6, 7, 12, 14, 16, 18, 19, 
20, 23, 29, 31, 32, 34, 35, 
36, 39 
Serine 
Staph Staphylococcal peptidase I 4 7, 12, 20, 35 Serine 
Therm Thermolysin 9 2, 13, 15, 17, 23, 28, 30, 
31 
Metallo 
Throm Thrombin 1 26 Serine 
Tryps Trypsin 3 15, 26, 30 Serine 
 
Figure 1.12 clearly shows the diverse specificity α2m has for a number of proteases. Not only do 
varieties of proteases cleave the bait region, note at least one from every major class, but many of 
them have multiple cleavage sites thus highlighting just how versatile the bait region is in terms of 
its specificity. 
Due to the dimensions of the entrances mentioned in the previous section, proteases are limited 
in size to about 20-30kDa. Once they have gained access to the central prey chamber and cleaved 
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the bait region leading to the cleavage of the thiolester bond also a molecular rearrangement 
occurs where the native α2m model it is speculated narrows closing off the entrances by which 
the protease accessed the prey chambers thus trapping the molecule within the ‘molecular cage’ 
of α2m. Utilising this mechanism α2m is known to trap the proteinases released by both self-cells 
and invasive pathogens. 
Among the self-proteinases α2m is known to trap are key inflammatory agents such as neutrophil 
elastase and chymase from mast cells, transferring the key serum iron transport protein, 
proteolytic members of the clotting cascade and defensins such as HNP-1 a key microbicidial 
protein. Foreign pathogens it is known to bind include, the collagenase from Clostridium 
histolyticum and proteases from Trichophytaon mentarophytes, Fusiformis nodosus and Bacillus 
subtilis (Rehman, et al., 2013) 
The α2m receptor LRP-1 clears bound proteases primarily on hepatocytes in serum and in tissues 
by a host of immune cells such as: fibroblast cells, monocytes and macrophages. These complexes 
are formed within a matter of a few minutes after their formation and with high affinity. Once 
bound the α2m-LRP-1 complex dissociates readily in mild acidic conditions, which are optimal for 
the endosomal proteins responsible for the breakdown of the α2m, where in some cases α2m is 
recycled back into circulation and in other it is broken down along with the protease in question 
(Borth, 1992) 
 
1.2.1.4.2 Human α2-Macroglobulin and its interactions with Surfactant Protein-D 
 
Human surfactant protein D (hSP-D) is a key molecule of the innate immune response to infection, 
primarily in the lungs (Crouch, 2000). It binds to bacterial and viral surface antigens via its 
carbohydrate recognition domain (CRD) in a calcium dependant manner. Each dodecamer of hSP-
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D contains 12 CRDs, providing 12 potential binding sites for polysaccharides. As a result, hSP-D 
can form large aggregates of multiple hSP-D molecules linking multiple pathogens. 
 
 
Figure 1.13. A molecule of hSP-D is capable of binding multiple pathogens thanks to its cruciform morphology. This 
allows large complexes to form of multiple bacteria linked by multiple hSP-D molecules, which are then targeted for 
clearance by the immune system (Figure adapted from Craig-Barnes, et al. 2010) 
 
hSP-D binds a variety of target saccharides on the surface of its ligands, ranging from maltose, 
which it binds with highest affinity, to mannose and GlcNAc amongst others (Persson, et al. 1990). 
α2-macroglobulin as mentioned earlier is highly glycosylated, with the human form having a 
variety of N-linked glycans such as high oligomannoses, galactose, fucose, GlcNAc and sialic acid 
(Arnold, et al. 2006). These oligomannose residues are found on a variety of molecules, perhaps 
most notably on the haemagglutinin of the influenza virus. It is these oligomannose residues that 
provide hSP-D binding capabilities to the influenza virus (Crouch, et al. 2011). Of the collectins, it 
was first shown that mannose-binding lectin (MBL), a constituent of the complement system. 
Binds to the oligomannose residues of human α2m found on Asn846, between the bait region and 
the thiol ester domain (Arnold, et al., 2006). However more recently it was shown that hSP-D 
binds to α2m and that the presence of α2m actually boosts the innate immune potential of hasps 
(Craig-Barnes, et al. 2010). It was shown that hSP-D bound to the surface glycans found on α2m, 
 34 
 
in particular those high oligomannose residues (Man5-7), which make up 8% of the glycan pool. 
They bind these by the CRDs in a calcium dependant manner mimicking the action against 
pathogenic targets. Due to the high number of surface glycans found on α2m, this then facilitates 
a cross-linking agglutination between multiple hSP-D molecules, which can also bind to pathogens 
during infection, as shown in Figure 1.13. The likelihood of such an interaction occurring is far 
more likely during infection as α2m is found in the lungs at 0.09-2.02μg/ml but during infection 
that concentration increases to 220μg/ml in the acute phase response (Van Vyve, et al., 1995). 
 
Figure 1.14. hSP-D binds the antigens on the surface of bacteria by its CRDs. The unbound CRDs are then free to bind 
to the oligomannose glycans on the surface of α2 macroglobulin (A2M) and its reacted form (cA2M). The presence of 
unreacted a2m offers protection to hSP-D from proteolytic cleavage by elastases, whilst the reacted forms still offer 
structural stability to the bacterial-hSP-D-a2m complexes (Craig-Barnes, et al., 2010). 
 
Not only does hSP-D bind to α2m facilitating the formation of large aggregates but it binds to both 
the native and the activated forms of the molecule, as demonstrated above in Figure 1.14. This 
provides the hSP-D with protection from proteases, in particular elastin. Elastin is released in the 
inflammatory response by neutrophils as well as a defence mechanism by invading pathogens. 
The elastin cleaves the CRD of hSP-D rendering it inactive. The formation of α2m–hSP-D 
complexes results in native α2m being present and available for protease encapsulation. Once the 
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protease has been trapped, the α2m molecule becomes more compact following a 
conformational change; thus highlighting the importance of hSP-D being able to bind both native 
and activated forms so as not to disturb the aggregate stability. To date there have been no 
structural studies on the complex formed between α2m and hSP-D, in its intact form or its 
recombinant heads and neck region. Insights into the mechanism of binding could shed light on 
exactly which of α2ms surface glycans is the primary target for binding, as well as providing new 
evidence for this novel role of α2m in the body.  The Limulus α2m homologue, also has high levels 
of mannose (31%) in the sugars that make up its surface glycans possibly pointing towards high 
oligomannose residues; ultimately implying that hSP-D could also bind to Limulus α2m (Iwaki, et 
al. 1996). 
 
1.2.1.4.3 α2-Macroglobulin and its Interactions Cytokines 
α2m is known to bind to several cytokines, some of which have their biological activity inhibited 
whilst bound to α2m, whilst others maintain their biological activity (Rehman, et al., 2013). 
Different cytokines bind to the native and activated forms with varying affinities. Among the 
cytokines that bind to α2m are: interleukin-6 (IL-6), interleukin -1β (IL-1β), tumour necrosis factor-
α (TNF-α),and various growth factors including, transforming growth factor β (TGF-β) and nerve 
growth factor (NGF) which binds to α2m with highest affinity (Rehman, et al., 2013). 
Free IL-6 in serum is readily broken down by roaming proteases. When bound to α2m IL-6 is 
bound in such a manner as its biological activity is preserved whilst offering it protection from the 
proteases in serum. The role of α2m is key in delivering IL-6 to lymphocytes, hepatocytes and 
haematopoietic stem cells, thus triggering a host of defence reactions such as: haematopoiesis 
and the release of acute phase proteins like C-Reactive protein. IL-1β produced in activated 
macrophages as a protein precursor before being cleaved into its final form by caspase 1. IL-1β 
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along with TNF-α and IL-6 is a key mediator of the acute phase response another key component 
of the innate immune system. IL-1β has been shown to bind to the activated form of α2m only 
and does so in a manner that preserves it’s activity, it does so in a Zn2+ dependant manner; this is 
due to the formation in the presence of Zn2+ of free sulfhydryl groups that act as cytokine binding 
sites on α2m itself (Athippozhy, et al. 2011; Borth, & Luger, 1989; Rehman, et al. 2013). TNF-α 
produced predominately by monocytes and macrophages is another key cytokine as previously 
mentioned in triggering the acute phase response as well as, as its name suggests, the ability to 
inhibit tumourigenesis, induce fever and apoptotic cell death. TNF-α binds with strong affinity to  
activated-α2m, but has been shown to also bind to the native form, and maintains biological 
activity regardless of the form of α2m it is bound to (Gourine, et al. 2002).It is thought that α2m  
again acts as a guardian of the cytokine protecting it from proteolytic degradation, something that 
is seen when TNF-α comes into contact with the proteases released by polymorphonuclear 
neutrophils The TNF- α/ activated-α2m complex has been shown to be endocytosed by the α2m-
receptor LRP-1 and thus a role is suggested for the clearance of and processing of circulating 
cytokines (Gourine, et al. 2002).  
One of the key growth factors that binds to α2m is platelet-derived growth factor (PDGF); a 
potent chemokine for pro-inflammatory cells and those involved in wound repair, making it a 
major component of the inflammatory response. Human α2m is capable of covalently binding to 
two molecules of PDGF, and has been hypothesised to reduce the amount of PDGF released at the 
site of inflammation; suggesting a regulatory effect on inflammation for α2m (Solchaga, et al. 
2012; Rehman, et al.2013). Transforming growth factor β (TGFβ) is a protein that mediates a 
broad range of cellular processes and as a cytokine is known to have a role in immunity, cancer, 
and acting as a chemokine for mesenchymal stem cells thus coordinating bone formation. It is 
activated from its latent form by proteases (Hinze, et al., 2012). When bound to α2m the TGF-β 
molecule reverts back to a latent form. The α2m interaction with TGF-β has been shown to 
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protect the lens from cataracts, as TGF-β has been shown to induce cataractous changes and that 
α2m is the principle inhibitor of these effects (Reneker, et al. 2010). 
Hepcidin a major peptide hormone involved in the role of iron metabolism has been shown to 
bind to α2m. It is thought that α2m facilitates the role of Hepcidin in regulating transmembrane 
iron transport by presenting Hepcidin to LRP-1 for endocytosis and passage into the cells 
(Rehman, et al. 2013). Leptin is a hormone released from adipose tissue and regulates appetite 
and energy expenditure and resultantly, bodyweight. It has recently been discovered that 
activated α2m is the leptin-binding protein, the rate at which α2m to binds to leptin resulting in 
its rapid clearance from circulation is thought to seriously affect it’s bioavailability and thus 
indicates yet another key regulatory role for α2m (Birkenmeier, et al., 1998; Rehman, et al. 2013).
  
  
1.2.1.4.4 α2-Macroglobulin and its role in Alzheimer’s Disease and Other Pathologies. 
 
As such a key mediator of the immune system it is no great surprise that α2m is involved in a 
number of disease pathologies. 
Alzheimer’s disease (AD) is a crippling neurodegenerative disease that affects individuals as are as 
49 through to their 80’s. Its symptoms start from short-term memory loss and as the disease 
progresses can lead to confusion, mood swings, and ultimately long-term memory loss. It is 
thought to be caused by a number of both environmental and genetic risk factors, such as metal 
consumption and the apolipoprotein E (APOE) allele ε4 (House, et al. 2004; Selkoe, 2001). It 
should be noted, as mentioned APOE is a common ligand for the α2m receptor, and has been 
linked with late onset AD (Kang, et al. 1997). A key neuronal transmembrane protein called 
amyloid precursor protein (APP) undergoes proteolysis in AD leading to smaller fragments. Two 
such smaller fragments are beta amyloid Aβ and tau amyloid, which become misfolded and Aβ 
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production leads the formation of neuronal plaques or fibrils of these misfolded proteins. The 
proteases responsible for the splicing of the APP molecule are α-,β- and γ- secretase, and the 
formation of Aβ is due to repeat actions of both β- and γ-secretase producing Aβ isoforms of 
varying lengths the most common being Aβ40 and Aβ42, which are 40 and 42 amino acids in 
length respectively. During the formation of the Aβ plaques reactive oxygen species are produced 
which cause the neurotoxicity responsible for the neurological symptoms seen in AD (Selkoe, 
2001). It has been shown that α2m binds to Aβ with high affinity, and it has been shown that 
activated α2m/Aβ complexes can be internalised via the α2m receptor (Narita, et al. 1997). α2m 
itself though has been shown to be contribute towards neurotoxicity and neuroprotective effects 
on cultured neurones. The formation of Aβ fibrils and the neurotoxicity associated with Aβ 
aggregation are both prevented by the binding of α2m to Aβ (Du, et al. 1998; Hughes, et al. 1998). 
The post-internalisation processes remain as yet unclear, but it is known that Aβ internalised by 
α2m does not follow the conventional lysosomal degradation pathway as it has been shown that 
internalised Aβ via α2m in microglial cells is subsequently released intact from the lysosomes 
(Chung, et al. 1999). In cells not expressing LRP-1, such as neuroblastoma cells, it has been shown 
that the presence of activated α2m increased the Aβ toxicity in those cells, due to the ability of 
α2m to bind to TGF-β, returning TGF-β to its latent form and thus interfering with its 
neuroprotective mechanisms (Fabrizi, et al. 1999). Studies utilising knockout mice have shown 
that an absence of α2m to have no effect on brain function, but increased levels have shown to 
have either neuroprotective or neurotoxic effects; suggesting there are other factors involved 
that determine which pathway α2m follows   (Kovacs, 2000). 
Human group G streptococcus makes up a portion of the typical flora seen on the skin, pharynx 
and the female genital tract. Despite this it is responsible for a number of severe infections; strain 
G148 expresses protein G on its surface, an IgG binding-protein which binds via both the Fc and 
Fab regions, thus inhibiting the binding capability of IgG. It is hypothesised that utilising protein G 
bacteria coat themselves in IgG thus allowing them to evade the immune system and vastly 
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increasing its pathogenicity (Sloan, & Hellinga, 1999). α2m has been shown to bind Protein G 
regardless of its activation state and also binds protein G-related α2-macroglobulin binding 
protein (GRAB), which is an important virulence factor for group A streptococci (Sloan, & Hellinga, 
1999; Rehman, et al.  2013). This could be a case of intelligent immune evasion on behalf of the 
evolution of the streptococci; which is dependent on releasing a mass of protease as well as 
triggering neutrophilic protease release resulting in increased tissue damage aiding the virulence 
of the bacteria. The fact that it expresses an α2m binding protein, which can protect the bacteria 
from host proteases such as neutrophil elastase that would otherwise seek to degrade virulence 
determinants on the surface of the bacteria (Nyberg, et al. 2004).Levels of α2m can vary 
dependent upon various disease states such as elevate levels in: diabetes, nephritic syndrome and 
chronic liver diseases (Ritchie, et al. 2004). A rare form of α2m known as cardiac isoform α2m (C-
α2m), a 182kDa serum protein, has been shown to play a key role in cardiac hypertrophy and is 
now resultantly used as an early biomarker in myocardial infarctions (Annapoorani, et al. 2006). 
Due to cardiac involvement in 25-40% of HIV cases C-α2m is also used as an early diagnostic 
marker in HIV patients with cardiac manifestations (Ramasamy, et al, 2006; Ramasamy, et al. 
2010). 
To summarise to merely describe α2m as a protease inhibitor does not give the molecule the 
credit it deserves. Not only is α2m a pan protease inhibitor with a unique binding mechanism, it is 
also an immunoregulatory protein capable of up or down regulating the immune response and 
playing key roles in many of today’s big diseases. 
 
1.2.2 α2-Macroglobulin of the Horseshoe crab Limulus Polyphemus 
In a species such a Limulus that relies entirely on an innate immune system, proteins such as α2m 
play key roles in a multitude of systems, acting as protective agents and immunoregulatory 
proteins (Swarnakar, et al. 2000) 
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1.2.2.1 Synthesis of α2-Macroglobulin in Limulus Polyphemus 
The human immune system has a plethora of blood cells at its disposal, however Limulus has only 
one – the granular amebocyte (Armstrong, et al. 1990); whose principle role it to act as a 
thrombocyte (akin to the human platelet) forming a cellular plug of adherent cells at the site of 
injury thus clotting the blood (Bursey, C. R. 1997), as well as the release of exocytotic vesicles. 
These vesicles contain the structural zymogen protein of the clot as well as an assembly of 
proteases that cleave the zymogen resulting in the activation of the protein and the formation of 
thrombogenic fibrils. Another protein exocytosed in the process, is α2m which is thought to 
control and limit the activity of proteases within the clot, but not those involved in the clotting 
cascade itself as it shows no activity towards those. Due to the relatively limited amount of study 
on α2m from Limulus, other sites of α2m are not known. It is known however, that the expression 
of α2m mRNA is seen in several tissues of the Japanese horseshoe crab (T. tridentatus) including; 
heart, hepato-pancreas, stomach, intestine, coxal gland, brain and skeletal muscle (Iwaki, et al. 
1996). Due to the closely related nature of these two species of horseshoe crab, maybe best 
demonstrated by the 86% homology in α2m molecules, it could be suggested that α2m is also 
produced at the same sites in Limulus (Iwaki, et al. 1996).  
1.2.2.2 Structure of Limulus α2-Macroglobulin 
Limulus α2m is a 370kDa protein made up of a homodimer of 185kDa subunits of which 165kDa is 
contributed by the peptide sequence of 1482 amino acids (inclusive of a 25 amino acid long signal 
peptide) and the remainder by the glycosylation sites (Iwaki, et al., 1996). The molecular weight of 
the molecular and it’s individual subunits have been verified using SDS-PAGE, sedimentation 
equilibrium and chromatographic techniques, after original misconceptions about its molecular 
weight being 480-550kDa leading to the belief it may be trimeric in nature (Armstrong, et al. 
1991). Two individual subunits are held together with disulphide bonds to form the functional 
dimer (Husted, et al. 2002). 
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Figure 1.15. Domain schematic representation of Limulus α2m, depicting domain boundaries, N-linked glycosylation 
sites (indicated with a black diamond), and disulphide bond sites with the intersubunit disulphide at Cys719 shown 
with an *. 
 Intrasubunit disulphide bridges occur between, Cys228-Cys269, Cys361-Cys382, Cys456-Cys580, Cys612-
Cys799, Cys657-Cys707, Cys849-Cys876, Cys874-Cys910, Cys946-Cys1328, Cys1104-Cys1155, Cys1362-Cys1475, and 
Cys1370-Cys1374 as depicted in Figure 1.15; in addition to a single intersubunit disulphide bridge 
between, Cys719 from one subunit to the same residue in the other subunit (Husted, et al. 
2002).Each subunit has seven potential N-linked glycosylation sites; Asn80, Asn275, Asn307, Asn866, 
Asn896, Asn1089, and Asn1145; with an estimated 31 Man, 19 GlcNAc, 3 GalNAc, 3 Gal and 5Fuc 
residues per subunit (Husted, et al., 2002; Iwaki, et al., 1996). The two main characteristics of the 
α2m molecule, the bait region and the thiol-ester are seen at residues Pro697 - Thr735 and Cys975 - 
Glx978 respectively (Armstrong, & Quigley, 1999). Transmission electron microscopy showed that 
native α2m was made up of two clearly defined dimers, and that chymotrypsin reacted Limulus 
α2m showed a much more compact structure where each subunit was then indistinguishable 
(Armstrong, et al. 1991). Initially based on sequence homology work it was proposed that Limulus 
α2m had four key functional domains. At the N terminal end the unique region identified as a C8γ 
domain, due to modest homology with C8γ of the human complement system, the bait region 
domain, the thiol ester domain and the receptor binding domain at the C terminal end 
(Armstrong, et al. 1999). However, structure prediction work completed in this thesis suggests 
that Limulus α2m actually represents human α2m and its family members with regard to domain 
organisation as demonstrated in detail in Chapter 5. As of yet there have been no published 
crystallographic studies on α2m of Limulus, but as the human model was finally published in 2012 
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(Marrero, et al., 2012), this may provide suitable starting conditions for the crystallographic 
structure solution of Limulus α2m as NMR cannot be considered for the structure solution of 
Limulus α2m due to its size. 
1.2.2.3 Functions of Limulus α2-Macroglobulin 
Very much like it’s human counterpart the principle role of α2m in Limulus is to act as a pan-
protease inhibitor; in fact it may be even more vital a role in Limulus as it is the only known 
circulating protease inhibitor (Armstrong, & Quigley, 1999; Quigley, & Armstrong, 1983). Whereas 
the human molecule is thought of as a dimer of dimers with one dimer being one active unit, the 
Limulus homologue is a single dimer and thus a single active unit but in its protease binding 
activity is very similar. The bait region of Limulus α2m is 38 amino acids long and has 18% 
homology with its human counterpart. 
 
Figure 1.16. ClustalW, alignment of the bait regions of both human and Limulus α2m highlighting the 
homologous amino acids. Identical residues are indicated with an *, residues with strong similarities are 
shown with a :, and weakly similar residues are shown with a .  (Larkin, et al., 2007) 
 
Cleavage of the bait region results in the same compaction of the molecule as it closes around it’s 
protease prey, this has been shown using electron microscopy and with polyacrylamide gel 
electrophoresis; which also showed that methylamine has the same reaction in Limulus as it does 
in humans, producing a similar gel migration distance to that seen with protease reaction, and is 
also thought to react with the thiol-ester (Armstrong, & Quigley, 1987; Armstrong, et al., 1991; 
Quigley, & Armstrong, 1985; Quigley, et al., 1991). Differences in the bait region, illustrated by 
Figure 1.16, infer that the human and Limulus molecules have different target proteases, which is 
likely as they are two very different species, likely to come into contact with very different 
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pathogenic invaders. Other similarities between human and Limulus α2m is that bound proteases 
retain their catalytic abilities as shown in trypsin digest assays where internalised trypsin was still 
able to cleave Na-benzoyl-DL-arginine p-nitroanilide (BApNA) (Armstrong, 2010). Following 
reaction with a protease Limulus α2m also internalises the protease for processing; this was 
shown using fluorescein-labelled proteins injected into the lumen of the heart and the clearance 
time was measured. Labelled trypsin complexed with α2m was half cleared in a time of around 
10-15 minutes and maximally cleared within 20-25 minutes, and this is thought to take place on 
the Limulus blood cell (Melchior, et al., 1995; Armstrong, 2010).Currently a receptor for protease 
reacted α2m, in invertebrates has yet to be found, but the LRP-1 family is an evolutionarily 
ancient as the α2m superfamily and family members of LRP-1 have been found (Armstrong, 2010), 
but whether these act as a receptor for α2m in invertebrates remains to be seen. The Limulus 
blood cell does however contain a very high molecular mass protein that like LRP-1 binds to LRP 
receptor-associated protein (RAP) which is known to bind to the human α2m (Aimes, et al. 1995). 
This however does need to be the focus of future research as current evidence remains 
inconclusive. 
Another family of proteins Limulus shares, with humans is the pentraxins; homologues are found 
for both C-reactive protein (CRP) and serum amyloid P component (SAP), but limulus has an 
additional member of the pentraxins, the sialic acid binding protein limulin (Armstrong, & Quigley, 
1999). Limulin is the sole cytolytic protein of the Limulus immune repertoire (Harrington, et al., 
2008, Armstrong, et al., 1996) which, taking place in a Ca2+ characteristic of its family, leads to 
membrane permeabilisation. This takes place when limulin, which is present in Limulus serum at 
concentrations of 30-50nM, inserts itself into the plasma membrane, via sialic acid binding, 
forming a hydrophilic pore (1.7nm). This pore too small for cytosolic proteins to pass through 
allows the passage of water into the cell, causing osmotic swelling leading to cell lysis (Swarnakar, 
et al., 2000). α2m regulates the limulin-based cytosolic system seen in Limulus; but only the 
activated form of α2m has any effect as native has been shown to have no effect (Swarnakar, et 
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al., 1995). The binding of activated α2m to limulin results in the negation of its cytolytic activity. 
This could form part of the pathogenic invasion strategy, to release proteases, activating α2m and 
thus disabling the cytosolic system. 
1.2.3 Conclusions, Aims and Objectives 
The emergence of α2m and its superfamily over 700 million years ago is a key moment in the 
evolutionary timeline (Sahu, & Lambris, 2001). This family of proteins that are present in a diverse 
range of species from humans and other mammals to fish, reptiles, nematodes, insects, 
arthropods and other invertebrates, are vital immune mediators (Armstrong, 2010). α2m 
superfamily members in humans make up part of the repertoire of the humoral component of the 
innate immune system as well providing links to the acquired/adaptive immune system (Janssen, 
et al. 2005; Kidmose, et al. 2012; Fredslund, et al. 2008). α2m itself is a multifaceted, 
multifunction protein capable of mediating the immune systems response to a variety of attacks 
as well as modulating it’s functions;, in its ability to protect immune molecules and deliver 
cytokines to the location of pathogenic invasion (Rehman, et al. 2013). The solution of the crystal 
structure of human α2m has generated a great many clues about its molecular mechanisms as 
well as comparisons to its fellow family members in humans (Marrero, et al. 2012). Already used 
as a molecular marker (cardiac isoform), the uses of α2m as a therapeutic agent are set to 
develop further as we understand it more, potentially reverse engineering it so that it’s bait 
region contains a cleavage site for a protease that we may wish to negate the effects of (Rehman, 
et al. 2013). Such information has yet to be revealed about the homologue from Limulus 
polyphemus, the American horseshoe crab, where the α2m molecule also forms an additional role 
by helping mediate the cytosolic system  within Limulus with the pentraxin protein limulin which 
serves as the MAC-esque homologue forming a pore in cell membranes leading to cell lysis 
(Swarnakar, et al. 2000). As an invertebrate Limulus lacks any acquired immune system and as 
such relies heavily on its innate immune system, of which there are many human homologues, to 
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protect it from infection. α2m is one such innate immune system and understanding its structural 
and functional mechanisms may lead to a better understanding of the human molecule as well as 
how the innate immune system evolved.  
Crystal structure data now exists for several α2m family members in humans, α2m (Marrero, et 
al. 2012),and C3, C4 and C5 of the complement system (Janssen, et al. 2005; Kidmose, et al. 2012; 
Fredslund, et al. 2008). Yet there not been any published crystallographic studies of the α2m 
homologue from Limulus. The aim of this thesis is to fill the existing gaps in our knowledge about 
this superfamily, building on the works of Prof. Peter Armstrong, Prof. James Quigley, Assoc. Prof. 
Lars Sottrup-Jensen and others, using x-ray crystallography and structure prediction software to 
reveal clues about the structure, mechanisms and function of α2m from Limulus. Focussing on 
predicted domain homologies, particularly in the highly conserved TED region of the protein, as 
well as domain arrangement and quaternary structure. 
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Chapter 2 – Isolation and Purification of α2-Macroglobulin from the serum of the Horseshoe 
crab, Limulus polyphemus 
2.1 – Introduction to the Isolation of alpha-2 macroglobulin of the Horseshoe crab, Limulus 
polyphemus. 
α2-Macroglobulin (α2m) was isolated from serum of Limulus polyphemus using a combination of 
the polyethylene glycol (PEG) cut procedure, affinity chromatography for the 
phosphoethanolamine (PE) binding proteins, and size exclusion chromatography for the removal 
of hameocyanin. The PEG cut procedure is used to facilitate the removal of large quantities of the 
haemocyanin present in serum as well as increasing the concentration of the remaining serum 
proteins.  Both of the pentraxin-like proteins bind to PE on the affinity column whereas only C-
Reactive Protein (CRP) will bind to phosphocholine (PC). Using PC in conjunction with PE, and 
manipulating the binding affinity of the two pentraxin-like proteins allowed not only for the 
separation of the pentraxins from the serum but also separate them individually from one 
another. The pentraxin depleted serum was then run down a size-exclusion chromatography 
column on our in house fast protein liquid chromatography (FPLC) system. This separates the 
remaining proteins (haemocyanin and α2m) by their molecular weight into fractions. These 
fractions were then concentrated and used in gel electrophoresis, to monitor the efficiency of the 
protocol and to monitor the purification process. For ease of visualisation a schematic of the 
purification process has been produced in Figure 2.1. Purified protein was then used in 
crystallisation trials. Various crystal conditions were trialled utilising Molecular Dimensions 
Structure Screens as well as existing conditions from the literature. α2m was used in crystal trials 
with methylamine acting as a ligand by cleaving the thiol-ester bond. 
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Figure 2.1. Schematic representation of the purification protocol for purifying Limulus α2m from PEG cut 
serum. Following removal of pentraxins via affinity chromatography on a PE agarose column, the 
breakthrough fraction which is now pentraxins depleted undergoes three rounds of size exclusion 
chromatography using a Superdex column to remove the remaining amounts of haemocyanin. SDS-PAGE 
and UV spectroscopy were used between size exclusion chromatography experiments to monitor and 
assess progress. After three size exclusion runs, the haemocyanin was removed and the isolated Limulus 
α2m was incubated with 0.2M methylamine/10mgml-1 α2m for a two hour period before the fast and 
slow forms are then separated on the size exclusion column to ensure homogeneity of the sample for 
crystallisation trials. 
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2.1.1 Obtaining Limulus polyphemus plasma and the PEG cut procedure. 
The methods discussed here (Armstrong, & Conrad, 2008) were not carried out by myself, 
however they’re included for completeness in order to understand the history of the serum and 
the proteins used. 
Polyethylene glycol (PEG)-cut serum from Limulus polyphemus was generously provided by 
Professor Peter Armstrong, of the Marine Resources Centre, Marine Biological Laboratory, Woods 
Hole, Massachusetts. Prior to bleeding the animals are chilled in a cold room (4°C) for one hour to 
minimise the risk of blood clotting. Typically a single horseshoe crab can yield 50-200ml of 
haemolymph. This is extracted by penetrating the heart, via the hinge, with a sterile 14 gauge 
needle to a 1-2cm depth (Armstrong, & Conrad, 2008).Once the blood is collected it is 
immediately centrifuged at 1000rpm for 5 minutes, to pellet the granular amebocytes, that 
contain the clotting agents. 
In Limulus, the oxygen transporting molecule is haemocyanin, a molecule similar to our own 
haemoglobin except with copper as its oxygen binding atom; and is the source of the serums blue 
colour. Another key difference from haemoglobin is that it is a free serum protein and not bound 
by the blood cells. As a result in order to study other Limulus serum proteins the majority of the 
haemocyanin needs to be removed. This was done via the PEG-cut procedure. The PEG-cut 
procedure utilises principles of molecular crowding to selectively precipitate out proteins – in this 
case haemocyanin. PEG in this case and in a similar way to it behaviour in crystallographic 
experimental setups interacts with the proteins via an excluded volume effect, whereby the 
presence of PEG minimises the available volume for the protein to reside (Herzfeld, 1996; Atha, & 
Ingham, 1981). The result is that the protein concentration following the addition of the PEG is 
increased, increased well beyond the point of supersaturation. As this achievement of 
supersaturation isn’t gradual as seen in the vapour diffusion experiments of crystallographers the 
result is the precipitation of the protein. Larger proteins and proteins with already high 
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concentrations are those to precipitate first (Herzfeld, 1996; Atha, & Ingham, 1981). Given that 
haemocyanin is the most abundant serum protein and also the largest, it is the protein that is 
precipitated out in the greatest quantity. To 1.5 litres of serum pheylmethylsulfonylfluoride 
(PMSF) – a serine protease inhibitor – was added to a concentration of 1mM, as well as PEG 8000 
to a concentration of 3%. This preparation was then incubated for 3-6 hours at 4°C before being 
centrifuged at 40,000g for 30 minutes, to form a pellet containing PEG and haemocyanin. PMSF 
and PEG were added to the supernatant again to a final concentration of 1mM and 10% 
respectively. The supernatant now containing 1mM PMSF and 10% PEG 8000 was incubated at 
4°C for approximately 1 hour and then centrifuged at 40,000g for 10 minutes to form another 
pellet. This pellet contains PEG, the pentraxins and the protease inhibitor α2-macroglobulin, and 
was redissolved in calcium free buffer (50mM Tris pH 7.5, 150mM NaCl and 0.2mg/ml NaN3) with 
1mM PMSF and left overnight at 4°C. Calcium Chloride was then added to a final concentration of 
5mM. The now PEG-cut serum has had the majority of the haemocyanin removed but a lot of it 
still contaminates the serum and so PEG-cut serum retains its blue colour.  
 
2.1.2 Introduction to Affinity Chromatography 
Affinity chromatography, a technique pioneered in 1968 (Cuatrecases, et al., 1968), is a method of 
macromolecular separation based upon a molecules binding affinity to an immobilised media 
bound ligand. Once the target molecule is bound it allows for non-ligand binding contaminants to 
be washed through – and if necessary collected. The target molecule is then eluted from the 
column with either a competitive ligand or an agent capable of disturbing protein-ligand 
interactions, in elution buffers (Catsimpoolas, in Heftmann, 1983). Using known ligands of the 
protein is a specific way to elute the protein from the media. Whereas using analogues of the 
ligand or new ligands to compete with the media can be especially helpful if multiple proteins are 
bound to the media, but have different binding affinities for the elution ligands (Villems, & 
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Toomik, in Kline, 1993). Using none specific agents such as detergents, chelating agents, changes 
in pH or salt concentration etc. are a good method of purging the media of all the bound proteins 
– helpful if only one protein has bound to the media (Cuatrecases, et al., 1968). 
Affinity chromatography in this instance was not used to isolate the protein of choice but two 
isolate two contaminants – the pentraxins, CRP and SAP. The PEG-cut serum provided by Peter 
Armstrong contains the serum proteins in high concentrations, the most abundant proteins being; 
haemocyanin, c-reactive protein, serum amyloid P- component and α2-macroglobulin (Armstrong, 
& Quigley, 1999). The use of affinity chromatography utilises the binding affinity of the pentraxins 
to phosphocholine (PC) and phosphoethanolamine (PE), and the none binding of the 
haemocyanin and the α2-macroglobulin to these molecules. Like their human counterparts, 
Limulus CRP and SAP differ in their binding affinities allowing for their separation via specific 
ligand elution. CRP will bind to both PC and PE (Volanakis, & Kaplan, 1971; Schwalbe, et al. 1992; 
Robey, & Liu, 1981). Conversely SAP will bind only PE (Shrive, et al. 1999; Tharia, et al. 2002). 
Importantly both molecules bind in a calcium dependant manner, meaning that they will only 
bind PE and PC in the presence of calcium ions acting as a cofactor. As a result calcium ions must 
be present in both the wash buffer and the elution buffers to ensure protein binding to the 
column and to ensure successful elution from the column when the ligands are added 
respectively. As both pentraxins bind to PE, they can be separated from PEG-cut serum using PE 
linked beaded agarose which is packed into a 25ml column. Buffer is pumped over this column at 
a low flow rate of 0.5ml/min, which prevents the agarose from compacting within the column 
which could lead to reduced flow rate and a reduction in surface area for pentraxins to bind to the 
PE. Due to the high stability and inert surface of agarose (Roe,  in Harris, & Angal, 1989), the 
pentraxins do not interact with it preferentially over PE.  
The pentraxins were eluted using an isocratic elution of single ligand buffer. An isocratic elution 
being one that does not change in composition during the elution, in this case 10mM PC and 
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30mM PE. As the serum was ran onto the PE agarose column the none PE-binding proteins – 
haemocyanin and α2-macroglobulin were collected in the breakthrough fraction. These were then 
concentrated and subjected to three runs of gel-filtration chromatography prior to α2-
macroglobulin being used in crystal trials. 
2.1.2.1 Materials and Procedures 
Materials, Equipment and Chemicals: 
 Acetate filter - 0.2μm pore size – (Sartorius) 
 Biologic Low Pressure System and HP controller (BIORAD) 
 O-Phosphoethanolamine agarose beads (Sigma) 
 Calcium Chloride dehydrate (Sigma) 
 Ethylenediaminetetraacetice acid (EDTA) (Sigma) 
 Phosphocholine chloride calcium salt tetrahydrate (Sigma) 
 O-Phosphoethanolamine (Sigma) 
 Sodium Azide (Sigma) 
 Sodium Chloride (VWR) 
 Tris(hydroxymethyl)methylamine (VWR) 
Buffers: 
 Calcium wash buffer: 50mM Tris pH 7.4, 10mM CaCl2, 150mM NaCl. 
 Phosphocholine elution buffer: 50mM Tris pH 7.4, 10mM CaCl2, 150mM NaCl, 10mM 
Phosphocholine chloride. 
 Phosphoethanolamine elution buffer: 50mM Tris pH 7.4, 10mM CaCl2, 150mM NaCl, 
30mM O-Phosphoethanolamine. 
 EDTA buffer: 50mM Tris pH 7.4, 150mM NaCl, 10mM EDTA. 
 Regeneration buffer A: 200mM Tris pH 7.4, 500mM NaCl, 10mM EDTA. 
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 Regeneration buffer B: 50mM Tris pH 7.4, 500mM NaCl, 10mM CaCl2.  
 Regeneration buffer C: 50mM Tris pH 7.4, 150mM NaCl, 10mM CaCl2, 0.02% NaN3. 
 
2.1.3 Introduction to Size Exclusion Chromatography 
Once the pentraxins were removed, size-exclusion chromatography (SEC) also known as gel 
filtration, was used to separate the remaining haemocyanin and α2-macroglobulin; following the 
removal of the pentraxins via affinity chromatography as mentioned above. This was performed 
on an AKTA Explorer FPLC system using a Superdex HiLoad 16/60 column. 
SEC separates molecules according to differences in their size, as they pass through a special 
medium filled column. Unlike other forms of chromatography, in SEC molecules do not bind to the 
medium meaning that buffer composition has a negligible effect on peak resolution. The medium 
is made up of specially selected spherical particles, chosen for their inertness and stability, which 
form a porous matrix which allows molecules below a certain size to be adsorbed. The 
interparticular pores are filled with a buffer which is often referred to as the stationary phase, and 
the buffer that passes around the outside of the particles being the mobile phase. As a sample is 
applied to the column, it moves with the mobile phase in and out of the pores of the matrix. The 
larger molecules are restricted by their size as to how deep into the matrix they can penetrate; as 
a result they do not interact with the column for as long as smaller molecules that is capable of 
moving deeper through the media. The detection of protein molecules is done using a 280nm 
wavelength lamp and analysis of the absorbance spectra of the solution as it exits the column. As 
a result when the fractions are collected at the end of a sample run, molecules come off the 
column in order of size, with the larger molecules coming off first having not interacted with the 
column for as long a period as the smaller molecules that come off later. This entire separation 
process takes place in just one column volume allowing a quick turnaround time if required. 
 53 
 
SEC affords a great deal of flexibility, with regard to the environmental conditions the target 
molecules are subjected to. It can be performed at either room temperature or in a cold room, 
molecules can be purified in any chosen buffer, the separation can be performed in the presence 
of a variety of molecules such as essential ions, cofactors etc.  
 
2.1.3.1 Materials and Procedures 
Materials, Equipment and Chemicals: 
 Acetate filter - 0.2μm pore size – (Sartorius) 
 AKTA Explorer FPLC System (GE Healthcare) 
 Superdex 200 HiLoad 16/60 Column (GE Healthcare)  
 Calcium Chloride dehydrate (Sigma) 
 Ethanol (VWR) 
 Sodium Azide (Sigma) 
 Sodium Chloride (VWR) 
 Tris(hydroxymethyl)methylamine (VWR) 
Buffers: 
 Calcium wash buffer: 50mM Tris pH 7.4, 10mM CaCl2, 150mM NaCl. 
Procedure: 
Effluent from the above mentioned affinity chromatography procedure was concentrated and 
injected onto the AKTA Explorer FPLC system, via the injection valve, typically at volumes of 
approximately 500µl and within a concentration range of 3-30 mg/ml. The system was brought 
out of storage by purging the tubes with deionised water before the column is washed with 
filtered and degassed deionised water prior to the equilibration step. During equilibration the 
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filtered and degassed Calcium wash buffer was ran through the column and the entire system for 
several column volumes to ensure uniformity within the system as well as within the Superdex 
media. The sample was then added to the system as described above and the system ran at a flow 
variety of flow rates until a flow rate of 0.2 ml/min was settled upon for optimum resolution of 
the chromatogram. As the void volume of the column is approximately 40 ml, sample collection 
was not started until just under that volume had passed through the column. At that point using 
the attached auto-sampler the effluent was collected in 24 3.5ml fractions A and B 1-12. Samples 
were then labelled and stored at 4°C for further analysis. 
 
2.1.4 Concentrating Proteins 
The effluents from both the affinity and size-exclusion chromatography experiment can be very 
large volumes (as much as 50 ml) as a result these solutions often need to be reduced in volume 
whilst minimising any losses in protein to provide a more appropriate working concentration and 
volume. This was done to allow for following purification steps, analysis by gel electrophoresis 
and ultimately crystal trials. This is done using molecular weight cut-off centrifugal filter devices. 
The use the centrifugal force to push the solution through a filter membrane of a stated 
porousness designed to withhold molecule over a stated molecular weight – 10kDa Amicron Ultra 
15ml and 4ml filters. Samples were spun at a speed of typically 3000g and 4°C until the desired 
volume was achieved. The filtrate should be devoid of protein whilst the retentate should be of a 
much higher concentration than first measured. 
In order to assess the effectiveness of this as well as to quantify the amounts of protein being 
produced in the lab I needed to measure the concentration of the effluents. This is done using the 
UV absorbance spectrophotometry, measuring the absorbance unit for full scale deflection (AUFS) 
of a solution at both 280nm a 320nm wavelengths of light. Absorbance at 280nm is provided 
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primarily by the aromatic rings of both Tryptophan and Tyrosine, as well as some absorbance 
from disulphide bonds. Absorbance of 320nm is used as a measure of background absorbance as 
peptide chains do not absorb at this wavelength. Using the online program Protparam from 
Expasy (http://web.expasy.org/protparam/) I can give the sequence of my target protein and 
determine the Molecular Extinction Coefficient (MEC) which is based on the absorbance of 1M 
solutions of both Tryptophan and Tyrosine as well as their abundance in the sequence of the 
target protein, this coefficient is equal to the absorbance of a 1M solution of the protein. When 
the MEC is divided by the molecular weight of the protein we are provided with the absorbance 
equal to 1mg/ml. Following that the AUF280nm of a sample is then subtracted by the AUF320nm to 
obtain the absorbance contributed solely by the protein before dividing by the MEC to give the 
mg/ml concentration for the sample. 
 
2.1.5 Introduction to Gel Electrophoresis 
Gel electrophoresis is a lab technique that allows for the separation of mixtures of DNA, RNA or 
proteins by their electrophoretic mobility - a function of their size to charge ratio.  Upon 
application of the electric current the biological molecules migrate through pores of variable size 
toward the positive electrode, and they migrate through at a rate determined by their 
electrophoretic mobility. The variable pore size allows for adjustments in migration rates, smaller 
pores will only allow smaller molecules to travel through with ease, larger pore sizes allow smaller 
molecules to travel much more quickly as well as enabling the mobility of larger molecules that 
would be limited by smaller pore sizes. 
Two types of gel medium are available for such separations; agarose and acrylamide. Agarose is a 
linear polysaccharide of galactose - 3, 6-anhydrogalactose repeats cross-linked with hydrogen 
bonds and is primarily used in gel electrophoresis of nucleic acids due to its relatively larger pore 
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size at low percentages (Gaal, et al., 1980; Andrews, 1986). Acrylamide gels on the other hand are 
capable of producing much smaller pores making them far more suitable gels for protein 
separation. Agarose gels simply set and become solid as the solution cools; acrylamide on the 
other hand needs to be polymerised in order to set. Acrylamide is polymerised initially to 
polyacrylamide in the presence of N, N’ -methylenebisacrylamide (bis-acrylamide) which acts as a 
cross-linking agent (Shi, & Jackowski, in Hames, 1998). To further polymerise the acrylamide 
ammonium sulphate is decomposed by N, N, N’, N’-tetramethylene diamine (TEMED), the result is 
the production of free radicals that promote the polymerisation of acrylamide monomers with 
one another as well as bis-acrylamide. Acrylamide composition is defined using two terms C% and 
T%. C% is the percentage of bisacrylamide (cross-linker) relative to the total, whereas T% is 
defined as the total percentage concentration of both acrylamide and bisacrylamide. These two 
values can be adjusted to vary the resolving power of the gel in addition to the use of correct 
buffers and optimum pH values (Shi, & Jackowski, in Hames, 1998).  
As mentioned above, electrophoretic mobility is a function of both size and charge, in order to 
separate proteins by size alone a method must be employed to ensure charge uniformity between 
proteins. This is done by utilising sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE), where the proteins are pre-treated with SDS; an anionic detergent that coats the 
length of the protein ensuring charge uniformity, of negative charge, along the chain as well as 
denaturing the protein to a linear form. In addition to SDS a second denaturant is added – β-
mercaptoethanol, which reduces disulphide bonds that holds both tertiary and some quaternary 
structures together. The result of these treatments is linear polypeptide chains with a net 
negative charge; this allows them to be separated by size only as their charge is uniform and 
prevents the three-dimensional packing of the molecule, as some molecules are packed tighter 
than others, from misleading researchers about their size. When composing an SDS-gel the gel 
can be formed in two ‘layers’, the resolving and stacking gels in a system known as a 
discontinuous system. Firstly the resolving gel is poured, it is typically a higher concentration than 
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the stacking gel and thus separates the proteins by their molecular weight, then the stacking gel is 
poured, the stacking gel is of a low concentration and this allows the proteins to concentrate into 
a single band prior to entering the resolving gel resulting in greater resolution (Shi, & Jackowski, in 
Hames, 1998). Continuous buffer systems are rarely used in protein separations as they often 
yield fuzzy and poorly resolved bands; they are commonly used for the separation of nucleic 
acids. Sample buffer is then added to the proteins, the buffer contains the optimum resolution 
conditions for the gel in question as well as a dye to help visualise the electrophoresis front, in 
order to prevent the over-running of the gel and resultantly having proteins of interest migrate 
out of the gel.  This sample is then heated to further denature the proteins to ensure maximum 
migration through the gel. If it is of interest to separate proteins by size and charge then native 
PAGE gels can be used. In native gels proteins are prepared in a non-denaturing and non-reducing 
sample buffer, as well as the gel being prepared without SDS. The lack of denaturants and 
reducing agents results in the maintaining of the secondary structure of the protein as well as it 
native charge density (Shi, & Jackowski, in Hames, 1998). Once both the gel and the samples have 
been prepared the samples are then loaded into the wells of the gel and an electric current is 
applied. The chloride ions already present in the gel migrate from the anode towards the cathode 
and do so faster than the proteins do resulting in an ion front. The glycinate ions, provided by the 
Tris-glycine running buffer, form an ion front behind the proteins. The leading ion (Cl-) moves 
through the gel ahead of the proteins, the trailing ions (glycinate) follow until they overtake the 
proteins and establish a linear voltage gradient that the proteins then sort themselves along in 
accordance with their size and charge. In SDS-PAGE gels the principle is the same, where the 
proteins are stacked between the leading and trailing ion fronts. When these fronts meet the 
interface between the stacking and resolving gels the % acrylamide increases greatly, restricting 
the migration of the proteins. The proteins are then only separated by size as their charge-to-
mass ratio is the same following SDS treatment and the result is proteins separated into band 
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patterns according to their molecular weights (Shi, & Jackowski, in Hames, 1998). In order to 
visualise the proteins they must be stained post-separation.  
2.1.5.1 Materials and Methods 
Materials, equipment and chemicals for gels: 
  Sodium dodecyl sulphate (Sigma) 
  N, N, N’, N’-tetramethylene diamine (TEMED) (Sigma) 
  Ammonium persulphate (VWR) 
  Tris(hydroxymethyl)methylamine (VWR) 
  Acrylamide and bisacryalmide (Sigma). 
 
Loading buffer: 
  Glycine (Fischer) 
  Glycerol (Sigma) 
  β-mercaptoethanol (Sigma) 
  Bromophenol blue (VWR) 
  Molecular weight markers (Biorad) 
Running buffer: 
  Tris(hydroxymethyl)methylamine (Fischer) 
   Sodium dodecyl sulphate (Sigma) 
               Glycine (Fischer) 
Procedure: 
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SDS-PAGE was used to analyse the success of various rounds of separation of proteins from the 
plasma of Limulus polyphemus. SDS-PAGE took place following every chromatographic step of 
purification to guide the process. Typical gels were made up a 12.5% acrylamide resolving gel with 
a 4% acrylamide stacking gel at a thickness of 1.5mm as per Table 2.1 and in reducing samples 
only β-mercaptoethanol was added to 6%. The samples prior to application to the gel were 
treated with the loading buffer also shown in Table 2.1 and then heated at 95°C for two minutes 
to further denature them. Gels were then loaded into their cassettes and electrophoresis tanks, 
running buffer was added, samples were loaded and the gels were ran at a voltage of 200V for 40-
50 minutes. 
Table 2.1. Table showing the components used to make and run two 1.5mm SDS-PAGE gels 
SDS-PAGE Components 
12.5% Resolving gel 6.66ml acrylamide/bisacrylamide (30%T 2.6%C) 
5.1ml deionised water 
4ml 1.5M Tris HCl pH8.8 
160μl 10% SDS 
10μl TEMED 
100μl 10% Ammonium persulphate 
4% Stacking gel 1.33ml acrylamide/bisacrylamide (30%T 2.6%C) 
6ml deionised water 
2.5ml 0.5M Tris HCl pH 6.8 
100μl 10% SDS 
10μl TEMED 
100μ 10% Ammonium persulphate 
Sample Buffer 125mM Tris-HCl pH6.8 
4% SDS 
0.02% bromophenol blue 
(reducing samples contained 5% β-mercaptoethanol) 
Running Buffer 3.13g Tris 
14.42g Glycine 
1g SDS 
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Materials for staining: 
 Instant Blue (Coomassie based from Expedeon) 
Once the gel had been running for 40-50 minutes at a voltage of 200V, it was removed from 
the tank and left in Instant Blue a Coomassie based stain on a rocker table for approximately 
an hour.  
 
2.2 Isolation and purification of α2-Macroglobulin from the serum of Limulus Polyphemus 
As mentioned previously, PEG Cut serum was provided by Prof. Peter Armstrong of the 
Marine Resources Centre, Marine Biological Laboratory, Woods Hole, Massachusetts. This 
serum was then applied to the phosphoethanolamine linked agarose affinity chromatography 
column in order to remove the pentraxins from the serum. Prior to the initial chromatography 
run PEG-cut serum was ran on an SDS-PAGE gel to assess its contents shown in Figure 2.2. 
 
Figure 2.2. SDS PAGE analysis of PEG-cut serum supplied by Professor Peter Armstrong. The gel was a 
7.5% SDS PAGE gel with all samples ran under reducing conditions. Lane 1 contains molecular weight size 
markers – Biorad All Blue Precision Markers from top to bottom – 250kDa, 150kDa, 100kDa, 75kDa, 
50kDa, 37kDa and 25kDa, smaller markers (20kDa, 15kDa and 10kDa) migrated out of the gel. Lanes 2 and 
3 contains PEG cut serum at a protein content of 28μg and 56μg respectively.  
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Protein content for the gel was extremely high. This was done to ensure that even proteins 
present in the smallest quantity would be visualised. It is clear from the gel that three major 
bands are present in both lanes. The band at the top lies between the markers for 250kDa and 
150kDa, the middle band runs equivalent to the 75kDa band and broad band at the bottom of 
the gel lies just above the 25kDa marker band in lane 1. It is known that the three most 
abundant proteins in the serum of Limulus Polyphemus are in order: haemocyanin, the 
pentraxins and α2-macroglobulin (Armstrong, & Quigley, 1999). It is known that haemocyanin 
is an enormous molecule capable of forming hexamers or oligiohexamers of subunits of 
around 75kDa (Martin, et al., 2007). Under SDS-PAGE reducing conditions the dissociation of 
these oligomers will yield various strands of approximately 75kDa as seen in the middle band 
produced in lanes 2 and 3 of the gel shown in Figure 2.2. Limulus pentraxins of which there 
are CRP and SAP homologues, can be found as stacked octomeric and heptameric rings of 
repeating 25kDa subunits (Shrive, et al. 2009). Based on this information it was concluded 
that the band that travelled furthest through the gel and was in line with the 25kDa marker 
was representative of the pentraxins which could not be distinguished from one another on 
the gel. α2-Macroglobulin has been shown to have a molecular weight of 185kDa per subunit 
in a homodimer arrangement (Iwaki, et al. 1996). Being the largest subunit of these three 
most abundant proteins, the band that travelled the least and fell between markers for 
150kDa and 250kDa was deemed to be the α2m band. Following the assessment of the PEG 
cut serum to ascertain the presence of α2m PEG cut serum was then passed through the 
affinity chromatography column.  
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Figure 2.3. Chromatogram from affinity chromatography run to remove the pentraxins from PEG cut 
serum. The markers shown on the chromatogram are as follows: 1 – protein loaded onto the column, 2 – 
breakthrough fraction collection started, 3 – breakthrough fraction collection finished, 4 – PC applied to 
the column and collection started, 5 – PC collection finished and calcium buffer reapplied, 6 –PE applied 
to the column and collection started, 7 – PE elution collection finished and calcium buffer reapplied, 8 – 
EDTA buffer applied and effluent collection started, 9 – EDTA collection finished, 10 – column 
regeneration started. 
Figure 2.3 shows the chromatogram from an affinity chromatography run of PEG-cut serum as 
described previously. Peak A represents the breakthrough peak of proteins that do not interact 
with the phosphoethanolamine-linked agarose column. In this case the vast majority of the 
absorbance of this peak is contributed by haemocyanin and α2m. Peak B is the phosphocholine 
elution peak, containing previously column bound proteins that bind to phosphocholine 
preferentially. In this case Peak B represents the CRP that was previously bound to the column. 
Peak C is the phosphoethanolamine peak where proteins that were column that bind to PE are 
eluted. Peak C represents the SAP peak where elution with PE ‘released’ it from the column. Peak 
D is the EDTA peak which removes any remaining column bound proteins. The breakthrough 
fraction was then concentrated using a centrifugal filter device prior to its application to the size 
exclusion FPLC column. 
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Figure 2.4. Chromatogram from size exclusion chromatography run (SEC1) using AKTA Explorer setup as 
described previously but with 2.5ml fractions taken from the moment of sample injection thus collecting 
the void volume. The blue line depicts absorbance of light by the sample detected at a wavelength of 
280nm indicating protein. The pink line shown indicates the point of sample injection. 
In Figure 2.4, there are two clear peaks visible. The first peak occurs almost 46ml after sample 
injection which indicates the void volume. A peak at this range shows a protein that was too large 
for the column to interact with. Given that it is known that the limitations of the column are 
proteins of 600kDa and that the smallest conformation of the haemocyanin molecule places it at 
900kDa with the larger oligohexamer weighing 3600kDa, it was expected that this peak is the 
haemocyanin peak which starts in fraction B6 and finishes in B10 before another peak appears. 
The second peak becomes visible in B10 approximately 53ml post-injection and carries on until 
B12. A third peak is then seen as a shoulder peak to the second peak starting in B12 60 ml after 
injection and finishing in C2.  
 
Figure 2.5. A 12.5% SDS-PAGE gel showing the fractions from the size exclusion chromatography. Lane 1 – 
Biorad All Blue precision markers: 250kDa, 150kDa, 100kDa, 75kDa, 50kDa, 37kDa, 25kDa, 20kDa & 15kDa 
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with the 10kDa band not visible. Lane 2 – contains the affinity chromatography breakthrough fraction at 
0.5mg/ml. Lanes 3, 4, 5, 6, 7, 8 9 and 10 – Contains fraction B5, B6, B7, B8, B9, B10, B11, B12, and C1 
respectively from the size exclusion chromatography run at concentrations between 0.2mg/ml and 
0.5mg/ml. 
Figure 2.5 shows the migration of protein bands from the initial size exclusion chromatography 
run of the affinity chromatography breakthrough fractions that showed absorbance at 280nm. For 
comparison some of the original affinity chromatography breakthrough fraction was held back to 
run in Lane 2 to assess its contents as well as seeing which fractions those contents appear in 
respectively. Lane 3/B6 shows a faint very high molecular weight band that has not migrated as 
far as the 250kDa marker has as well as a very faint band in line with the 75kDa marker. As this 
lane equates to fraction B6 and the fraction starts 42.5ml after the injection of the sample it is 
clear that this represents the end of the void volume, the point at which proteins too large to 
interact with the column are eluted. Lane 4/B7 contains the same bands as Lane 3 but with the 
75kDa band being marginally more prominent than the larger mW band. Lane 5/B8 sees a very 
clear and thick band present at 75kDa. As the molecular weights of the subunits are known as well 
as the expected elution order it is likely that this band is for the haemocyanin subunits. Lane 6/B9 
shows the same prominent band at 75kDa believed to be haemocyanin in addition to a band that 
lies between the 250kDa and 150kDa markers – this band is believed to be the start of the α2m 
elution. Lane 7/B10 shows a less intense peak at 75kDa (haemocyanin) and a more intense peak 
present at ~180kDa (α2m). Lane 8/B11 shows the same bands at Lane 7 with the same relative 
intensities but with the addition of a band in the region of ~25kDa believed to be the pentraxins. 
Lane 9/B12 shows a ~180kDa band (α2m) with reduced intensity relative to Lane 8, a 75kDa 
(haemocyanin) band with the same intensity as in the previous two lanes and a less intense 25kDa 
(pentraxin) band. Lane 10/C1 no longer shows the 25kDa band and shows a much fainter ~180kDa 
band however the 75kDa band persists. 
Given that size exclusion chromatography separates proteins by size with the largest being eluted 
first and the smaller proteins last; the first protein eluted should be haemocyanin. This is seen as 
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it is the first protein to appear on the gel, but is visible from fraction B5 through to C1. The 
presence of the haemocyanin in lanes that clearly equate to the elution volume of smaller 
proteins means that the haemocyanin is either present in such large quantities that it ‘leeches 
into the other fractions or that it is interacting with either the column or the lower molecular 
weight proteins in some way. The majority of the protein content of the affinity chromatography 
breakthrough should be haemocyanin followed by α2m and there should be no pentraxins 
present as they should have bound to the phosphoethanolamine affinity chromatography column. 
Therefore the next largest protein should be the ~370kDa α2m, which is appears to be eluted in 
fractions B9, B10, B11 and B12 as evidenced by the gel in Figure 2.5. The presence of the bands at 
75kDa and ~180kDa were anticipated based on the principles of size exclusion chromatography 
and what was known about the affinity chromatography breakthrough fraction. The appearance 
of the double band at ~25kDa was as such a surprise. Given that it occurs in the same fractions as 
the α2m peak it should be noted that it is of a similar molecular weight. The heptameric stacked 
pentraxins have 14 25kDa subunits reaching a net total molecular weight ~350kDa which puts it in 
the same range as α2m. If the affinity chromatography was successful, which it appeared to be 
based on the affinity chromatography trace, why are there pentraxins present in the gel following 
the size exclusion chromatography of the affinity chromatography breakthrough fraction? Whilst 
present in significantly lower levels proportional to those seen in native PEG cut serum (Figure 
2.2), this still presents a problem as the protein shouldn’t be present as it should’ve bound to the 
PE column. However it has been shown that with PEG cut serum the addition of the serum to a 
PE-agarose column leads to the precipitation of some of the pentraxins (Shrive, et al. 2009) these 
precipitated proteins would still be filtered by the centrifugal filter devices and behave on both 
the size exclusion column and the gel as they normally would. It was shown that PEG cut serum 
should be incubated with the resin prior to column packing and elution from the column to 
minimise pentraxins precipitation. 
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Following the SDS-PAGE analysis of the size exclusion chromatography fractions, those shown to 
contain α2m (B10, B11 and B12) were concentrated using centrifugal filter devices prior to UV 
spectrophotometry to assess protein content (0.4ml @ 2.83mg/ml) before being injected back 
onto the size exclusion chromatography system for a second pass. This was done to further 
remove the haemocyanin which should be eluted off approximately 47ml after the sample is 
injected whereas α2m isn’t eluted until ~54ml after sample injection. 
 
Figure 2.6. Size exclusion chromatography chromatogram (SEC2) using AKTA Explorer of a sample from 
fractions B9, B10, B11 and B12 of previous chromatogram collected into 2.5ml fractions at a flow rate of 
0.2ml/min for optimum resolution.  
In Figure 2.6 it is clear the effect of selectively reapplying fractions from the previous size 
exclusion run has had. The injection of the sample occurred at a volume of 242.94ml and the 
fractions were collected immediately thus collecting the void volume. The first peak appears in 
fraction B7 at approximately 289ml, 47ml after injection which is in line with the previous SEC run 
that saw its first peak occur at 46ml after injection. Therefore this peak is likely to be contributed 
by a protein that is large and did not interact with the column. As it is known that fractions B10, 
B11 and B12 were chosen from the first SEC run and they relate to lanes 7, 8 and 9 on the gel in 
Figure 2.5 it is clear that in those three lanes three bands of protein are visible; ~25kDa, ~75kDa 
and ~180kDa. The ~75kDa band which is present in all three lanes/fractions, is believed to be the 
tail end of the haemocyanin peak. This would then coincide with the appearance of a peak on this 
second SEC run immediately after the void volume as seen in Figure 2.6, as even the smallest 
oligohexamer of haemocyanin would be beyond the filtration capability of the column (~600kDa). 
A second peak forms in fractions B10, B11, B12 and C1 roughly 54ml after sample injection. This is 
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consistent with the previous SEC run, except that unlike in Figure 2.4, there is no shoulder peak 
present in C1 and as a result this peak doesn’t extend into fraction C2. 
 
Figure 2.7. SDS-PAGE analysis of fractions of the second SEC run. In Lane 1 Biorad All Blue Precision Plus 
Markers (250kDa, 150kDa, 100kDa, 75kDa, 37kDa, 25kDa and 20kDa with the 15kDa and 10kDa bands not 
on the gel), Lanes 2, 3 and 4 are Fractions B10,B11 and B12 respectively, of the second SEC run shown in 
Figure 2.6, at concentrations of  0.4-0.8mg/ml. The gel was edited to show only the lanes containing α2m. 
SDS-PAGE analysis of the SEC fractions shows similar results to the previous SEC run except that 
the relative amounts of haemocyanin to the proposed α2m band is diminished. This was further 
evidenced by UV spectrophotometric analysis of the fractions following collection. 
Table 2.2. The calculated concentrations using UV spectrophotometry of fractions from both size 
exclusion chromatography runs. 
mg/ml B8 B9 B10 B11 B12 C1 
SEC1 0.64 0.33 0.17 0.28 0.17 0.09 
SEC2 0.01 0.03 0.04 0.016 0.08 0.00 
 
The decline in protein content was visualised in the SEC chromatograms (Figures 2.4 and 2.6), as 
well as the SDS-PAGE analysis (Figures 2.5 and 2.7) and the UV spectrophotometric analysis of the 
fractions. The decline in protein content, primarily caused by the selective exclusion of the 
haemocyanin containing fractions from SEC1 has resulted in better visualisation of protein bands 
in Figure 2.7. It is known that the haemocyanin subunits range from 72kDa to 75kDa (Martin, et 
al., 2007), this is clearly shown in Figure 2.7 where better resolution between bands is visible 
meaning haemocyanin is now clearly represented by two very close bands one that has travelled a 
little further than the 75kDa marker and another which has travelled the same distance.  
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Pentraxins are at this stage still present in small quantities with very faint bands present loosely 
aligned with the 25kDa size marker. Following analysis of the SEC2 fractions by SDS-PAGE 
fractions B10, B11 and B12 were combined and concentrated using a centrifugal filter device to a 
concentration of 1.24mg/ml and a volume of 0.6ml, with the concentration determined by UV 
spectrophotometry. The purpose of this was to remove the remainder of the haemocyanin just 
leaving behind α2m. 
 
Figure 2.8. Size exclusion chromatogram (SEC3) of selected sample containing fractions B10, B11 and B12 
from SEC2, which were shown to contain α2m (Figure 2.6). The blue line depicts absorbance of the 
solution at 280nm and thus shows the quantitative presence of protein in each fraction. Conditions were 
identical to the two previous SEC runs to ensure the comparability of the chromatograms; the protein 
was eluted in 1x Ca buffer (10mM CaCl2, 150mM NaCl, 50mM Tris Base pH 7.4), at a flow rate of 
0.2ml/min for optimum resolution and collected into 2.5ml fractions from the moment of sample 
injection. 
 
Size exclusion chromatographic separation of the α2m containing fractions from SEC 2, yields a 
single peak that begins ~52ml and spans B10, B11, and B12 after the sample was injected onto the 
Superdex column. There is no distinguishable peak present at ~46ml which is the typical volume 
at which haemocyanin is eluted as shown in Figure 2.8. The absorbance does creep up a little in 
fraction B7 which is eluted 47ml after elution the typical range for the void volume and therefore 
haemocyanin.  
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Figure 2.9. SDS-PAGE analysis of fractions B10, B11 and B12 from SEC3. Analysis was performed on a 10% 
SDS-PAGE gel and stained with Expedeon Instant Blue a Coomassie based stain. Lane 1 contains the 
Biorad All Blue Precision Plus markers (250kDa, 150kDa, 100kDa, 75kDa, 50kDa, 37kDa and 25kDa, with 
the 20kDa, 15kDa and 10kDa markers having migrated out of the gel), Lanes 2 and 5 contain the native 
PEG cut serum at a protein content of 28μg. Lanes 3, 4 and 5 contain fractions B10, B11 and B12 from 
SEC3 at 0.2-0.5mg/ml. 
SDS-PAGE analysis of the fractions from the third size exclusion chromatography run, shows that 
fractions B10, B11 and B12, only contain one band that lies between the 150kDa and 250kDa 
markers at approximately 180kDa. Given that the known subunit size of Limulus α2m is ~185kDa 
once glycosylated it is assumed that this is the protein responsible for the visualisation of this 
peak. Furthermore the lack of any bands at both 25kDa – the known subunit size for Limulus 
pentraxins (Shrive, et al., 2009) and 72-75kDa – the known subunit size for Limulus haemocyanin 
(Martin, et al. 2007) it can be said with a reasonable certainty that the isolation of Limulus α2m 
from PEG cut serum is complete as no trace contaminants are visible on the gel in Figure 2.9. 
2.3 Reaction of Limulus α2-Macroglobulin with methylamine 
In order for α2m to allow proteases to access its bait region, it has a very high level of flexibility 
and is often referred to as being floppy. Transmission electron microscopy studies (TEM) have 
shown that α2m in its activated form is far more uniform in shape (Armstrong, et al. 1991). This 
molecular flexibility would no doubt pose a problem with regards to crystallisation of the 
molecule. As crystallisation utilises symmetry and the use of repeating building blocks, the unit 
cell, having an irregular protein capable of many orientations in its inactive form would be 
prohibitive to the formation of crystal contacts and thus crystal growth. As a result of this 
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activated α2m was the target molecule for crystallisation. Whilst a wide variety of potential 
ligands are available for α2m, thanks to its promiscuous bait region, and a broad range have in 
fact been reported and tried with the human α2m (Andersen, et al. 1991; Andersen, et al. 1994a; 
Andersen, et al. 1994b; Andersen, et al. 1995), there has been only one success of note, that is 
the production of diffraction spots to a resolution good enough to obtain a model,  the 
crystallisation of human α2m reacted with methylamine (Marrero, et al. 2012). A protocol was 
devised based upon that used by the group lead by Lars Sottrup-Jensen (Andersen, et al. 1991; 
Marrero, et al. 2012). In their protocol (Andersen, et al. 1991), human α2m at a concentration of 
10mg/ml is incubated with 0.2M methylamine and 10mM iodoacetamide, which is a protease 
inhibitor for cysteine proteases, for two hours. These concentrations were adjusted based on 
available concentrations of Limulus α2m to maintain the relative ratios. Following incubation for 2 
hours, the sample was then concentrated in a centrifugal filter device to remove any remaining 
methylamine and iodoacetamide before being applied to the size exclusion chromatography FPLC 
column to separate the two forms of α2m – native and methylamine reacted.  
 
Figure 2.10. Size exclusion chromatogram of sample containing Limulus α2m reacted with methylamine. 
The pink dashed line shows the point of sample injection; The blue line shows the absorbance of the 
effluent at 280nm thus indicating protein presence. The sample was ran at a flow rate of 0.2ml/min and 
collected in 2.5ml fractions. 
Size exclusion chromatography of the methylamine reacted Limulus α2m (SEC4) Figure 2.10, 
shows a single peak that starts in fraction B7 which occurs 47.5ml after sample injection and 
fraction C2 which is eluted 65ml after sample injection. The early region of the peak (fractions B7-
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B9) shows extremely shallow curvature and given the elution volume is consistent with the void 
volume and the region that typically contains haemocyanin, which may be present here in 
fractions B7, B8 and B9 in trace amounts. Whereas absorbance in fractions B10, B11 and B12 and 
to a lesser extent C1 and C2 fall in the typical elution volume range that α2m falls within, and 
those here that show the greatest absorbance. These fractions (B10, B11, B12, C1 and C2) were 
combined and concentrated in a centrifugal filter device before analysis via gel electrophoresis. 
 
Figure 2.11. Native PAGE gel (4%) analysis of the peak from SEC4 (fractions B10, B11, B12, C1 and C2). 
Lanes 1 and 5 contain native PEG cut serum at a protein content of 5.6μg. Lanes 2 and 4 both contain 
purified Limulus α2m from SEC3 at a concentration of 8.7μg. Lane 3 contains fractions B10, B11, B12, C1 
and C2 which contains Limulus α2m that has been incubated methylamine for two hours, at a protein 
content of 7.7μg.  
Analysis of the successful reaction of Limulus α2m with methylamine was carried out using a 4% 
native PAGE gel. This was done as SDS-PAGE analysis would not differentiate between the reacted 
and unreacted forms of α2m as the cause of the increased electrophoretic mobility is due to the 
condensing of the quaternary structure, which destroyed during sample preparation in SDS-PAGE 
and thus no discernible difference can be seen. Rather than use molecular weight markers, PEG 
cut serum was used to show the migration distance of unreacted α2m. There is a band consistent 
across Lanes 1, 2, 4 and 5, given that it is known that the only protein present in the samples used 
in Lanes 2 and 4 is made up of a protein with subunits between 250kDa and 150kDa as shown in 
Figure 2.11, it can be assumed that the consistent band seen in these lanes is α2m. As the sample 
used in Lane 3 is taken from the same protein stock used for Lanes 2 and 4, it again can be safe to 
Native α2m 
 
MA-reacted α2m 
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assume that the only protein present here is α2m. In this case it is clear that the principle α2m 
band has travelled further through the gel and thus indicating increased electrophoretic mobility, 
a defining characteristic of the reacted form of α2m. The other faint bands present in Lanes 2 and 
4 that appear to have travelled further than the proposed unreacted α2m band is caused by an 
unknown protein. Native PAGE gels are notoriously unreliable when it comes to resolving proteins 
(Shi, & Jackowski, in Hames, 1998). Given that one of the additional bands has a comparable 
migration distance with that proposed to be the α2m-MA band seen in Lane 3, it is possible that a 
proportion of the α2m present has become reacted as there are multiple opportunities for 
reaction to occur. Based on the evidence demonstrated in the chromatograms and gel images 
shown, the purification from PEG cut serum and the subsequent reaction with methylamine of 
Limulus α2m has been successful. Following this the process was repeated and up-scaled for 
production of sufficient quantities of pure methylamine-reacted Limulus α2-macroglobulin for the 
crystallographic trials that followed. 
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Chapter 3 – Crystal Studies of α2-Macroglobulin from Limulus Polyphemus 
3.1 Introduction to Biomolecular Crystallography 
As our curiosity into the fundamental mechanisms of life intensifies, a common theme has 
become apparent. The key to fully understand the function of anything in biology lies in its 
structure. This can be said of all structures in biology from the cellular level, all the way down to a 
molecular level. There are a variety of techniques available to structural biologists, which will be 
discussed later, the principle method however is x-ray crystallography (Jaskolski,  2010). 
3.1.1 Protein Structure 
Proteins, often considered the building blocks of life are the products of our genes translated 
from mRNA by the ribosome. The result is a linear chain of amino acids, a polypeptide which is 
folded in the Golgi apparatus before being released. Amino acids are chiral in nature, with a 
central chiral α-carbon atom bound to an amine group, a carboxyl group, a hydrogen atom and a 
variable side chain group. Shown in Figure 3.1, amino acids as with all chiral molecules there is an 
L-form and a D-form of almost all amino acids – the non-chiral glycine being the only exception . 
But in protein only the L-form is seen. 
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Figure 3.1. Basic amino acid structure of both the L- and D- isomers. The variable R group is what 
differentiates amino acids from one another and the interactions of these side chains contribute towards 
the structure of the molecule. Diagram edited from (Berg, et al. 2006) 
The variable side-chains of amino acids are what differs between them.  The side chains can be 
classified as polar or non-polar based upon the hydrophobicity of the side chain. The polar side 
chains can then be further classified into acidic (Glutamic acid - Glu/E),basic (Histidine – His/H) or 
neutral (Threonine – Thr/T). The properties of the side chains are key in the final spatial 
characteristics of the folded protein.  The sequence of these amino acids in the polypeptide chain 
is known as the primary structure of the protein. Secondary structures within proteins are 
primarily made up of α-helices and β-sheets, which are held together by inter-side chain hydrogen 
bonds (Branden, & Tooze, 1999).  
In the α-helix hydrogen bonds form between the carboxyl group f residue n and the amine group 
of residue n+4 of the main chain backbone. The helix has 3.6 residues per full turn In proteins due 
to the use of the L- form of the amino acids the helix is right-handed as the packing of the side-
chains would not allow for a left-handed screw of the helix. The β-strand is made up typically of a 
fully extended stretch of 5-10 amino acids, where hydrogen bonds between adjacently aligned β-
strand carboxyl and amine groups leads to the formation of β-sheets. If the sequence of the β-
sheet runs so that the N-Cα-C-N-Cα-C motifs of two aligned, adjacent, and hydrogen bound β-
strands run in the same direction a parallel β-sheet is formed, if they run in opposite directions an 
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anti-parallel β-sheet is formed, with mixed β-sheets also a possibility. Most protein based  β-
sheets have a twist to their strands, which like the α-helix is always right handed . 
Hydrogen bonds occur between oxygen or nitrogen atoms and hydrogen and are relatively weak 
compared to covalent bonds. Combinations of these secondary structures form motifs such as the 
pentraxin domain seen in pentraxins (Gewurz, et al. 1995), which is made up of a flattened β-jelly-
roll with a long α-helix folded on top of the β-sheet. Knowledge of the primary structure and the 
secondary structures often doesn’t reveal the function and mechanisms of a protein. There are a 
variety of techniques available to learn the primary and secondary structures of a protein. 
However, in order to fully grasp the function and mechanisms of action we must use techniques 
that reveal every atom of the structure. Tertiary structures arise from the folding of the peptide 
chain and the combination of secondary structure motifs. The tertiary structure often represents 
the individual subunit of a protein molecule. Internal bonds holding together the tertiary 
structure include: covalent disulphide bridges between cysteine residues, hydrophobic 
interactions where the hydrophobic side chains of the amino acids ‘hide’ away from the solvent 
by remaining buried within the core of the protein, hydrogen bonds, coordination of partially 
negatively charged side chains by metal or salt ions, and Van de Waals forces. Finally the 
quaternary structure of the molecule, the arrangement of subunits; stabilised by the same non-
covalent and disulphide bonds that hold together the tertiary structure of the protein. 
3.1.2. Benefits of Crystallography 
X-ray crystallography of macromolecules is the gold standard technique for atomic resolution 
structure determination. Structures solved by X-ray crystallography have been solved to 
resolutions as high as 0.5 Å, although structures are more commonly seen at ~2Å. It is this ultra-
high resolution that makes crystallography such a valuable technique. It allows us to see the 
molecular interactions of proteins both natively and with their target ligands at a molecular level; 
thus revealing the mechanism of action and the residues involved in binding. This is in itself a 
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valuable piece of information as it can lead to the development of new therapeutic agents in 
some cases where, drugs can be designed to fit or block binding pockets or proteins can be 
engineered to bind more effectively. A common argument against crystallography, raises issues 
the physiological relevance of the structures determined by x-ray crystallography. However 
crystallographers answer to this, is that the proteins are still biologically active as shown by 
binding of their natural ligand targets in crystal structures. X-ray crystallography has been used to 
determine the structure of DNA, small peptides, large macromolecules and even viruses.  
It would however be careless to neglect the disadvantages to crystallography. The rate 
determining step and often the major stumbling block is the production of diffraction quality 
crystals. Some crystals grow in a matter of weeks and other can take years if they grow at all; and 
even then they may not be suitable for x-ray diffraction. Hydrogen atoms cannot be seen as they 
only have one electron to diffract the x-rays; this may seem trivial but as mentioned earlier 
hydrogen bonds play a key role in inter-residue interactions giving rise to secondary structures. 
3.1.2.1. Other Techniques in Structural Biology 
Circular Dichroism spectroscopy is a technique that is capable of producing information on the 
polypeptide backbone conformation of proteins yielding information about the secondary 
structure and showing the presence of conformational changes by measuring the difference in 
absorbance of and left- and right- circularly polarised light by a chiral sample (Wallace, & Janes, 
2001). Whilst not capable of yielding the super high resolution data of x-ray crystallography, 
circular dichroism provides us with data such as % α-helix due to the spectral signature shown by 
helices. Despite the protein sample needing to be of similar purity to that needed for 
crystallography >95%, the sample does not need to be crystallised to yield data, thus providing a 
useful complimentary structural tool, that can yield data during the time variable stage of growing 
crystals while investigating a protein structure (Kelly, et al. 2005). 
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Cryo-electron microscopy (Cryo-EM), is the electron microscopy of an unstained biological 
specimen in a frozen state; it is capable of yielding structural models to an atomic resolution 
(Glaeser, & Hall, 2011). Currently cryo-EM has only been able to produce atomic resolution 
models of large macromolecular proteins >500kDa, and cryo-EM studies have struggled to hit 
ultra-high resolutions in molecules with multiple conformational states. A relatively new 
structural biology technique it can be expected that the resolution quality and size range capable 
with this technique only will improve as advances continue to be made (Glaeser, & Hall, 2011). 
 Nuclear Magnetic Resonance (NMR) – spectroscopy is also used to study the structures of 
proteins. It exploits the magnetic properties of certain atomic nuclei and yields structural data 
that can rival X-ray crystallography (Keeler, 2005). 
In the 1960s NMR spectroscopy, a technique that had been predominantly used to study the 
structure of small organic molecules began to be applied to larger organic molecules; proteins, 
nucleic acids and carbohydrates (Macomber, 1998). NMR-spectroscopy is a very useful and 
powerful tool for structural biologists to utilise, as is currently the only method that allows for the 
production of a high resolution 3-D structure determination of partially or wholly unstructured 
proteins. NMR-spectroscopy though does have its limits and protein structures solved by NMR-
spectroscopy are limited to around 35kDa in size. 
X-ray crystallography is still the gold-standard for protein structure determination, it is however 
not without its challenges it is for this reason that other techniques should be considered and 
used to compliment crystallographic data as well as providing alternatives for those difficult to 
crystallise proteins (Sengupta, 2010). 
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3.2 Protein Preparation and Crystal Growth 
In order to determine the structure of a protein molecule using crystallography we first need a 
crystal.  Different methods may be used in the growth and optimisation of the crystals in the 
search for diffraction quality crystals. Crystals grown for macromolecular crystallography are 
ideally large in nature (0.1-0.5mm), although smaller crystals may be used, making use of 
specialised beamlines (I-24 Microfocus – Diamond Light Source, Oxford). Ultimately the quality of 
the crystal determines the quality of the data, with protein purity being the most vital factor in 
crystal quality. 
3.2.1 Protein Preparation 
3.2.1.1 Protein Purification 
As stated above protein purity is a key ingredient in the successful growth of diffraction quality 
crystals. The protein needs to be >95% purity this is to ensure that when the crystal forms it is 
made a single protein type. Impurities will lead to the presence of multiple asymmetric units 
being present resulting in the absence of diffraction. Due to α2-macroglobulin possessing two 
conformational states (fast-form and slow-form, as shown with PAGE analysis (Barrett, et al. 
1979; Quigley, & Armstrong, 1985) homogeneity of the sample is key. This is but one obstacle in 
terms of sample preparation for crystallographic studies of α2m, as the slow-form is not as 
structurally rigid as its fast-form counterpart. The regularity and rigidity of the fast-form molecule 
makes it a more suitable target for crystallisation. The fast form can be obtained by reaction of 
α2m with methylamine or any protease that cleaves its bait region triggering the conformational 
change. There are a wealth of techniques available to produce purified protein in addition to 
those discussed in the previous chapter, a number of chromatographic techniques are typically 
used in combination with each other and verified using techniques such as SDS-PAGE and western 
blots etc.  
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3.2.1.2 Protein Concentration 
As discussed in greater detail earlier, the formation of crystals is dependant of supersaturation of 
the protein. Too high a protein concentration and supersaturation occurs too fast resulting in the 
formation of amorphous precipitate, too low and crystallisation will never occur. A number of 
techniques can be used to concentrate a protein but in the previous chapter I stated that for the 
experiments in this thesis, ultrafiltration by centrifugation was used. 
3.2.2 Crystal Growth: Dynamics & Techniques 
Thermodynamics are the driving force behind crystal formation. In forming a crystal rather than 
staying in solution the proteins are taking the route that is most thermodynamically favourable. 
This is because the crystalline state represents the greatest number of stable bonds and thus 
reducing the free energy. The fact that the crystalline form represents the more favourable 
energy state is shown by, the initial formation of precipitate before it’s dissolution, during which 
crystals form. The reverse cannot be observed. 
Crystals grow from supersaturated solutions, that is to say its concentration in solution is greater 
than the limit of their solubility. This is because in the supersaturated zone the nature of the 
equilibrium between solid phase and the solution encourages the movement of proteins into the 
solid phase. Achieving the appropriate level of supersaturation is a fine art; too low and crystals 
will never form, too high and the protein will fall out of solution as amorphous precipitate rather 
than beautifully order crystals. To help explain this, the phase diagram was devised to illustrate 
the relationship between protein concentration and precipitant concentration. 
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Figure 3.2. The phase diagram for crystallisation. It consists of two primary regions; the undersaturated 
and the supersaturated. The two regions are divided by the equilibrium line that represents the 
maximum solubility of the protein. The supersaturated region itself is divided into three zones; the 
precipitation zone where protein falls out of solution into amorphous precipitate, the labile zone where 
nucleation and crystal growth occurs, and the metastable zone where crystals do not nucleate but will 
sustain growth if present (McPherson, 2009). 
Once the protein is in the supersaturated region nucleation is required for the crystal to form and 
grow as opposed to the formation of nonspecific aggregates. The formation of a stable nucleus is 
key, ‘unstable’ nuclei form rapidly and spontaneously once the supersaturated state has been 
achieved but quickly dissolve into solution. A stable nucleus then is one that enlists new 
molecules onto its growing surfaces at a rate faster than others dissolve back into solution, 
resulting in a net gain of mass for as long as it remains in the supersaturated condition. Stable 
nuclei are almost exclusively found in the labile zone of the supersaturated region. The 
metastable zone does not produce stable nuclei, however if a stable nuclei were to be deposited 
by some method as in crystal seeding, that nuclei would continue to grow, so long as 
supersaturation was maintained. 
Using the phase diagram in Figure 3.2 that the nucleation zone is between the metastable growth 
zone of a crystal and the amorphous precipitate zone, which are both defined by the relationship 
 81 
 
between protein concentration and the concentration of a precipitant. In terms of crystal growth 
there are two types of nucleation; homogenous nucleation and heterogeneous nucleation. For 
homogenous nucleation to occur the [protein]:[ppt] has to be in the nucleation zone also known 
as the homogenous nucleation zone. Crystals that form from this zone have nuclei made solely of 
the target protein. When we grow crystals via heterogeneous nucleation we place a preformed 
nuclei in the metastable growth zone, also known as the heterogeneous nucleation zone, and the 
target crystal forms around this nuclei of non-target molecules. This process is called crystal 
seeding and shall be addressed in more detail further on. 
3.2.2.1 Thermodynamics of Crystal Nucleation 
The birth of a protein crystal from its mother liquor requires a central starting point, a nucleus. 
These nuclei are made up of growth units that vary from individual monomers to dimers or even 
tetramers. Growth units by successive aggregation form spherical nuclei known as embryos. 
Crystal embryos are spherical in shape as a sphere has a low surface area to volume ratio and thus 
is the typically thermodynamically favoured shape of crystal nuclei for reasons to be explained 
(Oxtoby, 1998). 
The lifetime of these nuclei is dependent upon the forces the growth units exert on one another 
and on the solution in which they sit. If we imagine that the growth units are spherical themselves 
and each has six perpendicular forces it can exert upon other growth units or the external 
solution. The forces they exert on one another are fighting to hold the embryo together whereas 
the forces they exert on the liquid phase are trying to pull the newly formed cluster apart. The 
forces that work to maintain the integrity of the embryo is proportional to the number of bonds 
between growth units and can be considered proportional to the volume of the embryo. The 
forces working to pull the embryo apart are proportional to the number of free bonds and are 
proportional to the surface area of the embryo (Garcia-Ruiz, 2003). 
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Therefore the energy balance can be written as: 
∆𝐺𝑡 = ∆𝐺𝑠 − ∆𝐺𝑣 
Where ΔGt is the total Gibbs free energy of an embryo and ΔGs is the free energy from 
unsaturated surface bonds and ΔGv is the free energy contributed by the internal saturated bonds. 
As stated previously ΔGs and ΔGv are proportional to the surface area and volume of the embryo 
respectively. As a spherical nucleus is the favoured embryonic form we can then substitute in the 
volume and surface area of a sphere in to the equation. 
∆𝐺𝑡 =
4𝜋𝑟2
𝑎2
𝛾 −
4𝜋𝑟3
3𝑎2
∆𝜇 
Where a is the size of the individual growth unit, r is the radius of the cluster, γ is the free energy 
of the surface bonds per unit area, also known as surface tension, and Δμ is the difference in 
chemical potential between the growth units of the solution and those of the embryo. 
 
Figure 3.3. Graph depicting the energy balances governing crystal growth. ΔGt is the total Gibbs free 
energy, ΔGs is the free energy from free unsaturated surface bonds and ΔGv. When depicted like this a 
clear maximum value for ΔGt is visible ΔG*, which is known as the nucleation barrier (Garcia-Ruiz, 2003) 
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If we attribute a value to a and plot ΔGt, ΔGs and ΔGv against increasing values of r we can see in 
Figure 3.3 that ΔGt, reaches a maximum value at a particle size called the critical size, r* the 
energy required to achieve critical radius is known as the nucleation barrier or ΔG*. When 
embryos reach the critical size they are now referred to as nuclei; embryos with r<r* dissolve back 
into solution, those nuclei with r>r* are likely to go on to form nuclei and eventually crystals. Once 
r* has been achieved it is clear that the expansion of r beyond that point lowers the total Gibbs 
energy further and is thus a spontaneous process (Garcia-Ruiz, 2003). Both the nucleation barrier 
and the critical radius can be written as a function of the degree of supersaturation: 
∆𝐺∗ =
16𝜋𝛾3
3[𝑘𝑇 ln(𝑆)2
 
 
𝑟∗ =
2𝛾𝑎
𝑘𝑇 ln 𝑆
 
 
Where S is the degree of supersaturation, as a result it is clear that both the critical radius and the 
nucleation barrier decrease with and increasing supersaturation. 
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Figure 17 Gibbs energy balance of crystal nucleation. Three examples of varying amounts of 
supersaturation (S) S=1, S=0.75 and S=0.5, showing that the greater the supersaturation the lower the 
energy required for successful nuclei formation resulting in a smaller required radius for said crystal 
nucleus (Garcia-Ruiz, 2003). 
By visualising these relationships in Figure 3.4 we can infer that at higher degrees of 
supersaturation the lower the nucleation barrier and thus the lower the critical radius required 
for a nucleus to form and continue to grow. At lower levels of supersaturation this energy barrier 
is higher and as a result the required critical radius is larger. It would seem then that the ideal 
degree of supersaturation is as high as possible to ensure that nucleation is as energetically 
favourable as possible. However, if we raise the degree of supersaturation so high that r* is 
smaller than the size of an individual growth unit the result is the production of the amorphous 
phase known as precipitate. Another outcome of having too high a degree of supersaturation is 
that nucleation occcurs to quickly due to the low energy and small radius required for it to occur 
and we see a shower of tiny crystals as too many nuclei have formed. In order to grow a small 
handful of large crystals it is better to have a supersaturation that sits at the lower end of the 
nucleation zone of the phase diagrams shown earlier in the chapter, whilst energetically less 
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favourable and thus requiring a larger nuclei to achieve r*, this will give fewer and ultimately 
larger crystals which are generally easier to extract data from downstream. 
Crystals that form more slowly are generally free of defects and the crystals would move out of 
the labile zone and into the metastable as the concentration went down as protein was recruited 
to the nuclei. 
3.2.2.2. Crystallisation Experimental Setup 
In order to grow crystals proteins are normally dissolved in a buffer containing a precipitant often 
of the PEG family. Using controlled evaporation, water is slowly moved from the solution, to 
achieve supersaturation and crystal growth. The most common technique utilising controlled 
evaporation is – vapour diffusion, of which there several permutations the two most common 
being the hanging and the sitting drop methods. 
The hanging and sitting drop both employ the same theory behind them; however, they differ 
slightly in experimental setup illustrated in Figure 3.5.   
                    
Figure 3.5. Schematic of both sitting and hanging drop experimental setups.  The blue area represents the 
reservoir solution normally containing precipitant, buffer and salt but importantly no protein. The grey 
droplets represent the protein droplet and ultimately the area where crystal formation will occur. The 
protein droplet normally consistent of an equal volume of protein solution and of reservoir solution. 
However this is not always the case. The tops of the wells are sealed with grease, in order to create an air 
tight isolated system. This is to prevent the reservoir solution from evaporating and drying out as the goal 
of vapour diffusion is for the droplet to dry out as described below.  
Vapour diffusion works on the principle of the concentration difference of the precipitant 
between the droplet and the reservoir solution will result in the net movement of water from the 
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droplet into the reservoir. This is because the concentration of the precipitant in the droplet in an 
equivolume setup is half that of the reservoir solution. Thus water via diffusion leaves the droplet 
in favour of the reservoir until a state of equilibrium is achieved. This loss of water from the 
protein droplet not only increases the precipitant concentration but also the protein 
concentration, thus pushing the protein into the supersaturated state. 
Other crystal growth techniques used are liquid-liquid diffusion and dialysis, but they work on the 
same principle – driving the protein concentration into the supersaturation leading to crystal 
formation.  
  
3.2.3 Radiation Damage 
Due to the photons of X-rays having such high energy levels, when they come into contact with 
the proteins they can form radicals within the molecules leading to crystal degradation. The 
oxygen or hydroxyl radicals can diffuse through the crystal causing further damage to the crystal 
structure that leads to a visible tailing off in the resolution of data being recovered from the 
crystal. The latest detectors used in x-ray crystallography allow shorter exposure times than their 
predecessors, reducing the crystals exposure to radiation and subsequently reducing radiation 
damage. Even if the correct precautions, such as the cryoprotective measures discussed in the 
next section, are taken radiation damage still occurs but just to a lesser extent. Disulphide bonds 
in particular are prone to cleavage as a result of radiation damage, the decarboxylation of 
carboxylic acids are all noted effects of radiation damage as well as an increase in atomic B-factors 
(Drenth. 2007). 
3.2.4 Cryoprotection 
Whilst often morphologically indistinguishable small molecule and macromolecular crystals differ 
greatly in their properties.  When compared to crystals formed by small molecules, protein 
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crystals are generally weaker; this is due to the fewer lattice interactions proportional to 
molecular mass. Thus the crystals are softer, more flexible and are much more sensitive to a 
subtle change in conditions.  When protein crystals form, there are gaps or channels between 
molecules in the crystal structure, these gaps are filled with solvent. This solvent which makes up 
on average 50% of the crystal is free to diffuse in and out of the crystal. These solvent channels 
are partly responsible for the reduced resolution seen in macromolecular crystals as opposed to 
small molecule crystals which diffract to much higher resolutions generally. This is because the 
large gaps between the molecules reduce the likelihood of every molecule lining up in its exact 
position, thus bringing about slight variation from lattice point to lattice point (McPherson, 2009).  
In order to minimise the radiation damage discussed, crystals are cryocooled. Upon their 
harvesting from the mother liquor, via nylon cryoloops available from companies such a Hampton 
Research, the crystals are then added to their vial caps and stored in liquid nitrogen until data 
collection. This freezing of the crystal leads to the immobilisation of the radicals produced by 
exposure to X-rays and thus minimises the damage they cause. Even during data collection the 
crystals will be kept under a constant cryostream ensuring they stay frozen. In the process of 
protecting the crystals from radiation damage another problem has been introduced; water 
molecules in the above mentioned solvent channels freeze due to the low temperature and form 
ice crystals. The formation of these ice crystals within the solvent channels of the protein crystal 
leads to crystal damage as water expands as it freezes. As a result the crystals are introduced to 
antifreeze solutions that subsequently act as a cryoprotectant preventing the water molecules 
from forming the ice crystals and leading to the disruption of the crystal. Cryoprotectants are 
typically molecules such as glycerol or , 2-Methyl-2,4-pentanediol (MPD) and low molecular 
weight PEG such as PEG 200 MME. Some crystals can be grown already in the presence of a 
cryoprotectant, and thus don’t need to be further cryoprotected as sometimes the addition of a 
cryoprotectant can lead to the crystal breaking up (Drenth, 2007). 
 88 
 
 
3.3 Protein Crystals 
3.3.1 Crystal Properties 
Crystals are made up of the periodic assembly of small building blocks, which can be small 
molecules, nucleic acids, proteins or even massive protein-protein complexes. In protein crystals 
there is a sparse network of weak intermolecular interactions between protein molecules. Due to 
the irregularity in shape of proteins as well as the sparsity and lack of strength of the interactions 
between protein molecules, protein crystals are often extremely weak, fragile and often soft. As a 
result proteins need to be handled with extreme care to avoid, disintegration, delamination or the 
breaking off of a desirable chunk. 
 The weak forces holding the protein molecules in the crystal lattice include: dipole-dipole 
interactions, hydrogen bonds and van der Waals forces. The gaps between molecules, the afore 
mentioned solvent channels, are filled with the mother liquor solution from which the crystal was 
grown, resulting in crystal solvent content of around 50%.  
As proteins are irregular in shape and contain multiple sites for these weak protein-protein 
interactions, the same protein may form more than one crystal morphology dependent upon the 
crystallisation conditions. This phenomenon may be helpful in trials where ligand soaking is the 
target and one crystalline morphology favours a larger ligand and allows for the successful 
soaking. 
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3.3.2 The Asymmetric Unit, Space Group Symmetry Operations and the Unit Cell 
The asymmetric unit of a crystal is the smallest structure that lacks any inherent symmetry; 
typically in protein crystallography the asymmetric unit is an individual protein molecule or 
subunit, on occasion it can be a half or quarter subunit depending upon self-symmetry within the 
molecule. In the next step of molecular organisation within the crystal, the asymmetric unit has a 
variety of symmetry operations applied to it; the result is a closely packed additional set of 
asymmetric units. Multiple symmetry operations may be applied to the asymmetric unit, these 
range from the simple; translation and rotation, which can combine to give: centres of symmetry 
and screw axes. These combinations of symmetry operations are known as the space group. 
There are limits however to which symmetry elements are allowed within a crystal, a 
comprehensive list is given in the International Tables for X-ray Crystallography Vol. 2 (Hahn,  
2005), combinations of all of the possible symmetry operations gives rise to 230 unique three-
dimensional space groups. The space group of a crystal might best be described as how using 
symmetry operations, a set of asymmetric units are related. Due to the stereoisomerism present 
in amino acids, and proteins only using the L-isomer, the space groups that require inversion 
symmetry (the changing of hands of the molecule), centre of symmetry, mirror plane and glide 
planes are all eliminated for selection by proteins reducing the available number of space groups 
for the molecules to assume within the crystal to 65 (Rupp, 2010).  
Screw axes a combination of a N-fold rotation followed by a successive translation, and hence the 
previous name in earlier literature of a roto-translation. With rotational symmetry the asymmetric 
unit with N fold rotational symmetry was returned to its starting position; this is not the case for 
screw axes. In the screw axes with N-fold rotational symmetry the translational vector t, has a 
magnitude of s/N, where s has values 1-N-1 meaning that as rotational symmetry increases the 
number of rotational axes also increases (Rupp, 2010). To explain space group nomenclature I will 
use P21 as an example. The capital letter at the beginning of the space group denotes the crystal 
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system in place – in this case primitive, with a symmetry operation of 21 (Rhodes, 2000).What this 
means in reality is that the asymmetric unit undergoes two fold- rotational symmetry, before 
undergoes a 1/2 or a c/2 translation along the c axis. 
The third stage in constructing the building blocks of a protein crystal is to construct the smallest 
possible parallelepiped that encloses the full set of symmetry operated molecules. The nature of 
the unit cell is in fact determined by the symmetry operations performed on the unit cell shown 
below in Figure 3.6. 
 
Figure 3.6.  The arrangement of the various building blocks of a protein crystal. A) The asymmetric unit, 
the smallest element of the crystal building block lacking any symmetry. B) The space group related 
symmetry operations upon the asymmetric unit. In this example the original asymmetric unit labelled i, 
undergoes two, twofold rotations. The first along the vertical axis to produce asymmetric unit ii and the 
second along the horizontal axis to produce asymmetric units iii and iv. C) demonstrates the imaginary 
boundary of the unit cell enclosing the complete collection of symmetry operated asymmetric units, and 
mimics the symmetry operations of the space group. D) the periodic packing of the unit cells along the 
unit cell axis forming he crystal lattice (McPherson, 2009). 
As the space group determines the characteristics of the unit cell, a nomenclature needs to be 
used when talking about the properties of the unit cell. The basis vectors of the unit cell are a, b 
and c all emanating from the origin 0. The angles between the basis vectors of the unit cell are 
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also determined by the symmetry functions of the space group. The angle between vectors a and 
b is γ, the vector between a and c is β, and the angle between b and c is α. The planes between 
vectors are also labelled so that the plane spanned by a and b is C, a and c is B and b and c is plane 
A.  
 
Figure 3.7. The dimensions, angles and planes of the unit cell of a crystal. Understanding these is key for 
the understanding of crystal systems and lattices. Diagram edited from (Drenth, 2007) 
These axes dimensions and the angles, shown above in Figure 3.7, help to classify the crystal 
system and eliminates certain space groups, and so the unit cell data is extremely valuable. 
 
3.3.3 Crystal Systems, Bravais Lattices and Point Groups 
There are seven crystal systems, as defined by the relationship between the axes and 
their enclosed angles. These crystal systems are described in Table 3.1 along with the 
types of lattices/Bravais lattices they can accommodate. The unit cell generally only 
contains one full complement of the symmetry operated asymmetric units, these crystal 
systems are known as primitive lattices, denoted P (McPherson, 2009). However in higher 
order crystals exhibiting more symmetry, there may be more than one full complement of 
symmetry operated asymmetric units. These make up the centred lattice systems that 
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may either be face centred, F/C where F has all planes centered as opposed to just plane 
C, body centred I, or rhombohedral centred R. The centred crystal systems make up the 
remaining 8 Bravais lattice systems to a total of 14. 
 
Figure 3.8. The 14 Bravais lattices organised by their crystal systems. Lattice aP is the primitive triclinic 
crystal system where the a stands for anorthic meaning of oblique axes. Lattices mP and mC are the 
monoclinic primitive and face centred, respectively. Note that mC has only the faces on the C planes 
centred and as such is not an mF system. Lattices oP, oI, oF and oC are the orthorhombic primitive, body 
centred, face centred (all faces and C-face only) respectively. Lattices tP and tI are the tetragonal 
primitive and body centred lattice systems respectively. Lattices hP and hR are the trigonal/hexagonal 
primitive and rhombohedral systems respectively. Finally the cP, cI and cF lattices are the cubic primitive, 
body centred and face centred (all faces) lattice systems. Diagram edited from Rupp 2010 (Rupp, 2010). 
The application of symmetry operations to the Bravais lattices, in Figure 3.8, leads to the 
organisation of 65 chiral space groups, in Table 3.1. 
Triclinic- Primitive      Monoclinic- Primitice P,  
Face centred C 
a ≠ b ≠ c       a ≠ b ≠ c 
α ≠ β ≠ γ ≠ 90°      α = γ= 90°  
       β ≠ 90° 
 
 
 
     Orthorhombic – Primitive P, Body centred I, 
                                     Face centred F & C. 
       a ≠ b ≠ c  
       α = β = γ = 90° 
 
 
 
      Tetragonal – Primitive P,           Trigonal,hexagonal -  
  Body centred I            Primitive P, 
                                a=b                                                                                 Rhombohedral R, 
  α = β = γ = 90°                     a = b 
                        α = β = 90°, γ = 120° 
 
 
     Cubic – Primitive P, Body centred I,  
        Face centred F 
  a = b = c 
  α = β = γ = 90° 
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Table 3.1. Crystal systems and their possible lattice types and space groups as well as their unit cells 
parameters. All 65 possible space groups for biological macromolecules are assorted by their crystal 
systems (Rupp, 2010; Drenth, 2007; McPherson, 2009).  
Crystal 
System 
Lattice 
Types 
Unit Cell 
Dimensions 
and Angles 
Unit Cell 
Symmetry 
Permissible Space Groups 
Triclinic P a ≠ b ≠ c,  
α ≠ β ≠ γ ≠ 90° 
None P1 
Monoclinic P a ≠ b ≠ c,  
α = γ = 90°, β ≠ 
90° 
A single 2 fold 
axis parallel to 
b. 
P2, P21 
C C2 
Orthorhombic P a ≠ b ≠ c,  
α = β = γ = 90° 
Three mutually 
perpendicular 2 
fold axes 
P222, P2221, P21212, P212121 
I I222, I212121 
C C2221, C222 
F F222 
Tetragonal P a = b ≠ c,  
α = β = γ = 90° 
4 fold rotation 
axis parallel to c 
P4, P41, P42, P43, P422, P4212, P4122, 
P41212, P4222, P42212, P4322, P43212 
I I4, I41, I422, I4122 
Trigonal P a = b ≠ c,  
α ≠ β = 90°, 
γ = 120° 
3 fold rotation 
axis parallel to c 
P3, P31, P32, P312, P321, P3112, 
P3121, P3212, P3221 
R R3, R32 
Hexagonal P 6 fold rotation 
axis parallel to c 
P6, P61, P62 P63, P64, P65,P622, 
P6122, P6222, P6322, P6422, P6522,  
Cubic P a = b = c,  
α = β = γ = 90° 
Four 3 fold axes 
along diagonals 
P23, P213, P432, P4232, P4332, P4132 
I I23, I213, I432, l4132 
F F23, F432, F4132 
 
This information regarding the alignment of molecules within the crystal, and the extent to which 
it is symmetrical, can greatly inform crystallographers on the data collection strategies required.  
Space in crystallographic terms is described in one of two concepts; real space, R and reciprocal 
space R*. As with the real lattice, a reciprocal lattice can be constructed which shares it’s 
symmetry with the real crystal lattice but its dimensions are inversely related. In order to 
construct the reciprocal lattice, the first step is the assignment of lattice planes. 
Lattice planes are effectively slices through the crystal that intersect two lattice points as shown 
in Figure 3.9. A lattice of a given type will have a variety of lattice planes within its structure. The 
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nomenclature for these planes, is based on a simple system of counting the number of unit cells 
the plane has to traverse until it meets a lattice point, this is done for all three axes. 
 
Figure 3.9. A two dimensional representation of three different planes intersecting a lattice d11, d2-1 and 
d31, using the Miller indexing nomenclature. Coloured in red the d11 lattice planes clearly span one unit 
cell in the a-axis and one in the b axis giving rise to d11. The blue lattice planes, has two planes that 
intersect the unit cell in the a axes, whereas in the b axes each plane intersects at a lattice point, all be it 
in the negative, giving rise to the d2-1. The green lattice planes intersect the a axis 3 times and just once in 
the b axis and thus d31. Edited from (Rupp, 2010). 
If using lattice planes in real space, planes that are parallel to the lattice vectors intercept at the 
infinite, which is why crystallographers use Miller indices, where the reciprocal of these values is 
taken giving rise to values of 0 for planes parallel to the lattice vectors. Miller indices define the 
parallel and equidistant lattice planes (h, k, and l), the higher the indices the much closer packed 
the planes and the more tightly the unit cell is sampled providing greater detail about the sample 
structure (Rupp, 2010). The real lattice of [0, a, b, c], shares its origin with that of the reciprocal 
lattice [0, a*,b*, c*], as the planes of real space hkl are equivalent to those of reciprocal space ℎ𝑘𝑙 
– the reciprocal lattice is centrosymmetric and retains its lattice type, this relationship is 
demonstrated in Figure 3.10. 
 
-1 
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Figure 3.10. The relationship between the real unit cell and the reciprocal unit cell of a orthorhombic 
crystal system. As all dimensions are inversed the relationship between them stays the same resulting in 
the retention of lattice type (McPherson, 2009). 
A working understanding of the relationships between real space and reciprocal space is vital 
during the data processing phase, in order to produce an electron density map from the images of 
scattered x-rays. 
3.4 Data Collection 
In order to understand how we obtain data, from the crystals we grow we must understand the 
nature of X-rays and their behaviour when they come into contact with the crystal. 
3.4.1  X-ray Sources and Detectors 
X-rays are a part of the electromagnetic spectrum that spans the wavelengths of 0.01-10nm or 0.1 
to 100Å; and due to the small wavelength these waves are very high energy 100eV to 100keV, 
with x-rays of around 10keV typically used for x-ray crystallography (Rhodes, 2000). X-rays can be 
produced by bombarding a metal target plate with an electron stream produced a heated 
filament, before it accelerated by an electronic field. When a high energy electron collides with 
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the metal plate the result is the displacement of the electron from a low-lying orbital in the metal 
atom, to fill the gap an electron from a higher valency orbital drops, in order to do this it needs to 
liberate itself of its excess energy and does so in the form of an X-ray photon. X-ray sources 
normally produce more than one wavelength of X-ray as the wavelength is proportional to the 
energy that needs to be lost and that depends on the orbital of the replacing electron The ideal 
source for X-rays is one that is monochromatic, that produces X-rays of a single wavelength thus 
resulting in a single set of reflections. 
The three most common X-ray sources seen are the X-ray cathode tube, the rotating anode tube 
and the particle storage ring, which are capable of producing synchrotron radiation as seen at 
Diamond Light Source, Oxford, UK. The X-ray cathode tube, as utilised by our in house Oxford 
Excalibur PX Ultra diffraction instrument, electrons from a hot cathode filament, are accelerated 
into a water cooled anode of target metal by electrically charged plates. Then ten times more 
powerful rotating anode tube setups use a rapidly rotating target which thus gives a larger target 
surface area, and better heat dissipation, the limiting factor of X-ray cathode tube setups. The 
most powerful X-ray sources, the particle storage rings, have the electrons stored in the giant 
rings are travelling at near to the speed of light. When a charged body such as an electron moves 
in a circular motion as seen in these accelerators radiation is given off – synchrotron radiation, in 
the form of X-rays. Tangential setups to the storage ring, known as beamlines use a system of 
mirrors, lenses and monochromators provide the experimenter with powerful monochromatic X-
rays at a wavelength that can be altered. 
Reflections of the X-rays are counted using scintillation counters, that count the photons and give 
accurate intensity readings, when the scintillator material absorbs an X-ray photon a flash of light 
is given off and a photocell counts these flashes. Charge-coupled devices (CCDs) are a common 
detector used in both the small scale Oxford Excalibur setup and large scale Diamond Light Source 
synchrotron setups. These detectors effectively count the photons that accumulate charge that is 
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directly proportional to the light that hits them. The CCD detector is coated with phosphors that 
emit visible light in response to X-ray photons. Specially designed for synchrotron applications the 
PILATUS3 detector, a hybrid-pixel X-ray detector, is a high performance detector that has 
improved count rates, which allows for shorter exposure times leading to an overall reduction in 
the radiation damage conferred to the crystal. The PILATUS3 detector is becoming the gold 
standard at synchrotron facilities replacing the older CCD detectors (Rhodes, 2000; Wright, et al. 
2012). 
3.4.2  The Behaviour of Waves 
Electromagnetic waves such as X-rays, where amplitude of these waves is the electromagnetic 
field strength and its frequency can be determined as a function of the relationship between the 
speed of light and its wavelength. When thinking of X-rays it sometimes helps to think of them as 
photons that the internal resonance frequency that classes them as X-rays. When these photons 
encounter a crystal, 99% absolutely nothing happens; the remaining 1% of the time sees the 
photons induce oscillations in the electrons. The electrons then emit a wave of identical 
frequency, which is a combination of all the scattered waves that have interfered both 
constructively and destructively.  Electromagnetic waves can be thought of as two sine waves that 
are perpendicular to the wave vector, s0 ; which the vector product of the electric field vector E 
and the magnetic field vector H, depicted in detail in Figure 3.11. 
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Figure 3.11. The wave or propagation vector s0, with its two perpendicular vector waves for the electronic 
field (E) and the magnetic field (H). The wavelength of the vectors is shown in green and is labelled λ. One 
full wavelength takes 2π radians or 360°, thus any phase variance between two waves is expressed in 
radians. The amplitude of the resultant wave vector s0 is defines as |s0|=1/λ (Rupp, 2010). 
When the X-rays interact with the electrons of the crystallised molecule, it is only the electric field 
vector E that stimulates the scattering response. As a result the electromagnetic radiation is 
described as a classical planar sinusoidal wave. When two waves are combined with one another 
the result can either be destructive or constructive. For example if two identical waves are out of 
phase with one another by π or 180°, their peaks and troughs are aligned so that they cancel each 
other out with a net amplitude of zero. If they are in phase with one another where the phase 
shift (φ) is either 0 or a multiple of 2π the result is that the peaks and troughs combine to form a 
wave with twice the original amplitude. This is important when we come to look at intensities 
later. 
3.4.3 Crystal Diffraction 
3.4.3.1 Bragg’s Law 
In protein crystallography the key to yielding structural data is the repeating lattice; it acts as a 
diffraction grating resulting in the scattering of photons in a variety of directions known as orders 
of diffraction. The father-son combination of W. Lawrence Bragg and W. Henry Bragg proposed a 
law that describes the reflection from sets of planes within the crystal. 
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Figure 3.12. Bragg’s Law describes the reflections of waves from sets of parallel planes within the 
crystalline structure. S0 and S1 are the incident and reflected waves respectively, the difference between 
which gives the scattering vector S, d is the distance separation between planes, λ is the wavelength of 
the x-rays which as stated above is the same in both incident and reflected waves, and n is an integer 
equivalent to the order of diffraction. Diagram edited from (Rupp, 2010). 
Because the angle of incidence is the same as the angle of reflection in both planes, two waves 
that arrive at the point of reflection in phase then become out of phase once reflected because 
the lower wave of the two has to travel an additional d sinθ in distance either side of the point of 
reflection, Figure 3.12. For constructive interference to occur n has to be an integer where it isn’t 
destructive interference will occur as the reflected waves will be out of phase (Rupp, 2010). 
Bragg’s Law gives the predicted position of any diffracted X-ray, it does not however yield any 
information about the intensity or the phase. 
3.4.4  Data Collection and Analysis 
Getting the data collection parameters correct in x-ray crystallography is key; a crystal may be a 
non-reproducible once in a lifetime opportunity to extract structural information about an 
important protein, the difference between 3Å data, where side chain conformations become 
visible, and 1.5Å data where the central pores on cyclic structures is visible, is stark. The further 
the diffracted waves are from their origin the greater the number and variety of phases are 
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present thus weakening the high resolution data. A more intense incident beam leads to a higher 
achievable resolution as does increasing the exposure time. Both of these factors can lead to 
increased radiation damage if not carefully monitored and adjusted as well as the increase in the 
low resolution diffraction spots intensities growing to the point that they become overloaded and 
thus unusable. In order to collect the full complement of unique reflections the crystal is turned 
through the phi (φ) axis, crystals with high orders of symmetry need to be rotated through a 
smaller phi angle than those with low levels of symmetry. 
The sinusoidal waves used in x-ray crystallography may be analysed as a series of waves that are 
the combined integral sums of a fundamental frequency known as a Fourier series. A direct 
Fourier transform from the variation of electron density leads to the calculation of the amplitudes 
and phases of all its Fourier components. As a result the reverse is also true, reverse Fourier 
transforms of the amplitudes and phases of the diffracted waves can give rise to the generation of 
a three dimensional electron density map that the protein molecule fits within and that leads to 
production of those diffracted waves. Figure 3.13 demonstrates the process a crystallographer 
must follow from data collection to producing an acceptable model of a protein and any 
potentially bound ligands or cofactors. 
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Each diffracted photon that the detector intercepts can be described in terms of the contributions 
of all of the scattering agents within the unit cell. The sum of these reflections hkls is the structure 
Validation 
Experimental Phasing 
Model in Unit Cell 
Molecular Replacement 
Merged Data 
Data Reduction 
Geometry and Data Fit 
Structural Analysis 
Final Model 
Refinement 
Model Building 
Density Improvement 
X-Ray Diffraction Data 
Initial Phasing 
Figure 3.13. Schematic representation of the data processing process carried out by crystallographers to 
elucidate a structural model from their data 
 102 
 
factor - Fhkl. This is important as the number of photons that terminate at a given position on the 
detector is dependent upon the scattering probability in that given direction, and to determine 
this the structure factor for each reflection needs to be calculated. Knowing the number of 
photons that accumulated provides an accurate measure of the proportionality to the structure 
factor intensity, and represents the squared structure factor amplitude and as a result can be 
accessed directly from the data. The result is that only the amplitudes of the reflections are 
measured and as such phase information is lost upon detection. This is known as the phase 
problem (Rupp, 2010). 
3.4.4.1 The Phase Problem 
The missing phase information that is lost upon diffracted photon detection results in the 
construction of an unusable electron density map as demonstrated by Figure 3.14 below. 
 
Figure 3.14. How Fourier transforms and reverse Fourier transforms can transform the physical repeating 
blocks of the unit cell into the diffraction patterns seen upon exposure of the crystals to x-rays and then 
from the relative positions and intensities of those diffraction spots to construction of the electron 
density map (Rupp, 2010). 
 
As phase is not discernible from the diffraction patterns produced it must be calculated by other 
means. If only a small fraction of the diffraction phases can be correctly deduced via the correct 
location of one or several atoms in their relative positions, this is often enough to commence the 
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structure solution. All existing phasing techniques initially provide a set of approximate phases  
that are derived from additional experimental data.  
Phasing methods depend upon the determination of marker atom substructure, atoms within the 
protein superstructure that provide a source of anomalous differences in the diffraction data - 
typically heavy metal ions that are either native to the protein structure or have been soaked in 
experimentally. This is technique is often referred to as isomorphous replacement. 
The result is a difference in atomic scattering factors ultimately resulting in a variation in the 
structure factor intensities relative to the reference structure. The variation in these data is then 
used to locate the source marker atoms within the structure. The creation of variation in 
intensities between data sets that lack and contain the marker atoms allows the problem to be 
reduced to solving a structure of fewer atoms compared to those of the whole protein (Perutz, 
1956). Dispersive and anomalous scattering factor contributions cause this intensity variation; by 
the variations that exist between the diffracted intensities of pairs of the same reflection 
recorded at the same wavelength and difference that arise between intensity/structure factor 
amplitudes between members of a Bijovoet pair (Perutz 1956).  
Shown in the Harker diagram in Figure 3.15 below (Rupp, 2010), the combination of structure 
factor amplitudes for the heavy atom structure FA, and the native protein FP is equal to the 
structure factor for the derivative protein, FPA.  
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Figure 3.15. The complex structure factors for protein (FP) in green, derivative (FPA) in blue and heavy 
atom (FA) in red. Intensity measurements only reveal the magnitude of the stricture factors for FPA and 
native FP, but from the difference data positions of the heavy atoms can be determined. Therefore, the 
entire complex structure factor for heavy atom FA is known, and two possible solutions for the phase 
angle can be deduced. 
 
Anomalous scattering is a second means of obtaining phases from heavy-atom derivatives which 
utilises the capability of the heavy atoms to absorb x-rays of a specific wavelength. Due to this 
absorption Friedel’s law does not apply and the result is that reflections hkl and -h-k-l are no 
longer of equal intensity. It is well established that atoms as well as diffracting x-rays also absorb 
them, absorption of x-rays however drops significantly at wavelengths just below the 
characteristic emission wavelength and this drop-off point is referred to as an absorption edge, 
Figure 3.16. 
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Figure 3.16. An x-ray emission spectrum. When an anode material, such as copper, is bombarded with 
high-energy electrons, a characteristic emission is observed. Characteristic radiation emanates when 
holes in core shells generated by the bombardment are filled with electrons from upper shells. 
 
Elements exhibit anomalous scattering when the x-ray wavelength nears this edge. As the 
wavelength of emissions are longer for elements with lower atomic numbers, light atoms such as 
carbon, nitrogen and oxygen do not contribute to anomalous scattering, but absorption edges of 
heavier atoms in this range do. Synchrotron sourced x-rays are tuneable to a chosen wavelength, 
and as such data can be collected under conditions that maximise anomalous scattering by heavy 
atoms. As with isomorphous displacement, anomalous scattering offers a direct way of estimating 
phase through the measurement of differences between normal and anomalous scattering; but 
rather than comparing the differences between structure factors of native and heavy atom-
soaked proteins, comparisons are made between intensities of (unequal) Friedel pairs. When the 
electron transition occurs in heavy atoms, the corresponding atomic scattering factor, f, behaves 
as a complex number, appearing with two correction terms: a real number (f’) and an imaginary 
one (f’’), whose total value is dependent on the frequency of the incident photon. In order to 
interpret how the correction factors modify the scattering factor, it is necessary to understand 
that that f’ is 180° out of phase with normally scattered waves, and f’’ is 90° out of phase.  
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The equation for the atomic scattering factor, f, during anomalous dispersion can be written in 
terms of f0, the normal atomic scattering factor: 
f = f0 + f’ + if’’ 
If all the atoms in a structure are heavy atoms and susceptible to anomalous dispersion, Friedel’s 
law is broken due to changes in their phases, although their intensities are still equal: 
IA(h,k,l) = IA(-h-k-l) 
And as such the structure factor of the reflection has a magnitude proportional to the square root 
of the observed intensity: FA(h,k,l) = FA(-h-k-l). 
 However, not all the atoms in the structure show anomalous dispersion of x-rays, and 
these differ from heavy atoms in both intensity and phase. As with isomorphous replacement, 
exacting phases using anomalous dispersion requires comparing three sets of data: one with 
native crystals to establish amplitudes for each reflection, FP; one for a heavy atom derivative to 
establish amplitude for FA; and finally one with a different wavelength to maximise anomalous 
scattering by the heavy atoms. The non-equivalence of Friedel pairs enable the crystallographer 
to gather the phases of the heavy atoms data, which is then used to derive structure factors of 
the native data. 
Similar to anomalous scattering, multiwave anomalous dispersion (MAD) exploits the effects of 
anomalous contributions by using Friedel pairs, but also utilises dispersive differences (that is, 
differences that exist between the diffracted intensities of pairs of the same reflection) between 
data sets collected at different wavelengths. To optimise the differences, an x-ray excitation scan 
for the phasing element must be recorded to define the absorption edge, and at least two MAD 
wavelengths are selected: one that maximises the anomalous signal, and a second that optimises 
the dispersive differences between wavelengths. This will give a peak data set and an inflection 
data set, corresponding to the positive and negative peaks of the absorption edge respectively. 
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Relative intensity differences exist between data recorded at different wavelengths due to 
anomalous contributions in the structure affecting the atomic scattering factors. In addition to 
wavelength-dependent differences between Friedel pairs, individual reflection intensities vary 
slightly with wavelength (dispersive differences), which also contain phase information that can 
be extracted by solving equations much like those for anomalous diffraction (Hendrickson, 1985). 
 
Another method bypasses the phase problem by using structures for which the phases are already 
known. Molecules that share homologies in domains and folds types that are often family 
members allow the matching of homologous regions leading to the estimation of the phases 
(Rossmann, & Blow, 1962; Rossmann, 1990). Using the suite of programs – CCP4 (Collaborative 
Computational Project No. 4), electron density maps are produced and then undergo several 
rounds of refinement before being ready to publish 
3.5. Crystallisation of α2-macroglobulin from Limulus Polyphemus 
The path to ascertaining successful crystallisation conditions for a protein is often a long one, for 
example the first published studies on the human α2m molecules were seen in 1991 (Andersen, 
et al. 1991) but not until 2012 was the structure solved (Marrero, et al. 2012) and at what was at 
the lower end of the scale. Between these years numerous other papers were published with a 
variety of conditions until ultimately the successful conditions were published. As there are no 
known conditions for the crystallisation of Limulus α2m, a combination of strategies was used. Of 
the many commercially available kits Molecular Dimensions Ltd.’s Structure Screens 1 and 2 as 
well as cacodylate free Structure Screens 1 and 2, were used to find initial starting conditions for 
crystallisation. Structure Screens contain 50 crystallisation conditions each, that were derived 
from known to result in the crystallisation of proteins they use a broad range of buffer, pH, 
precipitants, salts and additives (Jancarik, & Kim, 1991). In addition the crystallisation conditions 
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for the human α2m were used too as a potential starting point (Marrero, et al. 2012).  To these 
conditions the pre-concentrated and purified Limulus α2m-MA was added in equivolumetric 
drops with the crystallisation conditions, at a starting concentration between 5 and 8 mg/ml set 
up in a sitting drop method.  
If a condition produced crystals the crystals were then stained to ascertain the likelihood of them 
being protein or small molecule. Staining the crystals utilises the ability of dyes to move into the 
solvent channels that run through protein crystals. The majority of protein crystals take up the 
dyes and as a result assume the deep violet colour. The commercially available stain IzitTM and 
Crystal violet were used in assessing the potential of crystals grown. Staining protein crystals isn’t 
fool proof however as some protein crystals will not take up the dye as seen in work done by this 
research group with rfhSP-D. In experiments when the protein does take up the dye the cationic 
components of the dye once inside the solvent channels bind to the negatively charged amino 
acids on the proteins surface.   
Table 3.2. Conditions for the successful growth of crystals. Crystals of some description (protein/small 
molecule) were grown in the following wells, with all conditions being from or a derivative of the 
Molecular Dimensions Ltd Structure Screens. SS1-indicates structure screen 1, SS2-indicates structure 
screen 2, and SS1CD-indicates the cacodylate-free structure screen 1.  Full details of components and tray 
composition is laid out in the appendices. 
Crystal Tray Well Conditions Outcome 
MN01 A3 SS1-3 Small Mol. 
MN01 C2 SS1-14 Dissolved 
MN01 D3 SS1-21 Small Mol. 
MN02 A3 SS1-27  
MN02 B4 SS1-34 Small Mol. 
MN07 A2 Based on SS1-14:  0.1M Na Cacodylate pH 6.5, 20% (w/v) 
PEG8K, 0.2M (NH4)2SO4 
Small Mol. 
MN07 C1 Based on SS1-14:  0.1M Na Cacodylate pH 6.5, 40% (w/v) Small Mol. 
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PEG8K, 0.05M (NH4)2SO4 
MN07 C3 Based on SS1-14:  0.1M Na Cacodylate pH 6.5, 40% (w/v) 
PEG8K, 0.5M (NH4)2SO4 
Small Mol. 
MN19 C2 SS1CF-14 Small Mol. 
MN20 A4 SS1CF-28 No 
Diffraction 
MN20 B1 SS1CF-31  
MN20 C5 SS1CF-41 Dissolved 
MN20 C6 SS1CF-42 Small Mol. 
MN20 D1 SS1CF-43  
MN21 B4 SS2-8  
MN21 C1 SS2-11  
MN21 D5 SS2-21 Small Mol. 
MN22 C5 SS2-39  
 
Using the sparse matrix approach of the structure screens from Molecular Dimensions Ltd yielded 
a number of hits for potentially suitable conditions for producing crystals. However the crystals 
that were produced from the structure screens and their derivatives that survived cryoprotection 
and were tested upon either turned out to be small molecule or showed no diffraction at all. 
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Figure 3.17. A selection of crystal images from trials using the Molecular Dimensions Ltd Structure 
Screens 1 & 2 as well as Structure Screen 1 Cacodylate-free. A – Small flat pyramidal crystal grown in 
MN01A3 (SS1-3), tested at Diamond Light Source (DLS), was determined to be small molecule. B – Small 
hexagonal crystal grown in MN01C2 (SS1-14), dissolved upon addition of cryoprotectant. C – Thin 
trapezoid morphology of crystals grown in MN01D4 (SS1-21), tested at DLS, proved to be small molecule; 
and trapezoid morphology found in other wells containing tri-sodium citrate. D – Thicker trapezoid 
crystals found in MN02B4 (SS1-34), which also contains tri-sodium citrate. E – Typical morphology of 
ammonium sulphate crystals found in MN07C3, which had high levels of (NH4)2 SO4 (0.5M). F – Multiple 
crystal from MN20A4 (SS1CF-28), tested at DLS but no diffraction. G – A poorly formed crystal in MN20C5 
(SS1CF-41), that dissolved upon contact with cryoprotectant. H – Another example of ammonium 
sulphate crystals grown in MN20C6 (SS1CF-42), untested. I – An unusual multiple crystal grown in 
MN21D5 (SS2-21), tested at DLS, proved to be small molecule.                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Whilst a broad range of morphologies of crystals were grown utilising the structure screen 
conditions, demonstrated in Figure 3.17, not one of the screened conditions when tested showed 
protein spots. Fortunately the work that was based on the human conditions was more successful 
in this regard (Marrero, et al. 2012). 
Table 3.3. Partially successful crystallisation conditions for the growth of crystals using conditions derived 
from those used in the crystallisation of human α2-macroglobulin (Marrero, et al. 2012). For full crystal 
tray composition sees the appendices. 
Crystal Tray Well Conditions 
                                     A                                             B                                            C 
 
 
 
 
 
 
 
 
                                    D                                              E                                             F 
 
 
 
 
 
 
 
 
                                   G                                              H                                              I       
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MN04 A2 0.2M Ammonium Citrate, 15% (w/v) PEG 2000, 50mM NaF 
MN04 A3 0.2M Ammonium Citrate, 15% (w/v) PEG 2000, 75mM NaF 
MN04 B5 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
MN04 C4 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
MN04 D3 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
MN09 C1 0.2M Ammonium Citrate, 25% (w/v) PEG 2000, 50mM NaF 
MN09 C2 0.2M Ammonium Citrate, 25% (w/v) PEG 2000, 75mM NaF 
MN09 C3 0.2M Ammonium Citrate, 25% (w/v) PEG 2000, 100mM NaF 
MN11 A4 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
MN11 C1 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
MN11 D1 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
MN11 D3 0.2M Ammonium Citrate, 15% (w/v) PEG 3350, 50mM NaF 
 
Initial trials based on the human conditions of 0.2M Ammonium Citrate pH 6.4, 15% (w/v) PEG 
3350, 50mM NaF (Marrero, et al. 2012), that varied molecular weight PEGs from 2000-4000 as 
well as varying the concentration of NaF from 25mM to 75mM.  Following the appearance of 
crystals in some wells, additional trays and wells were added to screen around those conditions. 
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Figure 3.18. A selection of different crystal morphologies from crystal well conditions based on the 
successful crystallisation of the human α2m (Marrero, et al. 2012). A – Irregular shaped crystals grown in 
MN04A2, tested at DLS, protein spots to low resolution (20Å). B – Large rectangular crystals grown in 
MN04A3, tested at DLS, protein spots to 8-9Å. C - Irregular round crystalline objects grown in MN04B5, 
these were tested with stain, which they did not take up and so were untested. D -   Many irregular 
needles with poorly defined edges grown in MN09C3. E – Extremely thin kite shaped crystals that fan out 
around a single point of growth, grown in MN11A4 and tested at DLS with no diffraction visible. F – Small 
‘rugby ball’ shaped crystals grown in MN13A2 tested at DLS with no diffraction visible. Full details of the 
well conditions available in the appendices. 
The crystals in Figure 3.18 represent some of the less successful crystal morphologies grown using 
the human conditions as a basis (Marrero, et al. 2012). Some proved to be protein via the 
presence of diffraction spots, whereas some showed no diffraction at all. Those conditions that 
grew crystals that proved to be protein were screened around further. The most successful well 
that was laid down was MN04D3. The conditions for this well were 0.2M Ammonium Citrate pH 
6.4, 15% PEG 3350, 50mM NaF, with protein stocks at 8.319mg/ml used. Following the initial 
success seen in MN04A3, which showed protein spots to 8-9Å, additional wells were laid down 
varying the percentage weight to volume of the PEG in row D of the crystal tray. Six weeks after 
the wells were laid down crystal growth was discovered in MN04D3.  
A                                              B                                             C 
 
 
 
 
D                                              E                                              F 
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Figure 3.19. Well progression of crystals found in MN04D3. A – The first crystals detected were poorly 
ordered and diamond shaped. B – Four days later other crystals had begun to form the majority of which 
fit the diamond shape morphology but were well ordered with clean edges. C – Another four days later 
and the crystals had grown further with one or two really promising crystals present. 
Six weeks after the wells were set up the beginnings of the diamond shaped crystals visible above 
were present. As time progressed the crystals continued to grow and improve in quality until the 
appeared to grow no more (Figure 3.19 –C and Figure 3.20). 
 
Figure 3.20. Crystals from MN04D3 prior to cryoprotection and testing at DLS. Crystals are better ordered than those 
seen in MN04A3 which shared a similar morphology. 
The well was selected for testing at Diamond Light Source, prior to data collection and freezing 
the crystals needed to be cryoprotected. 2- Methyl, 2,4-pentanediol (MPD) was selected as a 
cryoprotectant due to trials carried out with crystals from similar conditions such as MN04A2 and 
A3. MPD was added by 5% incremental increases until 20% MPD/well solution was exchanged in 
the droplet (10μl taken out and 10μl added. Once the exchange had taken place the crystals were 
allowed to soak in the cryoprotectant with a view to as much as possible moving into the solvent 
channels thus offering protection during the freezing process.  
A                                                        B                                                        C 
 114 
 
 
Figure 3.21. Diffraction image from the data collection of MN04D32 with diffraction spots initially to 6Å, 
on beamline I02 at Diamond Light Source, Oxford, UK. The red circle indicates the extent of the low 
resolution diffraction spots. Higher resolution spots would be expected outside the red circle. 
Crystals were frozen and taken to DLS on beamline I02 where data was collected to 6Å (Figure 
3.21) on MN04D32 (the second crystal looped out from MN04D3) as well as two other data sets 
of slightly lower resolution.  
3.5.1. Discussion 
Unfortunately, as you will see if you tried to search the Protein Databank for a structure at 6Å, 
this data lacks the resolution required to build a model using the data processing software, this 
was however sufficient enough for EDNA (Enhanced automateD collectioN of datA) a program 
available at both DLS and the European Synchrotron Radiation Facility (ESRF), that proposed a 
strategy for data collection based on the radiation damage and symmetry information obtained 
from the initial few images (Incardona, et al. 2009). EDNA suggested that the crystals were in the 
P222 space group and had unit cell dimensions of a = 115Å, b = 141Å and c = 338Å.  Table 3.1 
shows that P222 is a primitive orthorhombic space group which has unit cell dimensions of a ≠ b ≠ 
c and α = β = γ = 90°. Interestingly the human model (Marrero, et al. 2012) has an orthorhombic 
space group of P212121 and unit cell dimensions of a = 130.7Å, b = 260.3Å, and c = 281.8Å. Whilst 
both the human and the Limulus asymmetric units undergo two symmetry operations in each of 
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the three axes the human asymmetric unit’s symmetry operations are screw axes as opposed to 
simple rotations around a point as seen in Limulus based on EDNA’s prediction. 
Future experiments should aim to build on the work carried out here; firstly by replicating the 
crystals grown in MN04D3 and then looking at how the conditions can be adjusted to improve the 
resolution to at least 4Å but preferably higher.  Key to this is the homogeneity and purity of the 
protein sample being used. Not only is the α2m purified from a serum that contains two 
significantly more abundant contaminants (haemocyanin and the pentraxins) but given the nature 
of the structural differences between reacted and unreacted, simply having purified α2m is not 
enough, as a result every effort should be made to ensure its homogeneity (Armstrong, & Quigley, 
1999). Secondly there are a number of known conditions that were published that showed 
diffraction with the human α2m with a variety of ligands. 
Table 3.4. Known conditions to provide protein crystals of the human α2m with a variety of ligands to low 
resolution when exposed to synchrotron X-rays. 
Reference Protein Conditions Resolution 
Andersen, et al. 
1991 
α2m-MA 20-30%  (NH
4
)
2
SO
4
 pH 7.3-7.8, 0.15%-1.5% β- 
octyl-glucoside, Tris-HCl 
9Å 
α2m-Trypsin 20-25%  (NH4)2SO4 pH 7.0-8.0, OR 1.5M Mg SO4 
pH 6.5-7.5, Tris-HCl 
10 
α2m-Plasmin 1.3-1.5M MgSO4 pH 6.75-7.25, Tris-HCl MOPS 11 
Andersen, et al. 
1994a 
α2m-MA 10% MPD, 0.5mM ZnCl2, 1M NaCl, pH6-7, at 4°C 8.5 
Andersen, et al. 
1994b 
α2m-MA 20mM Tris-HCl pH 7.7, 1.0M NaCl, 21mM MES, 
0.5mM ZnSO4, 13% MPD, 2:1 protein to 
reservoir ratio, at 4°C 
9 
α2m-MA 20mM Tris-HCl pH 7.7, 0.5M NaCl, 21mM MES, 15 
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0.5mM ZnSO4, 13% MPD, 2:1 protein to 
reservoir ratio, at 4°C 
  
This in addition to the existing condition (0.2M Ammonium Citrate pH 6.4, 15% PEG3350, 50mM 
NaF) that diffracted to 6Å in this body of work means there are a number of potential avenues to 
be explored during the continued pursuit of the crystal structure of Limulus α2m. 
Crystallography is a discipline that truly tests the patience of its practitioners; in 1991 the first 
published data of the crystallisation of human α2-macroglobulin (Andersen, et al. 1991) with 
crystals being diffracted to 9Å, the culmination of years of work was ultimately published by the 
same research group in 2012 (Marrero, et al. 2012) to a resolution of 4.45Å. Using this for 
perspective when looking at the work carried out in this thesis it is clear that whilst there is still 
work to be done to reach a resolution that will provide a workable dataset and ultimately an 
structural model, it is clear that a solid starting point has been found for the continued research 
into the structure of Limulus α2-macroglobulin. 
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Chapter 4 - Bioinformatic Analysis and Structure prediction of α2-Macroglobulin from Limulus 
Polyphemus. 
4.1. Introduction 
Bioinformatics provide powerful tools for the analysis of biological molecules, utilising multiple 
computing techniques with common uses including: proteomics, phylogeny studies, genomics, 
and sequence analysis of genes and the proteins coded by them. ExPASy is an online hub of 
bioinformatics resources providing bioinformatic data for the above mentioned studies and 
providing a great number of tools for this study. 
An ever blossoming field of bioinformatics lies in protein structure prediction. Due to the 
challenging nature of structure solution by x-ray crystallography, tools have been developed to 
provide highly accurate means of predicting the structure of a protein of known amino acid 
sequence, as an intermediate until, if possible, the structure is solved by experimental means. 
There are currently a wide range of programs available for the prediction of protein structure and 
knowing which one to use and whether its results are to be trusted or not is a difficult decision to 
make. However this is aided by The Critical Assessment of protein Structure Prediction (CASP). 
CASP can best be thought of as a competition and a quality assurance method for the structure 
prediction suites available. Running biannually since 1994 CASP invites the programs to take part 
in a blind assessment of their structure predicting abilities. Now in its 10th iteration with the 
results of the 11th pending it allows interested parties to assess the field and select the method of 
structure prediction that best suits their requirements. For the upcoming structure prediction 
work done, the Zhang labs I-TASSER server was used. More of an amalgamated suite of programs 
than one single program, it has been ranked 1st place in every CASP since its inception CASP7-10. 
For this reason as well as its ability to produce models for extremely large sequences such as that 
of α2m it was the obvious choice. 
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4.2. Sequence homology in the α2-Macroglobulin Superfamily 
Homology between amino acid sequences can infer a great deal of information about the 
molecules of interest, highlighting similar regions between molecules of the same family within 
the same organism and those family members from other organisms. If pre-existing structural 
data exists for one of the aligned sequences it can be used to deduce potential structural and 
functional features of the sequences that lack high resolution structural data. 
The sequence of α2-macroglobulin can be found using the ExPASy program UniProtKB under the 
code of O01717. This yields a 1507 residue long amino acid sequence that has since been proven 
experimentally to be 1482 with a 25 amino acid signal peptide (Iwaki, et al. 1996). This sequence 
was then fed into the ExPASy program BLAST, which searches through the UniProtKB database 
seeking out homologous sequences and ranking them by percentage homology. 
Table 4. The various members of the α2m superfamily, from various species showing their sequence 
length and their percentage homology to the α2m of Limulus polyphemus.  
UniProtKB 
code 
Organism Protein Sequence 
length (aa) 
% Sequence 
Homology 
O01717 Limulus polyphemus 
(Horseshoe crab) 
α2-macroglobulin 1482 100 
B8R3M2 Ixodes ricinus 
(Common tick) 
α2-macroglobulin 
splicing variant 
1486 43 
E2AC15 Camponotus 
floridanus (Florida 
Carpenter Ant) 
α2-macroglobulin-like 
protein 
1762 37 
G9BIX6 Pacifastacus 
leniusculus (Signal 
Crayfish) 
α2-macroglobulin 2 
isoform 3 
1598 33 
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K9J6H8 Sus scrofa (Pig) α2-macroglobulin 1478 33 
Q2VJB3 Xenopus laevis 
(African clawed frog) 
α2-macroglobulin 1474 33 
Q61838 Mus musculus 
(Mouse) 
α2-macroglobulin 1495 33 
Q5R4N8 Pongo abelii 
(Sumatran 
Orangutan) 
α2-macroglobulin 1474 32 
P01023 Homo sapien 
(Human) 
α2-macroglobulin 1474 32 
P20742 Homo sapien 
(Human) 
Pregnancy Zone Protein 
(PZP) 
1482 31 
Q6YHK3 Homo sapien 
(Human) 
CD109 1445 30 
W5J4Q1 Anopheles gambiae Thiol-ester containing 
protein 
1397 28 
P01024 Homo sapien 
(Human) 
Complement component 
C3 
1663 20 
P01031 Homo sapien 
(Human) 
Complement component 
C5 
1676 19 
 
Table 4.1 clearly shows that α2-macroglobulin is found in a wide variety of species from various 
phyla and is found in both vertebrates and invertebrates. The high homology levels between 
species not only indicates a high level of importance for the molecule but is also highly suggestive 
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of the molecule being evolutionarily ancient, further evidenced by its presence in the 
phylogenetically ancient Limulus polyphemus. 
 
Figure 1.6. A) A schematic representation of the domain organisation/tertiary structure of a subunit of 
human α2m; with the bait region represented as a dashed line and the star demonstrating a potential 
protease cleavage site. B) Ribbon and space fill representations of the tertiary structure of an α2m 
subunit (convex face) with the green arrow indicating the location of the bait region. C) The back/ 
concave face of the α2m subunit from humans demonstrating the bait region to the rear of the molecule. 
Diagrams edited from (Marrero, et al. 2012). 
In order to infer some of the possible structural characteristics of Limulus α2m more detailed 
comparisons need to be made with those family members whose structures are known and 
currently are available in the PDB. Initially a sequence alignment with the human homologue 
α2m, the sequence of which was obtained from the UniProtKB database on the ExPASy server, 
was performed using the ExPASy program CLUSTAL O. The aligned sequences were then broken 
down according to the domain structure of the human molecule: macroglobulin domains (MG) 1-
7, the bait region domain (BRD), the CUB domain, thiol-ester domain (TED) and the receptor 
binding domain (RBD), as per Figure 1.6, repeated above for clarity, to be able to properly 
compare both secondary and tertiary structure of the proteins. In all of the alignments described 
below residues in red indicate their presence in a helix, whereas blue residues are found in beta 
strands in accordance with the findings of Marrero et al. (Marrero, et al. 2012) for the Limulus 
α2m molecule the predicted secondary structure from the I-TASSER suite was used (Zhang, 2008; 
Roy, et al. 2010). 
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4.3. Structure Prediction of Limulus α2-Macroglobulin 
4.3.1. Introduction to the Protein Structure Prediction Server I-TASSER 
I-TASSER is an open source suite of programs available online via a server rather than direct 
download (http://zhanglab.ccmb.med.umich.edu/I-TASSER). It is capable of processing sequences 
up to 1500 residues in length, following submission of the sequence the I-TASSER server will email 
to inform the user that their query is complete. The completed query yields a mass of data, from 
the predicted secondary structures and solvent accessibility of the residues to up to five potential 
models with assigned confidence scores. In addition to this the I-TASSER results also inform the 
user of the templates it used from the PDB during the model building. This information can often 
yield clues to the structure, function and family of proteins to which the query sequence belongs. 
Querying of I-TASSER with the sequence from Limulus α2m, showed the top structural 
homologues from the PDB of which there were nine were with their respective PDB codes: 1 - 
TEP1r from Anopheles gambiae (PDB code - 2PN5), 2 - Complement C5 - in complex with SSL7 
from S. aureus (3KLS), 3 - Bovine Complement C3 (2B39), 4 - Complement C5b6 (4A5W), 5 - 
Human α2m 4ACQ, 6 - Complement C5 complexed with cobra venom factor (3PVM), 7 - 
Complement C4 in complex with MASP-2 (4FXG), 8 - Mammalian (Sus scrofa) Fatty acid synthase 
(2VZ9), 9 - Streptomyces avermitilis α-L-rhamnosidase. Of these only fatty acid synthase and α-L-
rhamnosidase are not part of the α2m superfamily of thiol-ester containing proteins. 
The first stage of I-TASSER processing is threading. Here template proteins are identified from the 
solved structures in the PDB. The first stage, involves the query sequence passing through a non-
redundant sequence database PSI-BLAST which identifies evolutionary relatives of the sequence 
and thus those most likely to share structural motifs. The result is the creation of a sequence 
profile, based on the multiple alignment of all the sequence homologues. This sequence profile is 
then utilised to produce the secondary structure prediction using PSIPRED. With the aid of both 
the sequence profile and the predicted secondary structure the query sequence is then threaded 
through a representative PDB structure library using the I-TASSER suite LOMETS, a locally installed 
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meta-threading server which is made up of 7 state-of-the-art threading programs (FUGUE, 
HHSEARCH, MUSTER, PROSPECT, PPA SP3, and SPARKS). Each individual program within the 
LOMETS server ranks the templates by a variety of sequence and structure based scores. The 
templates with the highest scores from each program are then selected for further consideration 
where the quality of their alignment is judged based on the statistical significance of the best 
threading alignment (Roy, et al. 2010). Stage two of I-TASSER processing results in the structural 
assembly of the query sequence model. Continuous fragments from the template structures in 
threading alignments are used to construct structural conformations of the well aligned regions. 
The unaligned sections, predominantly loop regions and tails, are built via ab initio modelling. A 
modified replica-exchange Monte Carlo simulation is used for fragment assembly which utilises; 
statistical data from the PDB, spatial restraints from threading templates and sequence based 
contact predictions from SVMSEQ. Conformations that were generated in the low-temperature 
replicas during the refinement simulation are clustered using SPICKER, to identify low-free energy 
states. The average of the 3D coordinates of all the clustered structural decoys is then to obtain 
cluster centroids. In the third stage, model selection and refinement, the cluster centroids 
produced earlier are fed back into the fragment assembly simulation, this removes steric clashes 
in addition to refining the global topology of the cluster centroids. The output is a second 
generation of decoys that are once more clustered before the lowest energy structures are 
selected to be input into REMO which produces the final structural models by building the full 
model from Cα traces from the hydrogen-bonding networks. The fourth stage of I-TASSER gives an 
inference to the function of the query molecule by structurally matching it to the same existing 
PDB structures that provided templates in the earlier stages. In addition to using those with 
similar global folds, the software also highlights those that differ in global fold but that do/may 
share a conserved active/binding site. Functional analogues are ranked using a number of criteria 
such as: TM-score (template modelling score, which is a measure of similarity of the two structure 
with values that range from 0 to 1), RMSD, and sequence identity. The TM-score is potentially the 
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best indicator in terms of modelling accuracy where a TM-score < 0.17 indicates a randomly 
selected protein, whereas a TM-score > 0.5 identifies the query protein and the template as 
sharing similar folds. The main assessment of prediction accuracy however is given as a 
confidence or C-score for each model produced by I-TASSER. The C-score is based on the quality 
of the threading alignments coupled with the convergence of the I-TASSER’s structural assembly 
refinement simulations. The C-score has been extensively tested in large-scale bench marking 
tests. This showed that the Pearson correlation between the C-score and the TM-score, which is 
equal to the absolute difference between the model and the native structure, was equal to 0.91 
which is a highly significant value when we consider that Pearson values range from 0 for random 
variables to 1 for identical variables. If a cut off score for the C-score of -1.5 is used the result is 
that 90% of quality predictions are correct.  
It should be noted that during its development I-TASSER has been optimised for modelling single 
domain proteins, however there is still a built in process for the prediction of multi-domain 
models. LOMETS defines the domain boundaries. It does so by assessing a segment of query 
sequence, if >80 residues gave no alignment with template proteins in the top two threading hits, 
it is identified as a multiple domain protein, and the domain boundaries are defined by the 
boundaries of aligned/unaligned regions. Following this, two types of assembly simulations are 
run, one that aims to model the whole chain with a view to guide the domain orientations in the 
tertiary structure of the molecule and the other that models each domain individually. Then to 
generate the full length model the models of the individual domains generated previously are 
docked together using the data from the whole chain simulation as a template.  This docking 
simulation is performed to produce a model that has similar domain organisation whilst 
producing the minimal amount of steric clashes. However this process is only carried out in 
instances that are multi-domain but that only have partial alignment with the top-scoring 
templates. If the top scoring templates are multi-domain as well and all of the domains from the 
query sequence align, the whole chain is modelled in I-TASSER using the full chain technique. 
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I-TASSER allows its users to specify whether or not they want their query structure to be based on 
a particular template. For example it may in this case have been advantageous to model the 
Limulus α2m on the human structure, by specifying that I-TASSER should use PDB code 4ACQ 
(Marrero, et al. 2012). However, given that the human structure shows α2m that has had its thiol-
ester reacted with methylamine, and thus represents the activated form of the molecule, using 
this as the I-TASSER template would most likely yield a model that represents the activated form 
of Limulus α2m rather than the native molecule.  
4.3.2. Protein Structure Prediction Results and Discussion 
 
Figure 4.1. From left to right: ribbon diagram of an individual subunit of Limulus α2m produced using I-
TASSER (Zhang, 2008; Roy, et al. 2010), a schematic diagram of the human subunit to show domain 
organisation and ribbon diagram of a single subunit of methylamine activated human α2m (Marrero, et 
al. 2012). Domains are coloured according to the central schematic from Marrero et al. (Marrero, et al. 
2012); MG1 - orange, MG2 - yellow, MG3 - light green, MG4 - magenta, MG5 - cyan, MG6 - pink, BRD - 
blue, MG7 - red, CUB - green, TED - purple, RBD - grey. 
Figure. 4.1 shows the I-TASSER model of the human subunit in comparison to its activated human 
counterpart. It is important to note that the human model is the methylamine activated structure 
given the structural reorientation that occurs during activation. It is however clear from the two 
diagrams that the general domain arrangement and topology remains conserved between 
species. The right-handed one-and-a-half turn ellipsoidal super helical structure formed by MG1-6 
(Marrero, et al. 2012) is visible with the BRD lying behind the coordinating MG domains. It should 
be noted that the Limulus CUB and TED domains both sit a little higher in relation to MG6 than 
they do in the human protein, which may be a functional outcome of the difference between 
native and activated molecules. It is known that upon activation the RBD becomes revealed as 
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part of the molecular reorganisation process, a process which may involve the descent of the CUB 
and TED domains to allow the exposure of the BRD. 
 
Figure 4.2. Overall domain organisation (A), formation of entrances one (B) and two (C) as well as 
schematic representation of domain architecture for the MG macroglobulin domains (D), the CUB domain 
(E), the TED domain (F) and the RBD (G) all seen in the methylamine activated human α2m structure 
(Marrero, et al. 2012). The colour scheme for A is retained for B and C, whilst in G the secondary 
structures shown in magenta highlight the difference between the RBD (G) and the MG domains (D). 
 
The respective domains of human and Limulus α2m have been aligned by sequence in Fig. 4.2 
below. In addition to the sequence alignment the confidence vales for the predicted secondary 
A                                                B                                                  C 
1 
D E F 
G 
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structure are also included with a scale of 0-9 for low to high confidence respectively. Residues 
shown in red indicate their presence/predicted presence in an α-helix; blue residues are 
present/predicted present in β-strands, whereas the black residues indicate no secondary 
structure present and represent loop regions. The alignment also shows the predicted solvent 
accessibility from the I-TASSER modelling, with values that range from 0 for a buried residue to 9 
for a highly exposed residue. The nature of these exposures may provide key insights into the 
functional roles played by certain residues. Residues in bold depict those that are N-glycosylated 
(Iwaki, et al. 1996). Residue numbers for the human sequence are included above the alignment 
for ease of navigation.  Work of this nature often presents as many questions as it does answers 
but it does present significant and reliable new clues about the structure of Limulus α2m. 
4.3.2.1. Macroglobulin Domain 1 
 
MG1 has 9.1% sequence homology between the human and Limulus molecules. They are 98aa 
and 102aa long and span, Gly4 – Glu102 and Lys1 – Asp102, for human and Limulus α2m respectively. 
 
 
Figure 4.3. Sequence alignment diagram of the MG1 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. 
Residues shown in bold are glycosylated. 
 
 
Based on the human structure (Marrero, et al. 2012) it is known that MG1 does not play a key role 
in quaternary structure of the α2m molecule but does play a role in coordinating the BRD along 
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with MG2 and 3. This may suggest why the sequence homology is lower than average as its role 
structurally is minimal. Despite a sequence homology of just 9.1% the secondary structures line 
up exceptionally well and with an average confidence score for the predicted secondary structure 
of the domain of 7.96 on a scale of 0-9 in Figure 4.3. This suggests a high level of structural 
homology even if the sequences lack that same level of homology. The low sequence homology 
seen in MG1 and to a lesser extent the other MG domains is not overly surprising, considering the 
evolutionary theory about the development of the α2m superfamily described previously 
(Janssen, et al. 2005; Sahu, & Lambris, 2001). It is known that Asn32 and Asn47 within MG1 in the 
human α2m are N-linked glycosylation sites (Sottrup-Jensen, et al. 1984). Of these two only Asn47 
is conserved in the Limulus homologue in Asn44 but the residue is not glycosylated (Iwaki, et al. 
1996). The lack of glycosylation of this residue may be due to the low predicted solvent 
accessibility of which it scores 3; if the residue is buried within the tertiary structure then it is 
easily conceivable that it is not glycosylated. There is however one glycosylation site present in 
MG1 and is found on residue Asn80, this residue also has a predicted solvent accessibility of three 
however but as this is a known and experimentally proven glycosylation site (Iwaki, et al. 1996), 
the low score may prove irrelevant. 
 
Figure 4.4. From left to right: the known human structure for MG1 of α2m (Marrero, et al. 2012); the 
predicted model for the Limulus MG1 domain. Β-strands are depicted in yellow, loop regions are shown 
in white, turns in blue and the glycosylation sites shown with the residues in red ball and stick. For ease 
of viewing the domains are both orientated with the N-terminal to the left and their C-terminal to the 
right. Figure generated using RASMOL (Sayle, & Milner-White, 1995). 
Figure 4.4 shows the domain topologies of human and Limulus MG1 from α2m. By analysing the 
3-D structure using RASMOL (Sayle, & Milner-White, 1995) it is clear that the 8-stranded β-
sandwich is conserved. I-TASSER however did not show Ile97 of the Limulus α2m as part of β8 this 
despite of the secondary structure prediction stating it should be part of β8 which was predicted 
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with a confidence score of 9. The reasoning for this gap in β8 is unknown. Whilst it was already 
known, that glycosylation of this domain varies between species, the production of the I-TASSER 
model for MG1 shows the variation in location of these glycosylation sites. The loop regions of the 
two models, whilst having to be similarly positioned to maintain the β-sandwich motif, show 
minimal structural homology which is a likely product of the low sequence identity of 9.1% for the 
domain. 
 
4.3.2.2. Macroglobulin Domain 2 
 
MG2 has 32.7% sequence homology between the human and Limulus molecules. They are both 
98aa long and span, Asp103 – Phe201 and Lys103 – Tyr201, for human and Limulus α2m respectively. 
 
Figure 4.5. Sequence alignment diagram of the MG2 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. Those 
shown in red indicate present or predicted α-helices. Residues shown in bold are glycosylated. 
 
MG2 in human and Limulus α2m have a significantly higher sequence homology than MG1. The 
human structure shows that MG2 plays a much more important role in the quaternary structure 
as well as the tertiary interaction with the BRD as seen in MG1. MG2, contributes towards the 
formation of entrance 2 (Figure 4.2) to the prey chamber of the molecule. The secondary 
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structures almost align almost as well, as shown in Figure 4.5, as those in MG1 apart from where 
the second β-strand lies in the human (Ser113 – Lys116) I-TASSER has predicted a small helical 
structure (Pro113 – Tyr115). This is highly unlikely as it disagrees with the architecture of the MG 
domains which is a fibronectin type III domain made up of 8 β-strands arranged in a β-sandwich. 
Further questions are raised about the validity of the prediction by the program itself with an 
average confidence score for the helical structure of only 4.3, compared to the average 
confidence of all the remaining β-strands of the domain which is 7.95. This in turn brings the 
overall confidence score for predicted secondary structures of the domain to an average of 7.5 
inclusive of what appears to be an error in the helical assignment. Of the three amino acid 
residues encompassed in this proposed helical structure of the Limulus model (Pro113, Leu114, and 
Tyr115) it is visible that Leu114 has a strong property correlation (:) with the Ile114 of the human 
structure and Tyr115 has direct identity (*), further strengthening the theory that this prediction is 
likely to be in error. 
 
Figure 4.6. From left to right the human and Limulus MG2 domains respectively from α2m (Marrero, et al. 
2012; Zhang, 2008; Roy, et al. 2010). Loop regions are labelled in white with turns in the Limulus model 
depicted in blue. The β-strands are indicated in yellow. Figure generated in RASMOL (Sayle, & Milner-
White, 1995). 
It is clear from comparing the two 3-D structures of MG2 (Figure 4.6) that this domain’s highly 
conserved sequence (32.7%) is reflected in the (predicted) structure of the domain. In addition to 
the conserved 8-strand β-sandwich motif, the highly flexible loop regions also show high levels of 
structural homology. 
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4.3.2.3. Macroglobulin Domain 3 
 
MG3 has 20.9% sequence homology between the human and Limulus molecules. They are 115aa 
and 106aa long and span, Phe206 – Thr321 and Phe206 – Tyr313, for human and Limulus α2m 
respectively.  
 
Figure 4.7. Sequence alignment diagram of the MG3 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. Those 
shown in red indicate present or predicted α-helices. Residues shown in bold are glycosylated. 
 
MG3 in human and Limulus α2m have a sequence homology of 20.9% which reflects its role in 
coordinating both tertiary and quaternary structure (Figure 4.7). In tertiary terms it acts in much 
the same way as the previous two MG domains in coordinating the BRD. It’s participation in the 
right-handed one-and-a-half turn ellipsoidal super-helix leads to it forming part of the boundary 
of entrance 1, as shown in Figure 1.5 (Marrero, et al. 2012). Perhaps most significant about this 
domain is its role in entrance 2 (Figure 4.2). As a contributing domain to the formation of 
entrance 2 it is di-sulphide bound to the MG4 of the neighbouring di-sulphide linked subunit. 
Interestingly Cys278 of this domain in the human structure does not share sequence identity with 
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the Limulus α2m. There is sequence identity with the two intra-domain disulphide linked residues 
Cys251 - Cys299 and Cys228 - Cys269 in human and Limulus respectively (Figure 4.7). This supports the 
work by Husted et al. (Husted, et al. 2002) as it was shown that the disulphide responsible for the 
dimerization in the Limulus α2m is between Cys719 of the Limulus BRD of each subunit. MG3 
throws up some interesting discrepancies when comparing the known secondary structure of 
human α2m to the predicted data of its Limulus counterpart. Similarly to MG2 the addition of a 
helix has occurred (Ser276, Ser277 and Ala278), this time not as a substitute for an expected β-strand 
but in addition to the 8 strands expected. This was placed by I-TASSER with an exceptionally low 
average confidence score of 3.33. Whilst no direct identity was present for these residues Se276, 
Ser277, Ala278 from the Limulus protein have strong property, weak property, and weak property 
similarity to the Thr283, Lys284 and Val285 respectively of human α2m. The overall confidence score 
for the domain is 6.26, which is brought down from 6.6 if we exclude the helix as an error. The 
lower overall confidence score for predicted secondary structures here is due to low confidence in 
some of the β-strands in spite of them being well aligned with their human equivalent, which is 
likely due to the lower sequence identity seen. The human α2m contains a single glycosylation 
site Asn224, whereas the Limulus α2m is glycosylated at both Asn275 and Asn307 (Iwaki, et al. 1996). 
Human Asn224 is not conserved with its aligned residue in the sequence being Thr224 which shares 
some similarities with them both having polar uncharged side chains. Limulus’ glycosylated 
residue Asn275 in the human molecule is substituted for Lys284. Both these residues have amine 
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groups in their R-groups with the Asn275 being bound to the sugar, with Lys284 the amine group is 
positively charged and so will look to make polar interactions. Asn307 aligns with Thr313, both, as 
mentioned above, loosely similar residues in terms of their properties. 
Upon analysis of the MG3 domains from both human and Limulus α2m, one noticeable feature is 
that the Limulus MG3 model lacks the α-helix present in the human α2m RASMOL rendition 
spanning the amino acids Lys282 - Phe286. The model is taken from the PDB structure of Marrero et 
al. (Marrero, et al. 2012), with the supplementary materials for this paper providing the 
secondary structure data used above in the alignment (Figure 4.7). In this published data there is 
no secondary structure feature shown in this region, so the appearance of a helix structure in this 
region is a likely product of RASMOL believing there is a helix present as it uses different 
parameters to those used by other programs. Counter to this the predicted secondary structure 
as discussed above for the Limulus MG3 domain states an α-helix exists through Ser276 - Ala278, 
however in the RASMOL rendition no helix appears during this region. Both the present and 
absent helices of MG3 from human and Limulus respectively are in alignment with one another. 
There is however clear structural homology between these regions as the Limulus MG3 render  
(Figure 4.8) shows a near helical structure in that loop region so the difference between the 
human structure and the Limulus models for MG3 with regard to this helix is likely negligible. 
Interestingly the positioning of the glycosylated Asn224 and Asn275 of human and Limulus α2m 
respectively is very similar with both sitting on the same face of the β-sandwich motif. Whilst not 
Figure 4.8.  From left to right: The human MG3 domain (Marrero, et al. 2012) and the Limulus MG3 as 
predicted by I-TASSER (Zhang, 2008; Roy, et al. 2010). Β-strands are depicted in yellow with α-helices are 
shown in magenta. Loop regions are shown in white with the turns in the Limulus model shown in blue. 
Residues that are glycosylation sites are shown in ball and stick display mode and in red. Figure 
generated in RASMOL (Sayle, & Milner-White, 1995). 
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conserved the fact that their relative positions are conserved is certainly significant. The 
glycosylated Asn307 of Limulus is however on the opposing face of the MG3 domain to Asn275. The 
placement of these residues and ultimately their bound sugars may prove to be physiologically 
significant. 
 
 
 
 
4.3.2.4. Macroglobulin Domain 4 
 
MG4 has 20.8% sequence homology between the human and Limulus molecules. They are 106aa 
and 124aa long and span, Arg322 – Val428 and Arg314 – Trp437, for human and Limulus α2m 
respectively.  
 
Figure 4.9. Sequence alignment diagram of the MG4 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. Those 
shown in red indicate present or predicted α-helices. Residues shown in bold are glycosylated. 
The fourth MG domain in human and Limulus α2m also share a good level of sequence identity, at 
20.8%. This domain plays a key role in the dimerization as well as the formation of entrance 2 
(Figure 4.2). It forms symmetrical contacts with the TED of its disulphide linked subunit and forms 
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part of the boundary of entrance 2 in this capacity as well as forming the boundary of entrance 1 
(Figure 4.2) as part of the right-handed one-and-half-turn ellipsoidal super-helix structure. Whilst 
the human MG4 has a disulphide bond as mentioned above between the Cys431 and the Cys278 of 
the disulphide linked subunit. In the case of Limulus these cysteine residues are not present and 
the Cys431 of MG4 has been substituted in Limulus to Gln440 (Marrero, et al. 2012; Husted, et al. 
2002). Areas of uncertainty lie within the predicted structure of this domain as a number of the 
predicted structural features have low confidence levels but those with even low confidence 
levels align well with the known human structure (Figure 4.9). In particular there is the two 
residue long strand structure (Tyr332 and Leu333) which has an average confidence of 1.5 over the 
two residues yet lines up reasonably well with an equally short region in the human sequence 
(Phe336 and Arg337). The overall sequence identity for the predicted features is 6.09 which isn’t 
particularly high but when looking at the alignment the fit is reasonably good with a few strands 
larger in one species and a few loops between strands larger in other areas. Of the two only MG4 
of human α2m is glycosylated with glycosylation occurring at Asn373 and Asn387.Neither of these 
residues are conserved with their aligned Limulus equivalent being Glu384 and Pro398 respectively.  
 
Figure 4.10. From left to right the human and Limulus MG4 domains (Marrero, et al. 2012; Zhang, 2008; 
Roy, et al. 2010). Β-strands are shown in yellow, α-helices are shown in yellow, loop regions are white 
and turns are in blue on the Limulus model only. Glycosylation sites are shown in ball and stick and 
coloured red. Figure generated in RASMOL (Sayle, & Milner-White, 1995). 
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Apart from the general topology being conserved, the most noticeable distinction between the 
two models is the appearance of an α-helix in the RASMOL rendition of Limulus α2m from Thr401 - 
Asp403 (Figure 4.10). This helix does not feature in the predicted secondary structure yielded by 
the I-TASSER results using the program PSIPRED. This may be due to LOMETS using a different 
model than the human α2m (Marrero, et al. 2012) being the primary template for this region or it 
maybe as suggested earlier an artefact of RASMOL rendering due to the similarities between 
helices and turns. The I-TASSER results ranked the templates used with the highest ranked 
template coming from TEP1r of Anopheles gambiae (Baxter, et al. 2007). This sequence does 
contain an α-helix in the equivalent position between residues Thr398 - Val399 and it has an 
additional helix between Ser348 - Val350. The Thr398 – Val399 helix is shared with the human thiol-
ester containing protein complement component C3. Whilst bovine C3 is not one of the ranked 
templates used by I-TASSER, it is ranked 3rd (Fredslund, et al. 2006). This shows that the inclusion 
of α-helices into the macroglobulin domains by I-TASSER may not be as erroneous as first though 
as both Human C3, and TEP1r of Anopheles gambiae (Baxter, et al. 2007) contain α-helices in the 
majority of their MG domains, without disrupting the conserved β-sandwich motif. 
 
4.3.2.5. Macroglobulin Domain 5 
 
MG5 has 33.0% sequence homology between the human and Limulus molecules. They are 109aa 
and 141aa long and span, Phe431 – Cys540 and Phe440 – Cys579, for human and Limulus α2m 
respectively. 
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Figure 4.11. Sequence alignment diagram of the MG5 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. Those 
shown in red indicate present or predicted α-helices. Residues shown in bold are glycosylated. 
MG5, a region of high sequence homology (33.0%) in human and Limulus α2m considering the 
evolutionary distance between the two species, is active in both the boundaries of entrance 1 and 
2 in the human structure (Marrero, et al., 2012). Despite the high sequence homology there are 
Figure 4.12. From left to right: The human MG5 domain from α2m (Marrero, et al. 2012), and the Limulus 
MG5 domain from α2m as predicted by I-TASSER (Zhang, 2008; Roy, et al. 2010). As with previous domain 
comparisons β-strands are shown in yellow, loop regions in white and turns in the Limulus model are 
shown in blue. The Limulus model also has a region highlighted in green that shows an inserted region 
spanning Lys502 - Pro535. Figure generated in RASMOL (Sayle, & Milner-White, 1995). 
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multiple misaligned regions with very low confidence levels (5.22) in the predicted structure 
(Figure 4.11). The 5th strand of the Limulus MG5 (Asp507 – Ile513) as well as the 6th and 7th strands 
(Thr516 – Leu520 and Val532 – Ile533 respectively) lies within an insertion compared to the human 
sequence. The respective confidences of these predicted strands are 3.7, 1 and 0. This could be 
due to the fact that they are found within a 34 residue long insertion (Lys502 – Phe535), compared 
to the human. As a result the software lacked a direct structural model in this region and as a 
result produced a low confidence region. If this region is excluded the remaining structure is a 7 
stranded domain with an average confidence level for the strands of 6.79. This is one strand less 
than the human structure, and when analysing the human sequence it is clear that at the 2nd 
strand (Leu445 – Phe446) there is an absence of a strand in the Limulus domain. Looking at the 
directly aligned residues Ile454 and Glu455 these residues have been designated C by I-TASSER for 
main chain but were done so with confidence scores of 2 and 3 respectively. It may be that 
because the β-sheet is so small, the program overlooked the possibility as it perhaps had a much 
lower confidence value when  designated as a strand. 
In MG5 it appears that the MG motif of a β-sandwich is conserved, but there is one glaringly 
noticeable difference between this domain in human and Limulus α2m. This difference is an 
inserted loop region of 33 residues spanning Lys502 – Pro535 visible in the sequence alignment and 
highlighted above in green in Figure 4.12 for ease of visualisation. This insertion in Limulus α2m 
relative to the human protein appears between strands 5 and 6, and has a predicted secondary 
structure (PSIPRED) containing three β-strands Asp507 - Ile513, Thr516 - Leu520 and Val532 - Ile533 as 
mentioned earlier. Upon evaluation of this region of the I-TASSER predicted model for Limulus 
MG5 it is clear that no β-sheets were in fact incorporated into the model, rather a short α-helix 
was built in at residues Glu527, Trp528, Glu529 and Asn530. Following the appearance of this 
unexpected helix, which may be a result of the top ranked template from Anopheles gambiae 
TEP1r, a sequence alignment using CLUSTAL was carried out. The results showed that compared 
to TEP1r the insertion is longer still at 41 residues, spanning His494 - Ser542 with an aligned region 
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sitting between Pro522 and Glu529. It may then be possible to infer that this inserted loop region 
plays a significant physiological role in Limulus α2m as the insertion of this region is distinct from 
the sequences of its human homologue (Marrero, et al. 2012), C3 and the TEP1r protein from 
Anopheles gambiae (Baxter, et al. 2007). 
 
 
 
 
4.3.2.6. Macroglobulin Domain 6 
 
MG6 has 44.6% sequence homology between the human and Limulus molecules. They are both 
98aa long and span, Leu541 – Asp578 and Glu706 – Ala765  for human α2m and Leu581 – Asp618 and 
Val757 – Gly816 Limulus α2m, sequence gap is shown where BRD is inserted. 
  
 
Figure 4.13. Sequence alignment diagram of the MG6 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus protein. 
Residues shown in bold are glycosylated. 
 
With the highest sequence identity between human and Limulus α2m of any domain MG6 
contains a break that accommodates the BRD as well as contributing to the boundary of both 
|BRD 
BRD | 
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entrance 1 and 2 (Marrero, et al. 2012) it also has a confidence rating of 6.55 which is lowered 
once again by a low confidence short β at Glu758 and Ile759 without when excluded result in a 
confidence score of 7.27 (Figure 4.13). A question should be asked however as to whether the 
residues following that short predicted strand (Arg760 – Thr766) should in fact be part of the strand 
and bridge to the next β-strand in the sequence (Trp766 – Leu771). The high sequence identity 
between human and Limulus α2m for this region suggests that this is indeed the case. Of the 
seven aligned amino acids in those strands, six share sequence identity, this coupled with the fact 
that the human equivalent β-strand is much longer (11 residues as opposed to 5) and have an 
average confidence of 3.14 might suggest that these residues should in fact form part of the 
strand.  
 
The comparison of the two domains shows the region of the Limulus domain with a large loop 
region contains a short helix Glu758 and Ile759 (Figure 4.14). Upon comparison with the top ranked 
template TEP1r from A. gambiae in this protein there is a large loop region present which may 
account for the loop in the predicted model of the Limulus α2m MG6 domain, but there is no β-
strand present in the aligned region. Given the confidence scores for the predicted secondary 
Figure 4.14. From left to right: Human MG6 from α2m excluding the BRD that is inserted between Asp578 
- Glu706 (Marrero, et al. 2012) and the MG6 domain of Limulus α2m as predicted by I-TASSER excluding 
the BRD inserted between Asp618 - Va757 (Zhang, 2008; Roy, et al. 2010). Figure generated in RASMOL 
(Sayle, & Milner-White, 1995). 
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structure for Glu758 and Ile759, 2 and 1 respectively, it may be that this is an area that requires 
further examination when the crystal structure for Limulus α2m is solved. 
 
 
 
4.3.2.7. The Bait Region Domain 
The BRD has 18.3% sequence homology between the human and Limulus molecules. They are 
both 126aa long and span, Gln579 – Thr705 and Lys619 – Val756, for human and Limulus α2m 
respectively. 
 
Figure 4.15. Sequence alignment diagram of the BRD domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus protein. 
Those shown in red indicate present or predicted α-helices.  
 
The bait region domain of Limulus α2m, one of the key characteristic features of α2m, actually has 
much lower sequence identity with the human protein than might be expected – 18.3%. However 
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upon application of context it is clear that the BRD of Limulus α2m should differ greatly in 
sequence to that of human α2m, as the two immune systems have evolved to combat and target 
different proteases. Of the total predicted secondary structures for Limulus α2m the average 
confidence in the predictions is just a mere 2.39 (Figure 4.15). As can be seen from the human 
secondary structure as well as the tertiary folding of the domain, the BRD is a largely disordered 
region to allow maximum accessibility to the cleavage sites of proteases. One possible reason for 
the low confidence scores, even for those secondary structures that align with their human 
counterparts, may be because other than human α2m the remaining structures in the PDB that I-
TASSER used lack bait regions and thus a BRD. In the other α2m family members different 
functionally defining domain is inserted into MG6 instead of the BRD, such as the linker (LNK) 
domain and anaphylatoxin (ANA) domain present in the complement proteins C3, C4 and C5 
(Janssen, et al. 2005). 
 
In the human structure and the Limulus α2m BRD models it is clear that the general topology is 
the same with conserved structures clearly visible (Figure 4.16). The addition of the bait-region 
itself in the Limulus model by I-TASSER is unlikely to yield potentially significant information 
Figure 4.16. From left to right: The human BRD excluding the bait-region - Pro667 - Thr705 as the region is 
highly flexible and thus isn’t built into the model (Marrero, et al. 2012)  and the predicted Limulus BRD of 
α2m (Zhang, 2008; Roy, et al. 2010), with the bait region itself shown in ball and stick mode to make it 
distinguishable. Colour schemes are the same as previous domains. Figure generated in RASMOL (Sayle, & 
Milner-White, 1995). 
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despite its absence from the human structure. There is an α-helix shown in the bait region of the 
Limulus model, Gln730 - Asn733, this conformation is unlikely as it is potentially inhibitive of 
protease cleavage, the inherent flexibility of the bait-region is why it is absent from the human 
structure and it is this property, in conjunction with its sequence, that allows it to be the target of 
multiple proteases.  
 
 
 
4.3.2.8. Macroglobulin Domain 7 
MG7 has 40.3% sequence homology between the human and Limulus molecules. They are 
119aa and 116aa long and span, Phe766 – Pro885 and Phe817 – Pro932, for human and Limulus α2m 
respectively.
 
Figure 4.17. Sequence alignment diagram of the MG7 domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus protein. 
Those shown in red indicate present or predicted α-helices. Residues shown in bold are glycosylated. 
 
MG7 in the human structure does not play a role in entrance 1 like many of the preceding MG 
domains (Marrero, et al. 2012) but it does play a role in the formation of entrance 2 (Figure 4.2). 
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MG7 can be found sat between MG6, which has the BRD inserted, and the CUB domain, which 
has the TED inserted. The fact that MG7 lies between these two domains that contain functionally 
and family defining domains inserted might account for its high sequence identity of 40.3% as it 
will play a key role in the placement of these domains spatially. The domains predicted secondary 
structure has an average confidence of 6.39 (Figure 4.17). The first predicted β-strand of the 
domain, Phe817 – Ser823, does in fact begin in the previous MG6 domain with the MG6 portion 
spanning Ala811 - Gly816. When compared to the secondary structure of the known human 
structure it could be suggested that that potentially the first three residues of MG7 (Phe817, Gln818, 
Pro819) and the last three residues of MG6 (Val814, Lys815, Gly816), should not in fact be part of a β-
strand to bring the structure more in line with the human model. The relatively high confidence 
for Phe817, Gln818, and Pro819 of 8, 6 and 7 respectively suggest that the predicted secondary 
structure is in fact correct. The second strand which is only a short one Ser829 – Ile831, has a very 
low confidence of 2, 2 and 0 respectively despite the 100% sequence identity for that strand. This 
seems to be a common problem that I-TASSER has when predicting secondary structures. It 
appears to correctly predict the structure for that region but the low confidence levels are highly 
typical of short length strands. The predicted secondary structure for the domains assigns ten β-
strands to MG7; this is as previously stated out of keeping with the architecture and general motif 
of the MG domain which is typically a seven/eight stranded β-sandwich. Judging from the 
sequence alignment it is clear that the eight strands seen in the human structure align well with 
eight Limulus counterparts. There are two Limulus strands however that lack a human partner 
(Phe862 – Met864 and Cys910 – Tyr915). The respective confidences of 6 and 4, are not as low as 
expected from a potentially erroneous result especially as Ser829 – Ile831 appears to be a correct 
prediction in spite of the average confidence of 1.3, but the evidence does suggest that these 
represent a potential error in the predicted secondary structure of the MG7 domain. 
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Human α2m has one glycosylation site in its MG7 domain at Asn846, which is conserved in the 
Limulus homologue at residue Asn896, in addition to this glycosylation site Limulus α2m MG7 is 
also glycosylated at Asn866. 
Perhaps the most significant observation noted when comparing these two domains is the 
appearance of an α-helix in the Limulus model between residues Leu904 - Glu907 (Figure 4.18). In 
addition to this the predicted secondary structure, by the program PSIPRED, states a β-strand is 
present between Cys910 and Tyr915. In spite of this following template search and model 
refinement the actual Limulus α2m model produced shows no such β-strand through these 
residues. 
 
4.3.2.9. The CUB Domain 
The CUB domain has 38.6% sequence homology between the human and Limulus molecules. They 
are both 114aa long and span, Glu886 – Ile931 and Thr1247 – Phe1316 for human α2m and Glu933 – 
Leu981 and Lys1279 – Lys1346 Limulus α2m, sequence gap is shown where the TED domain is inserted. 
  
Figure 4.18. From left to right: the human MG7 domain of α2m (Marrero, et al. 2012) and the I-TASSER 
predicted structure of the MG7 domain of Limulus α2m (Zhang, 2008; Roy, et al. 2010). Colour schemes 
as on previous domains with glycosylation sites shown in ball and stick configuration and in red. Figure 
generated in RASMOL (Sayle, & Milner-White, 1995). 
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Figure 4.19. Sequence alignment diagram of the CUB domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. Those 
shown in red indicate present or predicted α-helices.  
The CUB domain that contains an inserted family defining thiol-ester domain is highly conserved 
between the two species in question. Not only does it have the same number of amino acids in 
length but at 38.6% sequence identity it is also one of the domains which have the greatest 
sequence homology. In humans the domain is arranged as two four-stranded antiparallel β-sheets 
with the TED inserted between strands 3 and 4. The predicted secondary structure suggest that 
the TED in Limulus mimics the humanoid protein in that it lies between the 3rd and 4th β-strands it 
does however have a proposed seven strand conformation with the 7th and 8th strands effectively 
joined into one large strand according to the prediction data. This predicted large 7th strand 
|CUB 
CUB | 
Figure 4.20.  From left to right: The CUB domains from human α2m and Limulus α2m as shown by 
Marrero et al. and I-TASSERs prediction respectively (Marrero, et al. 2012; Zhang, 2008; Roy, et al. 2010). 
Colour schemes are as per previous figures. Figure generated in RASMOL (Sayle, & Milner-White, 1995). 
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(Pro1318 - Tyr1337) however can be queried due to Ser1326, Gly1327, Cys1328, having respective 
confidence scores of 3, 2 and 3 (Figure 4.19). With two of these three residues aligning with the 
gap between the 7th and 8th strands in the human protein the case for this argument is strong 
especially as the CUB domain motif is well conserved in the α2m superfamily. 
The unglycosylated CUB domains of both human and Limulus α2m Figure 4.20 both show the 
conserved all-β motif made up of two four stranded antiparallel β-sheets. Interestingly, although 
the LOMETS  secondary structure predicts that residues Thr1324, Gly1325, Ser1326, Gly1327 and Cys1328 
are all part of the proposed extended β-strand the reality is that the I-TASSER model shows these 
residues as a turn between β-strands 7 and 8. As a result the model coincides well with the 
human structure of the CUB domain (Marrero, et al. 2012).  
 
4.3.2.10. The Thiol Ester Domain 
The TED domain has 40.8% sequence homology between the human and Limulus molecules. They 
are 314aa and 296aa long and span, Leu932 – Phe1246 and Met982 – Tyr1278, for human and Limulus 
α2m respectively. The thiol-ester bond participating residues have been highlighted in yellow. 
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Figure 4.21. Sequence alignment diagram of the Thiol Ester domains of human and Limulus α2m, with 
confidence score for the predicted secondary structures and solvent accessibility for the Limulus protein. 
Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus protein. 
Those shown in red indicate present or predicted α-helices. Residues in bold are glycosylated. 
The α-helix dominated, α- α toroid TED that defines the α2m superfamily of proteins is highly 
conserved in all species due to its key functional roll in addition to its family defining 
characteristics. Despite being slightly shorter in length the Limulus TED still share 40.8% sequence 
homology with the human protein. The yellow highlighted residues of Figure 4.21 are involved in 
the thiol-ester bond, Cys949 – Gln952 and Cys999 – Gln1003 from human and Limulus respectively, are 
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all conserved as this is a key functional region that sees high conservation across all family 
members (Armstrong, & Quigley, 1999). From the alignment of the secondary structures the 
majority of the helices align with great accuracy however there are a few areas that I-TASSER may 
have gotten wrong. Tyr1052 and Ser1053 have been designated β-strands and it has done so with 
high confidence, both scoring seven. These two residues are conserved between both species and 
in human α2m do not feature in a β-strand. The α-helix predicted from Pro1180 – Thr1195 for the 
Limulus α2m may contain an error towards its back end with residues Ile1194, Thr1195 as well as the 
following residue Glu1196 predicted to be not included in the helix, having confidence scores of 3, 3 
and 0 respectively. These three residues are aligned with a short β-strand in the human molecule 
in Val1152, Lys1153, and Lys1154. These three amino acids form the first of the β-sheets of the 
domain seen in the human structure (Marrero, et al. 2012). The human structure has shown us 
that these two β-sheets are linked by a β-hairpin that may play a key role in the reorientation of 
the TED following thiol-ester cleavage. Both human and Limulus α2m thiol-ester domains are 
glycosylated. The human domain is glycosylated at Asn968 which is not conserved in the Limulus 
homologue, the Limulus domain shows glycosylation at two sites - Asn1089 and Asn1145. 
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The above comparison (Figure 4.22) of the two family defining domains clearly shows a high level 
of conservation in this domain. Plainly visible is the α/α-toroid topology in the arrangement of six 
concentric α-hairpins as an α-propeller with a central axis.This gives rise in both models to a thick 
two-faced disc. The glycosylation sites on both human and Limulus sit on the same face of the 
domain. 
4.3.2.11. The Receptor Binding Domain 
The RBD domain has 31.3% sequence homology between the human and Limulus molecules. They 
are 128aa and 129aa long and span, Pro1317 – Ser1445 and Gly1347 – Glu1476, for human and Limulus 
α2m respectively. 
 
Figure 4.23. Sequence alignment diagram of the receptor binding domains of human and Limulus α2m, 
with confidence score for the predicted secondary structures and solvent accessibility for the Limulus 
Figure 4.22. From left to right the human α2m TED domain (Marrero, et al. 2012), and the I-TASSER 
predicted structure for the Limulus α2m TED domain (Zhang, 2008; Roy, et al. 2010). Colour scheme is as 
on other domain comparison figures, with the glycosylated residues shown in red and ball and stick 
configuration for ease of identification. Figure generated in RASMOL (Sayle, & Milner-White, 1995). 
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protein. Residues highlighted in blue indicate a β-strand in humans or a predicted β-strand in the Limulus. 
Those shown in red indicate present or predicted α-helices. Residues in bold are glycosylated. 
 
The RBD is a key functional domain that allows the α2m-protease complex to be endocytosed by 
the immune system for processing and clearance. LRP-1 the human receptor for α2m is part of an 
evolutionarily ancient family of proteins and a homologue found in Limulus LRP – receptor 
associated protein, does bind the human protein but its binding of the Limulus α2m has yet to be 
assessed. This cross species recognition may be due to the 31.3% sequence homology between 
the two receptor binding domains which also show a very good secondary structure fit. The 
predicted Limulus model (Figure 4.23) lacks the first α-helix seen in the human structure (Lys1333, 
Ala1334, His1335, and Thr1336) which correspond to Arg1360, Asp1361, Cys1362 and Ile1363 in Limulus. 
These residues were predicted C for main chain with respective confidences of 6, 6, 6, and 4. 
Although Lys1333 in human and Arg1360 in Limulus are both positively charged and have similar 
properties, the remaining three residues are entirely dissimilar. Ala1334, in human is a very passive 
amino acid whereas Asp1361 with its interactive carboxylic acid is far more likely to interact with 
other molecules. His1335 and Cys1362 in human and Limulus respectively, are reactive but in 
different ways Cys1362 forming an intrasubunit disulphide bond with Cys1475, the penultimate 
residue of the domain. Whether or not the absence of this helix in Limulus is correct remains to 
be seen, it may in fact be correct if that region is the part that interacts with its receptor. Only the 
human RBD has any glycosylation which takes place at Asn1435. 
Figure 4.24. From left to right, the human RBD of α2m (Marrero, et al. 2012), and the I-TASSER predicted 
structure of the Limulus α2m RBD (Zhang, 2008; Roy, et al. 2010). The colour scheme is as before, with β-
strands in yellow, α-helices in magenta, loop regions in white and turns in the loops shown in blue. Figure 
generated in RASMOL (Sayle, & Milner-White, 1995).  
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Interestingly upon observing and comparing the two RBD models above, it was clear that an α-
helix that was predicted by the secondary structure prediction is missing. The predicted helix that 
runs from Glu1397 - Val1404 with only an average confidence of 3.0, is in fact replaced with a loop 
region and a small strand running from Ile1400 - Lys1401. Another interesting discrepancy is seen in 
the helix of the human α2m RBD which the supplementary materials to Marrero et al. (Marrero, 
et al. 2012), state runs from Lys1369 - Ser1379. The model in fact however shows that the α-helix 
runs only from Lys1374 - Ser1379. Judging however from the backbone depiction of the RBD it is 
clear that all the residues, Lys1369 - Ser1379 are arranged in a helical manner but one that lacks 
uniformity in diameter of the central cavity of the helix that may be why it has not shown all of 
the residues as part of an α-helix. This may be once again due to the way in which RASMOL 
renders the coordinates into a three dimensional model (Figure 2.24). 
 
4.3.2.12. Tertiary and Quaternary Structure 
Sequence homology varies greatly between the various domains with the lowest homology seen 
in MG1 (9.1%) and the highest seen in MG6 (44.6%) whilst the functionally significant and family 
defining TED also has a high sequence homology for such an evolutionarily distant species 
(40.8%). An encouraging sign for the competence of the software is the alignment of known 
secondary structures with those predicted by the software. One could argue that this is to be 
expected as the human structure was indeed one of the PDB models used to build the theoretical 
one and thus determine the proposed secondary structure of Limulus α2m ranking 5th in the 
structure homology for known structures. This means a difficult question must be asked, and one 
that currently there is no answer for: Does Limulus α2m genuinely have greater structural 
homology with TEP1r from Anopheles gambiae than it does with its human homologue? The only 
way to truly answer this question lies in the solution of the crystal structure of the molecule and 
then making a direct comparison of the structures in question.  
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The human structure is currently the best functional homologue within the PDB to Limulus α2m. 
Given that the model above produced by I-TASSER represents a non-activated form compared to 
the activated human structure, it was decided to run a second I-TASSER simulation with the 
human model defined as the primary template in order to produce a model with similar domain 
positioning to the human model and thus yielding potential information about the rearrangement 
of the domains upon activation.  
 
 
As shown in Figure 4.25 the ‘native’ model to the left is the original I-TASSER prediction with no 
template specified, the ‘activated’ model to the right was built by I-TASSER when the human 
model (PDB code – 4ACQ) (Marrero, et al. 2012) was specified as the template. The result 
unsurprisingly, is an activated structure that far greater resembles that of the human model in 
terms of domain organisation. Upon closer inspection using RASMOL it is clear that there are a 
few major differences in terms of the relative positions of the domains between the native and 
activated Limulus models. MG1-6 and the BRD in the native Limulus α2m model seem to have 
Figure 4.25. To the left is the "native" model of Limulus α2m and to the right is the “activated” model. The 
“native” model is based on an open search with I-TASSER without specifying a template to use, whereas 
the “active” model was built with the human structure specified as the template. Figure generated in 
RASMOL (Sayle, & Milner-White, 1995). 
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twisted ~90° with respect to MG6. It is known that these domains form the right handed one-and-
a-half turn ellipsoidal super-helix that forms entrance 1 (Marrero, et al. 2012).  This twisting of the 
super-helix may inhibit access through entrance 1 to the central prey chamber where the bait 
region and thiol-ester lie.  In addition the thiol ester domain of the activated model seems to have 
‘dropped’ with respect to MG6 which could be described as the apex of the subunit.  In the 
‘native’ Limulus α2m model the higher position of the TED, means that the CUB domain limits the 
accessibility of the RBD. However in the ‘activated’ model the TED drops and the result is that it 
pulls the CUB domain down further alongside the RBD causing more of it to be revealed to the 
solvent.  During the ‘dropping of the TED’ the TED also appears to undergo a massive internal 
shift. In the ‘native ‘ Limulus α2m model the residues that form the thiol ester Cys999 and Gln1003 
are positioned up by the RBD, in the ‘activated’ Limulus α2m model however they appear much 
lower down relative to the RBD due to the angle of α-helix-2 having shifted by ~15°. 
It may then be proposed that upon activation of α2m the ellipsoidal super-helix twists, thus 
closing off entrance 1, and simultaneously the thiol ester domain drops, pulling with it the CUB 
and exposing the RBD. The result is a more compact structure, with entrance 1 closed off, the 
thiol ester residues moving more centrally and the RBD exposed which allows the activated 
Limulus α2m to bind its receptor for clearance.  The inherent flexibility of the native α2m 
molecule has been known and demonstrated for some time (Armstrong, et al. 1991). Once 
activated the TED domain shifts as a result trapping the protease within it.  
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Figure 4.26. The activated human molecule shown as a dimer thus representing the activated Limulus 
dimer, the TED domains have been highlighted in red to highlight their relative positions in both a side on 
(A) and top view (B) of the molecule (Marrero, et al. 2012). Figure generated in RASMOL (Sayle, & Milner-
White, 1995). 
Figure 4.26 shows the human α2m structure manipulated into a dimer, to highlight the shift 
expected to be seen in Limulus. It depicts a rather “demonic” looking molecule with the TED 
domains extended and thus inhibiting the ‘escape’ of a potential prey molecule. In the native 
structure the TED domains would be withdrawn higher up, thus restricting access to the RBD. This 
allows greater flexibility around the MG1-6 and MG7-CUB-TED interface allowing access to the 
BRD by proteases, and upon cleavage of the bait region the thiol ester bond is broken as a result, 
thus triggering the drop of the TED and entrapment of the protease in question. However the 
mechanics of this model don’t appear to work for the dimerisation, certainly based on the human 
structure. The final positions of the TED domains demonstrated in red in Figure 4.24 represent the 
positions after activation, it is difficult to imagine how when moving from a higher position how 
exactly they would trap a protease. To further understand this the interface between the two 
subunits of the human dimer was investigated. Disulphide bonds hold the human dimer in 
position occurring between Cys255A (MG3) and Cys408B (MG4) and Cys408A and Cys255B where, as 
described earlier A represents one subunit and B represents the other disulphide bonded subunit 
(Marrero, A., et al. 2012). The Limulus dimer is formed due to disulphides forming between Cys719 
of each subunit, which resides in the bait region of the molecule (Iwaki, et al. 1996). Using this as 
the anchor point for the two subunits, the result is something quite different. 
A                                                                                 B 
 155 
 
 
Figure 4.27. The proposed structure for the native Limulus α2m dimer. MG1-6 are coloured, orange, 
yellow, light green, magenta, cyan , and pink respectively. The BRD is shown in blue, MG 7 in red, the Cub 
domain is dark green whilst the TED and RBD are coloured purple and grey respectively as per the colour 
scheme used in the domain illustrations in Marrero et al. (Marrero, et al. 2012). Cys719 of each subunit I 
shown in black and in spacefill display to show them more clearly. The subunits were manipulated into 
position so that their relative distances were close to disulphide linkages. The result is a large dimer with 
flexibility around the disulphide that links the two subunits. Figure generated in RASMOL (Sayle, & 
Milner-White, 1995). 
The disulphide linked dimer created and shown in Figure 4.27 creates a ‘Pacman’ shaped 
molecule  opposed to the ‘Donnie Darko’ shaped molecule proposed in Figure 4.26, which allows 
access to its bait region through the mouth of the ‘Pacman’. The ‘mouth’ of this model measures 
~35Å across which is large enough to allow the passage of a 20-25kDa protease into the prey 
chamber and is consistent with what is seen in the human structure (Marrero, et al. 2012). 
Cleavage of the bait region results in the cleavage of the thiol ester bond between Cys999 and 
Gln1003, by a mechanism in Limulus yet to be revealed.  
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Figure 4.28. Native Limulus α2m dimer model produced by I-TASSER, maintaining the colour scheme in 
Figure 4.27, with trypsin (shown in black) in the prey chamber. Upon activation the purple TED domains 
will move centrally thus closing off the 35Å wide mouth behind the trypsin rendering it trapped. The 
resultant exposure of the RBD then allows for this protease-inhibitor complex to be cleared from 
circulation. Figure generated by COOT and RASMOL (Emsley, et al. 2010; Sayle, & Milner-White, 1995). 
 
This then allows for the TED domain to shift as is the norm for α2m family members upon 
activation (Janssen, et al. 2005; Baxter, et al. 2007), this shift in the TED domain results in the 
entrapment of the protease as ‘Pacman’ effectively closes his jaws around the molecule and 
revealing the RBD previously partially covered by the CUB domain which has also descended with 
the tethered TED. 
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Figure 4.29. The proposed activated Limulus dimer based on the I-TASSER results using human α2m-MA 
activated structure as its principle template. Colour schemes as in Figure 4.26. The two subunits are 
bound as before by disulphide bonds between the Cys719 of their respective bait regions. As with all 
family members upon activation of Limulus α2m the CUB-TED complex has dropped relative to MG7, thus 
closing the binding pocket behind the protease. The Cys999 of one of the TED domains is shown by a gold 
star to show it’s position. 
Due to activation the thiol ester of the TED domains are now accessible. In the human structure 
the broken thiol ester then forms and anchor to the protease covalently binding it, while in 
Limulus this is not the case (Armstrong, & Quigley, 1999). This is likely to occur so that once the 
thiol ester has been cleaved Limulus Cys999 is then free to bind to the cytolytic protein limulin 
(Swarnakar, et al. 2000). As described earlier in part 1.2.2.3 - Limulin is a sialic acid binding 
pentraxin that causes cell lysis by binding surface sialic acid and then inserting itself into the 
membrane forming a pore. Activated but not native Limulus α2m inhibits this by binding limulin 
via Cys999. The model activated dimer depicted in Figure 4.29 does not initially appear much 
smaller than the native dimer shown in Figure 4.27 and 4.28, which appears to contradict the gel 
electrophoretic evidence shown in Figure 2.11. This may be due to the fact that the native 
molecule shown in Figure 4.27 is highly flexible and not in one set conformation unlike that seen 
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in Figure 4.29, and whilst the depiction in 4.27 is accurate as seen in transmission electron 
microscopy studies, the native form actually takes on multiple ‘conformations’ (Armstrong, et al. 
1991).  
In summary the bioinfomatic analysis and structure prediction presented here provides structural 
models of various kinds as well as insights into the mechanism that Limulus α2m undergoes upon 
activation and how this might relate to its functions downstream. 
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Chapter 5 – General Discussion: Conclusions and Future Work 
In invertebrates which lack an adaptive immune system, the importance of the innate immune 
system cannot be overstated. The roles performed by the innate immune system have allowed 
phylogenetically ancient species such as the horseshoe crab, Limulus polyphemus to remain 
unchanged evolutionarily for 400-500 million years. Whilst as the scientific world has seen, the 
adaptive immune system is a marvelously specific and powerful weapon in the immunological 
arsenal, its initial response time is slow. As a result, to stop initial infection running rampant a 
background system must stem the tide of the rate of infection. The innate immune system does 
this with a combination of barriers and protein molecules. The innate immune family members 
are broad and interestingly have homologues in a wide-range of species. The existence of 
homologous proteins in animals that lack an adaptive immune system is further evidence of the 
importance of the innate immune system. This is further emphasized by the fact that for many 
innate immune proteins; no absence has ever been reported, suggesting that their absence is 
incompatible with life and further highlighting their significance in the struggle against infection. 
Thiol ester containing proteins such as α2-macroglobulin can be found in a variety of species, with 
humans having multiple family members as well as the α2m protease inhibitor itself. In Limulus 
polyphemus the α2-macroglobulin homologue is the only known circulating protease inhibitor and 
thus its role in protection from proteolytic attack is potentially more important than that of the 
human α2m which also has a battery of specific active-site inhibitors to aid it in this role (Quigley, 
& Armstrong, 1983). In addition to its pan-protease inhibitor role Limulus α2m has also been 
shown to be a regulator of the Limulus cytosolic system, where activated α2m binds and negates 
the activity of limulin the cytosolic pentraxin (Swarnakar, et al. 1995). The aim of the research 
presented in this thesis was to shed light on the structure of α2-macroglobulin from Limulus 
polyphemus using crystallographic and bioinformatic techniques. This thesis represents the first 
ever reported instance of Limulus α2m being crystallised. Of the crystals grown those that grew in 
crystallization well MN04D3 were tested at a synchrotron light source, Diamond Light Source in 
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Oxford, and they diffracted to a resolution of 6Å. Whilst not a high enough resolution for the 
production of a model this does provide a starting point for future crystallographic study. The 
range of possibilities for future crystallographic studies is broad, but firstly the methodology of 
the production of α2m should be assessed. Here the protein was purified from PEG cut serum 
using multiple stages of affinity and size exclusion chromatography to remove the contaminants 
haemocyanin and the pentraxins.  PEG cut serum was used due to the reduced levels of 
haemocyanin, in theory making the purification of α2m easier. As shown in Figure 2.2 however 
PEG cut serum still contains very high quantities of haemocyanin and this was further evidenced 
in SEC1 (Figure 2.4) and the SDS-PAGE gel of the products of SEC1 (Figure 2.5). Haemocyanin 
persistence is but one obstacle as the addition of PEG cut serum to a phosphoethanolamine linked 
agarose column results in the precipitation of some of the pentraxins (Shrive, et al. 2009). One 
possible method to avoid excess contaminants would be to treat the α2m with trypsin or another 
protease. Whilst methylamine treatment results in the cleavage of the thiol ester bond, it will not 
impact greatly upon any other contaminant proteins. Treatment of a ‘semi-pure’ stock of α2m 
with trypsin would render the bait region cleaved and thus α2m activated and complexed with 
trypsin, as well as cleaving any remaining protein contaminants. This requires available proteolytic 
sites and whilst all of the subunits of haemocyanin, CRP and SAP contain multiple trypsin cleavage 
sites (as shown in Table 5.1), many of those sites may be inaccessible to the protease due to 
tertiary and quaternary folding of the protein.  
Table 5.1. The subunits of the key serum proteins of Limulus polyphemus, showing the number of 
proposed trypsin cleavage sites assessed by peptide cutter of the ExPASy server. (Gasteiger, et al. 2005). 
Uniprot Ascension Code Protein Length 
(aa) 
Proposed Trypsin 
Cleavage sites 
P06205 Limulus CRP 1.1 242 20 
P06206 Limulus CRP 1.4 242 16 
P06207 Limulus CRP 3.3 242 19 
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Q8WQK3 Limulus SAP-like pentraxin 234 14 
A2AX56 Limulus Haemocyanin subunit II 629 64 
A2Ax57 Limulus Haemocyanin subunit IIIa 627 66 
A2AX58 Limulus Haemocyanin subunit IV 624 62 
A2AX59 Limulus Haemocyanin subunit VI 638 58 
G8YZR0 Limulus Haemocyanin subunit IIIb 628 59 
 
The feasibility of such an experiment would be easily tested as during the purification process 
pure stocks of haemocyanin, CRP and SAP were produced. These stocks could be incubated with 
trypsin prior to SDS-PAGE and possibly size exclusion chromatographic analysis to assess the 
success of the digest.  Should the digest prove to be successful then the stocks of α2m that have 
been purified already could then be treated with trypsin to digest any remaining contaminants. 
This would then be followed by a SEC run to isolate the reacted α2m with trypsin trapped within 
from the digested contaminants and any free trypsin not trapped by α2m. This of course would 
now differ from the α2m stocks that were used in this thesis where α2-macroglobulin was reacted 
with methylamine, but as the mechanism of structural change has been shown to be the same 
between methylamine and protease activated α2m, this may have little impact on the 
crystallisation of the complex.  The example above uses only trypsin as an example protease but 
such work could be carried out with any protease that will sufficiently digest the contaminant 
proteins to an extent that would ease purification. 
Given the importance of the innate immune system in invertebrates such as Limulus polyphemus, 
future work with Limulus α2m should focus on its ability to block the cytolytic activity of limulin 
the sialic acid binding pentraxin. Only the activated form of Limulus α2m has been shown to have 
this effect (Swarnakar, et al., 1996), the reaction of α2m in Limulus generating a free thiol at 
Cys999. This free thiol is thought to be crucial to the inhibition of limulin mediated cytolysis as to 
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treatment of methylamine reacted α2m with the alkylating agent iodoacetamide results in the 
alkylation of the thiol group and removes the inhibitive ability of the protein on cytolysis 
(Swanakar, et al. 2000). Coupled with the fact that none of the sugars on the surface of the 
glycosylated Limulus α2m are sialic acids (Iwaki, et al. 1996) this suggests that this free thiol at 
Cys999 is the primary means of interaction between Limulus α2m and limulin. In humans the 
complement based system of cytolysis is extensive and requires many components, making the 
simple model in Limulus utilising the sialic acid binding of limulin of great interest. 
Crystallographic studies of the interaction between activated α2m and limulin could provide key 
functional insights into this cytolytic mechanism as well as shedding light on the evolution of such 
mechanisms. Isolation and purification of limulin from PEG cut serum has already been performed 
by the Armstrong group (Swarnakar, et al. 2000), suggesting that following the same protocols 
followed by crystal trials should be a relatively, simple process and an avenue well worth 
investigating. 
In this thesis the structure of the native model of Limulus α2m has been proposed based on the 
structure prediction by the I-TASSER server (Zhang, 2008; Roy, et al. 2010). The thesis also leads to 
the proposal that upon activation Limulus α2m undergoes a conformational change that results in 
the twisting of MG1-6 by approximately 90° as well as the ‘dropping’ of the thiol ester domain 
with respect to the CUB domain.  This proposal is supported by the structural evidence of the 
mechanism of C3 activation into C3b (Janssen, et al. 2005), where, upon cleavage into C3b, the 
TED drops a distance of 85Å as shown in Figure 5.1.  
 163 
 
 
Figure 5.1. Domain representation of the structures of human C3 and the activated form C3b (Janssen, et 
al. 2005; Marrero, et al. 2012). MG1-6 are depicted in green, the LNK domain is coloured blue, MG7 is 
shown in red, the CUB and TED domains in pink and the MG8, ANK and C345c domains are all shown in 
grey as well as the ANA domain of C3 which is released when C3 is activated. Upon activation the TED 
domain drops 85Å relative to MG 7.  
Analysis of the structures that exist of the α2m family members show that the MG1-6 and MG7-
CUB-TED act almost as two independent bodies which twist around one another upon activation 
and as a result leads to the dropping of the TED. This argument is further strengthened by the 
results of the initial I-TASSER run used TEP1 of the native form of Anopheles gambiae as its 
principle template, which showed its TED domain tucked up in its inactivated starting position 
(Baxter, R. et al. 2007). The ‘activated’ Limulus α2m model produced by I-TASSER used the human 
α2m-MA (thus activated) as its principle template and so best represents the activated form of 
the molecule as shown in Figure 5.2A. Figure 5.2B shows the comparison between the activated 
and native forms of Limulus α2m showing the dropping of the TED domain. 
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Figure 5.2. A. Overlay of the models for the predicted structure of activated Limulus α2m, shown in blue, and the 
structure for the activated human α2m (Marrero, et al. 2012), shown in green. B. Overlay of the models for the 
predicted structure of native Limulus α2m, shown in blue and the model for the predicted structure of the activated 
Limulus α2m shown in green, with the TED domains labelled to highlight the shift upon activation. 
 
The mechanism for activation of Limulus α2m proposed here may thus shed further light upon the 
mechanisms at play once the α2m molecule has been activated such as the inhibition of the 
limulin mediated cytolytic system (Swarnakar, et al. 2000).  One experiment that would yield 
results to support this would be to perform Small Angle X-ray Scattering (SAXS) which provides 
very low resolution structural data but can clearly show the shape of the molecule. Whilst the lack 
of structural homogeneity with regard to conformations in the native might confound this process 
it may provide confirmation of the conformation of the activated Limulus α2m dimer proposed in 
this thesis. 
Further afield, the human α2m structure was recently published in its methylamine reacted form 
(Marrero, et al., 2012) so this too requires investigation in terms of its native form, as well as 
exploration of the structural differences, if any occur, between the methylamine reacted and 
protease reacted forms. Additionally human α2m provides further avenues for exploration due to 
its interactions with h-SPD, and various cytokines (Craig-Barnes, 2010; Rehman, et al. 2013). H-
SPD has been shown to bind to a wide range of sugars and it is known that it will bind to the 
sugars on the surface of α2m. Unfortunately as fascinating as it would be especially to those 
A                                                                          B 
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whose research focuses on innate immune proteins there are one or two key obstacles that may 
prove insurmountable in this line of research. The first problem would lie in ensuring 
homogeneity between h-SPD binding sites on α2m. Each subunit of the human α2m molecule has 
eight glycosylation sites, and ensuring homogeneity of binding in each α2m-h-SPD complex may 
prove a barrier to success. Secondly long chain sugars are highly flexible mainly around their 
glycosidic bonds greatly reducing the possibility for regular ordered asymmetric units to form and 
thus further limiting the chances of crystal growth. The cytokine binding activity of α2m however 
may be a more tractable area for investigation with some factors binding with native α2m and 
others binding only with activated α2m (Rehman, et al., 2013). Of interest are those cytokine that 
bind via the Zn2+ of free sulfhydryl groups such as IL-1β a key immune mediator. Finally, 
interactions of α2m with its receptor could be investigated in both species. This work would have 
to involve the use of reacted α2m as only upon activation does α2m expose its previously 
concealed receptor binding domain. 
This work represents the first chapter in crystallography based structural studies of Limulus α2-
macroglobulin with a broad horizon for future research opportunities that are set to reveal 
fascinating secrets, as well as the first proposed activation and molecular reorganisation 
mechanism consistent with the early work in the literature. 
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Appendix 
Appendix 1 
Molecular Dimensions Structure Screen Conditions 
Structure Screen 1 – Catalogue Number MD1-01 
1 0.02M Calcium chloride 
dihydrate 
0.1M Na Acetate trihydrate 
pH 4.6 
30% v/v 2-methyl-2,4 
pentanediol 
2 0.2M Ammonium acetate 0.1M Na Acetate trihydrate 
pH 4.6 
30% w/v PEG 4000 
3 0.2M Ammonium 
sulphate  
0.1M Na acetate trihydrate 
pH 4.6 
25% w/v PEG 4000 
4 None  0.1M Na acetate trihydrate 
pH 4.6  
2.0M Sodium formate 
5 None  0.1M Na acetate trihydrate 
pH 4.6 
2.0M Ammonium sulphate 
6 None  0.1M Na acetate trihydrate 
pH 4.6 
8% w/v PEG 4000  
7 0.2M Ammonium acetate 0.1M tri-sodium citrate 
dihydrate pH 5.6 
30% w/v PEG 4000 
8 0.2M Ammonium acetate  0.1M tri-sodium citrate 
dihydrate pH 5.6 
30% v/v 2-methyl-2,4-
pentanediol 
9 None  0.1M tri-Sodium citrate 
dihydrate pH 5.6 
20% w/v 2-propanol, 20% 
w/v PEG 4000 
10 None  0.1M Na Citrate pH 5.6 1.0M Ammonium 
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dihydrogen phosphate 
11 0.2M Calcium chloride 
dihydrate 
0.1M Na acetate trihydrate 
pH 4.6 
20% v/v 2-propanol 
12 None 0.1M Na Cacodylate pH 
6.5 
1.4M Na acetate trihydrate 
13 0.2M tri-sodium citrate 
dihydrate 
0.1M Na Cacodylate pH 
6.5 
30% v/v 2-propanol 
14 0.2M Ammoniium 
sulphate  
0.1M Na Cacodylate pH 
6.5 
30% w/v PEG 8000 
15 0.2M Magnesium acetate 
tetrahydrate 
0.1M Na Cacodylate pH 
6.5 
20% PEG 8000 
16 0.2M Magnesium acetate 
tetrahydrate  
0.1M Na Cacodylate pH 
6.5 
30% v/v 2-methyl-2,4-
pentanediol 
17 None 0.1M Imidazole pH 6.5 1.0M Sodium acetate 
trihydrate 
18 0.2M Sodium acetate 
trihydrate 
0.1M Na Cacodylate pH 
6.5 
30% w/v PEG 8000 
19 0.2M Zinc acetate 
dihydrate  
0.1M Na Cacodylate pH 
6.5 
18% w/v PEG 8000 
20 0.2M Calcium acetate 
hydrate 
0.1M Na Cacodylate pH 
6.5 
18% w/v PEG 8000 
21 0.2M tri-sodium citrate 
dihydrate 
0.1M Na Hepes pH 7.5 30% v/v 2-methyl-2,4-
pentanediol 
22 0.2M Magnesium chloride 0.1M Na Hepes pH 7.5 30% v/v 2-propanol 
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hexahydrate 
23 0.2M Calcium chloride 
dihydrate 
0.1M Na Hepes pH 7.5  28% v/v PEG 400 
24 0.2M Magnesium chloride 
hexahydrate  
0.1M Na Hepes pH 7.5 30% v/v PEG 400 
25 0.2M tri-sodium citrate 
dihydrate  
0.1M Na Hepes pH 7.5 20% v/v 2-propanol 
26 None  0.1M Na Hepes pH 7.5 0.8M K, Na tartrate 
tetrahydrate 
27 None 0.1M Na Hepes pH 7.5 1.5M Lithium sulphate 
monohydrate 
28 None 0.1M Na Hepes pH 7.5 0.8M Na dihydrogen 
phosphate 
    0.8M K dihydrogen 
phosphate monohyd. 
  
29 None  0.1M Na Hepes pH 7.5  1.4M tri-Sodium citrate 
dihydrate 
30 None  0.1M Na Hepes pH 7.5  2% v/v PEG 400, 2.0M 
Amm sulphate 
31 None  0.1M Na Hepes pH 7.5 10% v/v 2-propanol, 20% 
w/v PEG 4000 
32 ,None 0.1M Tris HCl pH 8.5 2.0M Ammoniium sulphate 
33 0.2M Magnesium chloride 
hexahydrate 
0.1M Tris HCl pH 8.5 30% w/v PEG 4000 
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34 0.2M tri-sodum citrate 
dihydrate 
0.1M Tris HCl pH 8.5 30% v/v PEG 400 
35 0.2M Lithium sulphate 
monohydrate 
0.1M Tris HCl pH 8.5 30% w/v PEG 4000 
36 0.2M Ammonium acetate 0.1M Tris HCl pH 8.5 30% v/v 2-propanol 
37 0.2M Sodium acetate 
trihydrate  
0.1M Tris HCl pH 8.5 30% w/v PEG 4000 
38 None  0.1M Tris HCl pH 8.5 8% w/v PEG 8000 
39 None  0.1M Tris HCl pH 8.5 2.0M Ammonium 
dihydrogen phosphate 
40 None None 0.4M K, Na Tartrate 
tetrahydrate 
41 None  None 0.4M Ammonium 
dihydrogen phosphate 
42 0.2M Ammonium 
sulphate 
None  30% w/v PEG 8000 
43 0.2M Ammonium 
sulphate  
None  30% w/v PEG 4000 
44 None  None  2.0M Ammonium sulphate 
45 None  None  4.0M Sodium formate 
46 0.05M Potassium 
dihydrogen phosphate 
None 20% w/v PEG 8000 
47 None  None 30% w/v PEG 1500 
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48 None  None  0.2M Magnesium formate 
49 1.0M Lithium sulphate 
monohydrate 
None 2% w/v PEG 8000 
50 0.5M Lithium sulphate 
monohydrate 
None 15% w/v PEG 8000 
 
Structure Screen 2 – Catalogue Number MD1-02 
1 0.1M Sodium chloride 0.1M Bicine pH 9.0 30% w/v PEG 
monomethylether 550 
2 None  0.1M Bicine pH 9.0 2.0M Magnesium chloride 
hexahydrate 
3 2% w/v Dioxane 0.1M Bicine pH 9.0 10% w/v PEG 20,000  
4 0.2M Magnesium chloride 
hexahydrate 
0.1M Tris pH 8.5 3.4M 1,6 Hexanediol 
5 None 0.1M Tris pH 8.5 25% v/v tert-Butanol 
6 0.01M Nickel chloride 
hexahydrate 
0.1M Tris pH 8.5 1.0M Lithium sulphate 
7 1.5M Ammonium sulphate 0.1M Tris pH 8.5 12% v/v Glycerol 
8 0.2M Ammonium 
phosphate monobasic 
0.1M Tris pH 8.5 50% v/v MPD 
9 None  0.1M Tris pH 8.5 20% v/v Ethanol 
10 0.01M Nickel chloride 
hexahydrate 
0.1M Tris pH 8.5 20% w/v PEG 
monomethylether 2000 
 195 
 
11 0.5M Ammonium sulphate 0.1M Hepes pH 7.5 30% v/v MPD 
12 None  0.1M Hepes pH 7.5 10% w/v PEG 6000, 5% 
v/v MPD 
13 None  0.1M Hepes pH 7.5 20% v/v Jeffamine M-600 
14 0.1M Sodium chloride 0.1M Hepes pH 7.5 1.6M Ammonium sulphate 
15 None 0.1M Hepes pH 7.5 2.0M Ammonium formate 
16 0.05M Cadmium sulphate 
octahydrate 
0.1M Hepes pH 7.5 1.0M Sodium acetate 
17 None 0.1M Hepes pH 7.5 70% v/v MPD 
18 None 0.1M Hepes pH 7.5 4.3M Sodium chloride 
19 None 0.1M Hepes pH 7.5 10% w/v PEG 8000 
  8% v/v Ethylene glycol     
20 None 0.1M Mes pH 6.5 1.6M Magnesium sulphate 
heptahydrate 
21 0.1M Na phosphate 
monobasic 
0.1M Mes pH 6.5 2.0M Sodium Chloride 
  0.1M K phosphate 
monobasic  
    
22 None 0.1M Mes pH 6.5 12% w/v PEG 20,000 
23 1.6M Ammonium sulphate 0.1M Mes pH 6.5 10% v/v Dioxane 
24 0.05M Cesium chloride 0.1M Mes pH 6.5 30% v/v Jeffamine M-600 
25 0.01M Cobalt chloride 0.1M Mes pH 6.5 1.8M Ammonium sulphate 
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hexahydrate 
26 0.2M Ammonium sulphate 0.1M Mes pH 6.5 30% w/v PEG 
monomethylether 5000 
27 0.01M Zinc sulphate 
heptahydrate 
0.1M Mes pH 6.5 25% v/v PEG 
monomethylether 550 
28 None 0.1M Hepes pH 7.5 20% w/v PEG 10,000 
29 0.2M K/Na Tartrate 0.1M Sodium citrate pH 
5.6 
2.0M Ammonium sulphate 
30 0.5M Ammonium sulphate 0.1M Sodium citrate pH 
5.6 
1.0M Lithium sulphate 
31 0.5M Sodium chloride 0.1M Sodium citrate pH 
5.6 
4% v/v polyethyleneimine 
32 None 0.1M Sodium citrate pH 
5.6 
35% v/v tert-butanol 
33 0.01M Ferric chloride 
hexahydrate 
0.1M Sodium citrate pH 
5.6 
10% v/v Jeffamine M-600 
34 0.01M Manganese 
chloride tetrahydrate 
0.1M Sodium citrate pH 
5.6 
2.5M 1,6 Hexanediol 
35 None  0.1M Sodium acetate pH 
4.6 
2.0M Sodium chloride 
36 0.2M Sodium Chloride 0.1M Sodium acetate pH 
4.6 
30% v/v MPD 
37 0.01M Cobalt Chloride 
hexahydrate 
0.1M Sodium acetate pH 
4.6 
1.0M 1,6 Hexanediol 
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38 0.1M Cadmium chloride 0.1M Sodium acetate pH 
4.6 
30% v/v PEG 400 
39 0.2M Ammonium sulphate 0.1M Sodium acetate pH 
4.6 
30% w/v PEG 
monomethylether 2000 
40 2.0M Sodium Chloride None 10% w/v PEG 6000 
41 0.01M Cetyl trimethyl 
ammoniumbromide 
None 0.5M Sodium chloride 
0.1M Magnesium chloride 
hexahydrate 
42 None  None 25% v/v Ethylene glycol 
43 None  None 35% v/v Dioxane 
44 2.0M Ammonium Sulphate None 5% v/v Isopropanol 
45 None  None  1.0M Imidazole pH 7.0 
46 None None 10% w/v PEG 1000, 10% 
w/v PEG 8000 
47 1.5M Sodium Chloride None 10% v/v Ethanol 
48 None None 1.6M Sodium citrate pH 
6.5 
49 15% w/v 
Polyvinylpyrolidone 
    
50 2.0M Urea     
 
Structure Screen 1 Eco Screen – Catalogue Number MD1-01-ECO 
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1 0.02M Calcium chloride 
dihydrate 
0.1M Na Acetate trihydrate 
pH 4.6 
30% v/v 2-methyl-2,4 
pentanediol 
2 0.2M Ammonium acetate 0.1M Na Acetate trihydrate 
pH 4.6 
30% w/v PEG 4000 
3 0.2M Ammonium 
sulphate  
0.1M Na acetate trihydrate 
pH 4.6 
25% w/v PEG 4000 
4 None  0.1M Na acetate trihydrate 
pH 4.6  
2.0M Sodium formate 
5 None  0.1M Na acetate trihydrate 
pH 4.6 
2.0M Ammonium sulphate 
6 None  0.1M Na acetate trihydrate 
pH 4.6 
8% w/v PEG 4000  
7 0.2M Ammonium acetate 0.1M tri-sodium citrate 
dihydrate pH 5.6 
30% w/v PEG 4000 
8 0.2M Ammonium acetate  0.1M tri-sodium citrate 
dihydrate pH 5.6 
30% v/v 2-methyl-2,4-
pentanediol 
9 None  0.1M tri-Sodium citrate 
dihydrate pH 5.6 
20% w/v 2-propanol, 20% 
w/v PEG 4000 
10 None  0.1M Na Citrate pH 5.6 1.0M Ammonium 
dihydrogen phosphate 
11 0.2M Calcium chloride 
dihydrate 
0.1M Na acetate trihydrate 
pH 4.6 
20% v/v 2-propanol 
12 None 0.1M MES pH 6.5 1.4M Na acetate trihydrate 
13 0.2M tri-sodium citrate 0.1M MES pH 6.5 30% v/v 2-propanol 
 199 
 
dihydrate 
14 0.2M Ammoniium 
sulphate  
0.1M MES pH 6.5 30% w/v PEG 8000 
15 0.2M Magnesium acetate 
tetrahydrate 
0.1M MES pH 6.5 20% PEG 8000 
16 0.2M Magnesium acetate 
tetrahydrate  
0.1M MES pH 6.5 30% v/v 2-methyl-2,4-
pentanediol 
17 None 0.1M Imidazole pH 6.5 1.0M Sodium acetate 
trihydrate 
18 0.2M Sodium acetate 
trihydrate 
0.1M MES pH 6.5 30% w/v PEG 8000 
19 0.2M Zinc acetate 
dihydrate  
0.1M MES pH 6.5 18% w/v PEG 8000 
20 0.2M Calcium acetate 
hydrate 
0.1M MES pH 6.5 18% w/v PEG 8000 
21 0.2M tri-sodium citrate 
dihydrate 
0.1M Na Hepes pH 7.5 30% v/v 2-methyl-2,4-
pentanediol 
22 0.2M Magnesium chloride 
hexahydrate 
0.1M Na Hepes pH 7.5 30% v/v 2-propanol 
23 0.2M Calcium chloride 
dihydrate 
0.1M Na Hepes pH 7.5  28% v/v PEG 400 
24 0.2M Magnesium chloride 
hexahydrate  
0.1M Na Hepes pH 7.5 30% v/v PEG 400 
25 0.2M tri-sodium citrate 0.1M Na Hepes pH 7.5 20% v/v 2-propanol 
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dihydrate  
26 None  0.1M Na Hepes pH 7.5 0.8M K, Na tartrate 
tetrahydrate 
27 None 0.1M Na Hepes pH 7.5 1.5M Lithium sulphate 
monohydrate 
28 None 0.1M Na Hepes pH 7.5 0.8M Na dihydrogen 
phosphate 
    0.8M K dihydrogen 
phosphate monohyd. 
  
29 None  0.1M Na Hepes pH 7.5  1.4M tri-Sodium citrate 
dihydrate 
30 None  0.1M Na Hepes pH 7.5  2% v/v PEG 400, 2.0M 
Amm sulphate 
31 None  0.1M Na Hepes pH 7.5 10% v/v 2-propanol, 20% 
w/v PEG 4000 
32 ,None 0.1M Tris HCl pH 8.5 2.0M Ammoniium sulphate 
33 0.2M Magnesium chloride 
hexahydrate 
0.1M Tris HCl pH 8.5 30% w/v PEG 4000 
34 0.2M tri-sodum citrate 
dihydrate 
0.1M Tris HCl pH 8.5 30% v/v PEG 400 
35 0.2M Lithium sulphate 
monohydrate 
0.1M Tris HCl pH 8.5 30% w/v PEG 4000 
36 0.2M Ammonium acetate 0.1M Tris HCl pH 8.5 30% v/v 2-propanol 
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37 0.2M Sodium acetate 
trihydrate  
0.1M Tris HCl pH 8.5 30% w/v PEG 4000 
38 None  0.1M Tris HCl pH 8.5 8% w/v PEG 8000 
39 None  0.1M Tris HCl pH 8.5 2.0M Ammonium 
dihydrogen phosphate 
40 None None 0.4M K, Na Tartrate 
tetrahydrate 
41 None  None 0.4M Ammonium 
dihydrogen phosphate 
42 0.2M Ammonium 
sulphate 
None  30% w/v PEG 8000 
43 0.2M Ammonium 
sulphate  
None  30% w/v PEG 4000 
44 None  None  2.0M Ammonium sulphate 
45 None  None  4.0M Sodium formate 
46 0.05M Potassium 
dihydrogen phosphate 
None 20% w/v PEG 8000 
47 None  None 30% w/v PEG 1500 
48 None  None  0.2M Magnesium formate 
49 1.0M Lithium sulphate 
monohydrate 
None 2% w/v PEG 8000 
50 0.5M Lithium sulphate 
monohydrate 
None 15% w/v PEG 8000 
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Appendix 2 
Α2m crystal tray conditions based on human trials. 
Crystallisation Tray        No: MN04 
                    Set up By: Michael Nicosia 
        Date of Trial: A1-C3 - 12/6/12, D1-D5 – 12/7/12, A4-C6 – 21/9/12 
                     Protein and Concentration: Limulus α2-Macroglobulin (8.319mg/ml) 
  Summary of Protein Separation: PEG cut serum was cleared of pentraxins by affinity 
chromatography. Prior to the purification of α2-Macroglobulin by Gel filtration. 
 
Non-variable conditions: 0.2M Ammonium Citrate pH 6.4 
Variable Conditions as indicated by table: 15% PEG 2000, 3350, 4000 
        25, 50 & 75mM NaF 
 1 2 3 4 5 6 
A 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 2000 
25mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 2000 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 2000 
75mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
B 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
25mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
75mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
C 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 4000 
25mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 4000 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 4000 
75mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
D 0.2M 
Ammonium 
Citrate pH 
6.4 
5% w/v 
PEG 3350 
50mM NaF  
0.2M 
Ammonium 
Citrate pH 
6.4 
10% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
20% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
25% w/v 
PEG 3350 
50mM NaF 
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Crystallisation Tray        No: MN09 
                    Set up By: Michael Nicosia 
        Date of Trial: 25/7/12 
                     Protein and Concentration: Limulus α2-Macroglobulin-Methylamine (7.79mg/ml) 
  Summary of Protein Separation: Separation: PEG cut serum was cleared of pentraxins by 
affinity chromatography. Prior to the purification of α2-Macroglobulin by Gel filtration. 
 
 
Non-variable conditions: 0.2M Ammonium Citrate pH 6.4 
 
Variable Conditions as indicated by table: 
 
 1 2 3 4 5 6 
A 0.2M 
Ammonium 
Citrate pH 
6.4 
5% w/v 
PEG 2000 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 2000 
75mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
5% w/v PEG 
2000 
100mM NaF 
   
B 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 2000 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 2000 
75mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v PEG 
2000 
100mM NaF 
   
C 0.2M 
Ammonium 
Citrate pH 
6.4 
25% w/v 
PEG 2000 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
25% w/v 
PEG 2000 
75mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
25% w/v PEG 
2000 
100mM NaF 
   
D  
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Crystallisation Tray        No: MN11 
                    Set up By: Michael Nicosia 
        Date of Trial: 17/8/12 
                     Protein and Concentration: Limulus α2-Macroglobulin-Methylamine (7.79mg/ml) 
  Summary of Protein Separation: Separation: PEG cut serum was cleared of pentraxins by 
affinity chromatography. Prior to the purification of α2-Macroglobulin by Gel filtration. 
 
 
Non-variable conditions: 0.2M Ammonium Citrate pH 6.4 
 
Variable Conditions as indicated by table: 
 
 1 2 3 4 5 6 
A 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
  
B 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
  
C 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
  
D 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
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Crystallisation Tray        No: MN13 
                    Set up By: Michael Nicosia 
        Date of Trial: 15/1/13 
                     Protein and Concentration: Limulus α2-Macroglobulin (7.79mg/ml) 
  Summary of Protein Separation: PEG cut serum was cleared of pentraxins by affinity 
chromatography. Prior to the purification of α2-Macroglobulin by Gel filtration. 
 
Non-variable conditions: 0.2M Ammonium Citrate pH 6.4 
 
Variable Conditions as indicated by table: % PEG 3350,   35, 50 & 65mM NaF 
 1 2 3 4 5 6 
A 0.2M 
Ammonium 
Citrate pH 
6.4 
12.5% w/v 
PEG 3350 
35mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
12.5% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
12.5% w/v 
PEG 3350 
65mM NaF 
   
B 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
35mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
65mM NaF 
   
C 0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
35mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
50mM NaF 
0.2M 
Ammonium 
Citrate pH 
6.4 
15% w/v 
PEG 3350 
65mM NaF 
   
D  
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Appendix 3 
List of amino acids. 
Amino Acid Three letter code Single letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic Acid Asp D 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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Appendix 4. 
I-TASSER output for the ‘native’ Limulus α2m 
Details of the three models of ‘native’ Limulus α2m produced by I-TASSER with the description of 
the significance of these numbers described below. 
Name C-score Exp. TM-Score Exp. RMSD No. of decoys Cluster Density 
Model 1 0.06 0.72 ± 0.11 9.7 ± 4.6 434 0.1251 
Model 2 -0.10   308 0.1251 
Model 3 -0.62   124 0.1059 
 
C-score is a confidence score for estimating the quality of predicted models by I-TASSER. It is 
calculated based on the significance of threading template alignments and the convergence 
parameters of the structure assembly simulations. C-score is typically in the range of [-5,2], where 
a C-score of higher value signifies a model with a high confidence and vice-versa. 
 
TM-score and RMSD are known standards for measuring structural similarity between two 
structures which areusually used to measure the accuracy of structure modeling when the native 
structure is known. In case where the native structure is not known, it becomes necessary to 
predict the quality of the modeling prediction, i.e. what is the distance between the predicted 
model and the native structures? To answer this question, we tried predicted the TM-score and 
RMSD of the predicted models relative the native structures based on the C-score.  
 
In a benchmark test set of 500 non-homologous proteins, we found that C-score is highly 
correlated with TM-score and RMSD. Correlation coefficient of C-score of the first model with TM-
score to the native structure is 0.91, while the coefficient of C-score with RMSD to the native 
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structure is 0.75. These data actually lay the base for the reliable prediction of the TM-score and 
RMSD using C-score. Values reported in Column 3 & 4 are the estimated values of TM-score and 
RMSD based on their correlation with C-score. Here we only report the quality prediction (TM-
score and RMSD) for the first model, because we found that the correlation between C-score and 
TM-score is weak for lower rank models. However, we list the C-score of all models just for a 
reference. 
 
What is TM-score?  
 
TM-score is a recently proposed scale for measuring the structural similarity between two 
structures. The purpose of proposing TM-score is to solve the problem of RMSD which is sensitive 
to the local error. Because RMSD is an average distance of all residue pairs in two structures, a 
local error (e.g. a misorientation of the tail) will araise a big RMSD value although the global 
topology is correct. In TM-score, however, the small distance is weighted stronger than the big 
distance which makes the score insensitive to the local modeling error. A TM-score >0.5 indicates 
a model of correct topology and a TM-score<0.17 means a random similarity. These cutoff does 
not depends on the protein length. 
 
What is Cluster density? 
 
I-TASSER generates full length model of proteins by excising continuous fragments from threading 
alignments and then reassembling them using replica-exchanged Monte Carlo simulations. Low 
temperature replicas (decoys) generated during the simulation are clustered by SPICKER and top 
five cluster centroids are selected for generating full atomic models. The cluster density is defined 
as the number of structure decoys at an unit of space in the SPICKER cluster. A higher cluster 
density means the structure occurs more often in the simulation trajectory and therefore signifies 
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a better quality model. The values in the second last columns of the above mentioned table 
represents the number of structural decoys that are used in generating each model. The last 
column represents the density of cluster.  
 
The models below depict the domain in the same colour scheme as seen in the paper for the 
human structure (Marrero, et al. 2012). MG1 - orange, MG2 - yellow, MG3 - light green, MG4 - 
magenta, MG5 - cyan, MG6 - pink, BRD - blue, MG7 - red, CUB - Green, TED - purple, and RBD - 
grey. 
Model 1 of I-TASSER simulation of the ‘native’ structure of Limulus α2m 
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Model 2 of I-TASSER simulation of the ‘native’ structure of Limulus α2m 
 
Model 3 of I-TASSER simulation of the ‘native’ structure of Limulus α2m 
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The Top 10 templates used by I-TASSER in the rendering of model 1. 
Rank PDB - protein Ident1 Ident 2 Cov Norm. Z-score 
1 2pn5A - TEP1 0.26 0.26 0.85 4.79 
2 2pn5A - TEP1 0.25 0.26 0.85 3.49 
3 2pn5A - TEP1 0.25 0.26 0.85 10.52 
4 2pn5A - TEP1 0.25 0.26 0.85 8.26 
5 2pn5A - TEP1 0.25 0.26 0.85 4.30 
6 2pn5A - TEP1 0.25 0.26 0.85 4.97 
7 2pn5A - TEP1 0.25 0.26 0.85 3.63 
8 4acqA - Human α2m 0.32 0.29 0.82 5.23 
9 2pn5A - TEP1 0.27 .26 0.66 7.16 
10 3cu7A - Human C5 0.21 0.25 0.94 13.56 
 
Where: Ident1 is the percentage sequence identity of the templates in the threading aligned 
region with the query sequence. Ident2 is the percentage sequence identity of the whole 
template chains with query sequence. Cov. represents the coverage of the threading alignment 
and is equal to the number of aligned residues divided by the length of query protein. Norm. Z-
score is the normalized Z-score of the threading alignments. Alignment with a Normalized Z-score 
>1 mean a good alignment and vice versa. The top 10 alignments reported above (in order of their 
ranking) are from the following threading programs:       1: MUSTER   2: dPPAS   3: Neff-PPAS   4: 
PPAS   5: wdPPAS   6: SPARKS-X   7: SP3   8: HHSEARCH2   9: PROSPECT2   10: FFAS03    
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Top 10 Identified Structural Analogues in PDB, of which there were only 9 available, used by I-
TASSER in the prediction of the ‘native’ model of Limulus α2m. 
Rank PDB-protein TM-score RMSD IDEN COV 
1 2pn5A - TEP1 0.841 1.12 0.25 0.847 
2 3klsB - C5/SSL7 0.603 5.90 0.167 0.702 
3 2bs9A - C3 0.573 5.90 1.66 0.671 
4 4a5wA - C5b6 0.370 9.64 0.094 0.544 
5 4acqA - Human α2m 0.368 8.94 0.107 0.522 
6 3pvmB - C5/CVF 0.363 9.21 0.070 0.527 
7 4fxgB - C4/MASP2 0.357 4.50 0.208 0.395 
8 2vz9B - fatty acid synthase 0.278 10.42 0.032 0.434 
9 3w5mA - α-L-Rhamnosidase 0.273 8.16 0.048 0.368 
 
Ranking of proteins is based on TM-score of the structural alignment between query structure 
and known structures in the PDB library. RMSD is the RMSD between residues that are 
structurally aligned by TM-align. IDEN is the percentage sequence identity in the structurally 
aligned regions. COV. Represents the coverage of the alignment by TM-align and is equal to the 
number of structurally aligned residues divided by length of the query protein. 
